date generated: 2022-05-18
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Here is the first few lines of the input profile.
## metric
## PDE4D -11.973717
## DAB1 -11.614000
## PCDHGA1 5.901466
## HOXC4 -11.363650
## LPP -6.110680
## PTPRN2 -2.331781
Here are some metrics about the input data profile:
Profile metrics | |
---|---|
num_genesets | 2546 |
num_genes_in_profile | 26148 |
duplicated_genes_present | 0 |
num_profile_genes_in_sets | 10252 |
num_profile_genes_not_in_sets | 15896 |
Here is a plot of the input profiles. Note the dynamic ranges.
Here is the contour plot of the profile including all detected genes.
Gene sets metrics | |
---|---|
num_genesets | 2546 |
num_genesets_excluded | 1018 |
num_genesets_included | 1528 |
Significance is calculated by -log10(p-value). All points shown are FDR<0.05.
Significance is calculated by -log10(p-value). Top N sets shown irrespective of FDR.
set | setSize | pANOVA | s.dist | p.adjustANOVA |
---|---|---|---|---|
Folding of actin by CCT/TriC | 10 | 2.12e-04 | -0.676 | 8.52e-04 |
FOXO-mediated transcription of cell cycle genes | 16 | 1.18e-05 | -0.632 | 8.23e-05 |
NOTCH4 Activation and Transmission of Signal to the Nucleus | 11 | 6.00e-04 | -0.597 | 1.99e-03 |
Repression of WNT target genes | 13 | 3.20e-04 | -0.576 | 1.20e-03 |
Crosslinking of collagen fibrils | 10 | 2.15e-03 | -0.560 | 5.89e-03 |
Processing of Intronless Pre-mRNAs | 19 | 2.36e-05 | -0.560 | 1.41e-04 |
Disorders of Developmental Biology | 11 | 2.04e-03 | -0.537 | 5.65e-03 |
Disorders of Nervous System Development | 11 | 2.04e-03 | -0.537 | 5.65e-03 |
Loss of function of MECP2 in Rett syndrome | 11 | 2.04e-03 | -0.537 | 5.65e-03 |
Pervasive developmental disorders | 11 | 2.04e-03 | -0.537 | 5.65e-03 |
POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | 10 | 3.31e-03 | -0.536 | 8.35e-03 |
Transcriptional regulation of testis differentiation | 12 | 1.52e-03 | -0.529 | 4.47e-03 |
Beta defensins | 32 | 2.31e-07 | 0.528 | 2.70e-06 |
Regulated proteolysis of p75NTR | 11 | 2.50e-03 | -0.526 | 6.65e-03 |
Diseases associated with glycosylation precursor biosynthesis | 15 | 4.33e-04 | -0.525 | 1.53e-03 |
Processing of Capped Intronless Pre-mRNA | 28 | 1.57e-06 | -0.524 | 1.59e-05 |
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 14 | 7.00e-04 | -0.523 | 2.25e-03 |
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | 11 | 2.75e-03 | -0.521 | 7.22e-03 |
Beta-catenin phosphorylation cascade | 16 | 3.30e-04 | -0.518 | 1.23e-03 |
Defensins | 40 | 1.96e-08 | 0.513 | 2.98e-07 |
Physiological factors | 12 | 2.49e-03 | -0.504 | 6.64e-03 |
SLBP independent Processing of Histone Pre-mRNAs | 10 | 7.21e-03 | -0.491 | 1.62e-02 |
Signaling by FGFR2 IIIa TM | 19 | 2.14e-04 | -0.490 | 8.52e-04 |
Signaling by PDGFRA extracellular domain mutants | 12 | 4.00e-03 | -0.480 | 9.79e-03 |
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 12 | 4.00e-03 | -0.480 | 9.79e-03 |
MET receptor recycling | 10 | 9.46e-03 | -0.474 | 2.05e-02 |
WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 13 | 3.13e-03 | -0.473 | 8.03e-03 |
CTNNB1 S33 mutants aren’t phosphorylated | 14 | 2.19e-03 | -0.473 | 5.94e-03 |
CTNNB1 S37 mutants aren’t phosphorylated | 14 | 2.19e-03 | -0.473 | 5.94e-03 |
CTNNB1 S45 mutants aren’t phosphorylated | 14 | 2.19e-03 | -0.473 | 5.94e-03 |
CTNNB1 T41 mutants aren’t phosphorylated | 14 | 2.19e-03 | -0.473 | 5.94e-03 |
Signaling by CTNNB1 phospho-site mutants | 14 | 2.19e-03 | -0.473 | 5.94e-03 |
Signaling by GSK3beta mutants | 14 | 2.19e-03 | -0.473 | 5.94e-03 |
Antimicrobial peptides | 82 | 3.37e-13 | 0.464 | 1.01e-11 |
RAF-independent MAPK1/3 activation | 22 | 1.65e-04 | -0.464 | 6.83e-04 |
RUNX3 regulates p14-ARF | 10 | 1.15e-02 | -0.461 | 2.41e-02 |
RUNX2 regulates bone development | 29 | 1.96e-05 | -0.458 | 1.24e-04 |
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 12 | 6.09e-03 | -0.457 | 1.40e-02 |
alpha-linolenic acid (ALA) metabolism | 12 | 6.09e-03 | -0.457 | 1.40e-02 |
RUNX2 regulates osteoblast differentiation | 22 | 2.13e-04 | -0.456 | 8.52e-04 |
APC truncation mutants have impaired AXIN binding | 13 | 4.45e-03 | -0.455 | 1.07e-02 |
AXIN missense mutants destabilize the destruction complex | 13 | 4.45e-03 | -0.455 | 1.07e-02 |
Signaling by AMER1 mutants | 13 | 4.45e-03 | -0.455 | 1.07e-02 |
Signaling by APC mutants | 13 | 4.45e-03 | -0.455 | 1.07e-02 |
Signaling by AXIN mutants | 13 | 4.45e-03 | -0.455 | 1.07e-02 |
Truncations of AMER1 destabilize the destruction complex | 13 | 4.45e-03 | -0.455 | 1.07e-02 |
RNA Polymerase III Transcription Initiation From Type 2 Promoter | 27 | 4.18e-05 | -0.455 | 2.23e-04 |
Nephrin family interactions | 21 | 3.31e-04 | -0.452 | 1.23e-03 |
Cleavage of the damaged purine | 11 | 9.51e-03 | -0.451 | 2.06e-02 |
Depurination | 11 | 9.51e-03 | -0.451 | 2.06e-02 |
set | setSize | pANOVA | s.dist | p.adjustANOVA |
---|---|---|---|---|
Folding of actin by CCT/TriC | 10 | 2.12e-04 | -0.676000 | 8.52e-04 |
FOXO-mediated transcription of cell cycle genes | 16 | 1.18e-05 | -0.632000 | 8.23e-05 |
NOTCH4 Activation and Transmission of Signal to the Nucleus | 11 | 6.00e-04 | -0.597000 | 1.99e-03 |
Repression of WNT target genes | 13 | 3.20e-04 | -0.576000 | 1.20e-03 |
Crosslinking of collagen fibrils | 10 | 2.15e-03 | -0.560000 | 5.89e-03 |
Processing of Intronless Pre-mRNAs | 19 | 2.36e-05 | -0.560000 | 1.41e-04 |
Disorders of Developmental Biology | 11 | 2.04e-03 | -0.537000 | 5.65e-03 |
Disorders of Nervous System Development | 11 | 2.04e-03 | -0.537000 | 5.65e-03 |
Loss of function of MECP2 in Rett syndrome | 11 | 2.04e-03 | -0.537000 | 5.65e-03 |
Pervasive developmental disorders | 11 | 2.04e-03 | -0.537000 | 5.65e-03 |
POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | 10 | 3.31e-03 | -0.536000 | 8.35e-03 |
Transcriptional regulation of testis differentiation | 12 | 1.52e-03 | -0.529000 | 4.47e-03 |
Beta defensins | 32 | 2.31e-07 | 0.528000 | 2.70e-06 |
Regulated proteolysis of p75NTR | 11 | 2.50e-03 | -0.526000 | 6.65e-03 |
Diseases associated with glycosylation precursor biosynthesis | 15 | 4.33e-04 | -0.525000 | 1.53e-03 |
Processing of Capped Intronless Pre-mRNA | 28 | 1.57e-06 | -0.524000 | 1.59e-05 |
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 14 | 7.00e-04 | -0.523000 | 2.25e-03 |
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | 11 | 2.75e-03 | -0.521000 | 7.22e-03 |
Beta-catenin phosphorylation cascade | 16 | 3.30e-04 | -0.518000 | 1.23e-03 |
Defensins | 40 | 1.96e-08 | 0.513000 | 2.98e-07 |
Physiological factors | 12 | 2.49e-03 | -0.504000 | 6.64e-03 |
SLBP independent Processing of Histone Pre-mRNAs | 10 | 7.21e-03 | -0.491000 | 1.62e-02 |
Signaling by FGFR2 IIIa TM | 19 | 2.14e-04 | -0.490000 | 8.52e-04 |
Signaling by PDGFRA extracellular domain mutants | 12 | 4.00e-03 | -0.480000 | 9.79e-03 |
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 12 | 4.00e-03 | -0.480000 | 9.79e-03 |
MET receptor recycling | 10 | 9.46e-03 | -0.474000 | 2.05e-02 |
WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 13 | 3.13e-03 | -0.473000 | 8.03e-03 |
CTNNB1 S33 mutants aren’t phosphorylated | 14 | 2.19e-03 | -0.473000 | 5.94e-03 |
CTNNB1 S37 mutants aren’t phosphorylated | 14 | 2.19e-03 | -0.473000 | 5.94e-03 |
CTNNB1 S45 mutants aren’t phosphorylated | 14 | 2.19e-03 | -0.473000 | 5.94e-03 |
CTNNB1 T41 mutants aren’t phosphorylated | 14 | 2.19e-03 | -0.473000 | 5.94e-03 |
Signaling by CTNNB1 phospho-site mutants | 14 | 2.19e-03 | -0.473000 | 5.94e-03 |
Signaling by GSK3beta mutants | 14 | 2.19e-03 | -0.473000 | 5.94e-03 |
Antimicrobial peptides | 82 | 3.37e-13 | 0.464000 | 1.01e-11 |
RAF-independent MAPK1/3 activation | 22 | 1.65e-04 | -0.464000 | 6.83e-04 |
RUNX3 regulates p14-ARF | 10 | 1.15e-02 | -0.461000 | 2.41e-02 |
RUNX2 regulates bone development | 29 | 1.96e-05 | -0.458000 | 1.24e-04 |
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 12 | 6.09e-03 | -0.457000 | 1.40e-02 |
alpha-linolenic acid (ALA) metabolism | 12 | 6.09e-03 | -0.457000 | 1.40e-02 |
RUNX2 regulates osteoblast differentiation | 22 | 2.13e-04 | -0.456000 | 8.52e-04 |
APC truncation mutants have impaired AXIN binding | 13 | 4.45e-03 | -0.455000 | 1.07e-02 |
AXIN missense mutants destabilize the destruction complex | 13 | 4.45e-03 | -0.455000 | 1.07e-02 |
Signaling by AMER1 mutants | 13 | 4.45e-03 | -0.455000 | 1.07e-02 |
Signaling by APC mutants | 13 | 4.45e-03 | -0.455000 | 1.07e-02 |
Signaling by AXIN mutants | 13 | 4.45e-03 | -0.455000 | 1.07e-02 |
Truncations of AMER1 destabilize the destruction complex | 13 | 4.45e-03 | -0.455000 | 1.07e-02 |
RNA Polymerase III Transcription Initiation From Type 2 Promoter | 27 | 4.18e-05 | -0.455000 | 2.23e-04 |
Nephrin family interactions | 21 | 3.31e-04 | -0.452000 | 1.23e-03 |
Cleavage of the damaged purine | 11 | 9.51e-03 | -0.451000 | 2.06e-02 |
Depurination | 11 | 9.51e-03 | -0.451000 | 2.06e-02 |
Recognition and association of DNA glycosylase with site containing an affected purine | 11 | 9.51e-03 | -0.451000 | 2.06e-02 |
RNA Polymerase III Transcription Termination | 23 | 1.91e-04 | -0.449000 | 7.77e-04 |
Glucocorticoid biosynthesis | 10 | 1.39e-02 | 0.449000 | 2.83e-02 |
FGFR2 alternative splicing | 26 | 7.40e-05 | -0.449000 | 3.53e-04 |
mRNA Capping | 28 | 5.87e-05 | -0.438000 | 2.98e-04 |
RNA Polymerase III Chain Elongation | 18 | 1.34e-03 | -0.436000 | 4.01e-03 |
SUMOylation of immune response proteins | 10 | 1.69e-02 | -0.436000 | 3.33e-02 |
Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | 12 | 9.04e-03 | -0.435000 | 1.97e-02 |
Condensation of Prophase Chromosomes | 12 | 9.07e-03 | -0.435000 | 1.97e-02 |
Uptake and function of anthrax toxins | 11 | 1.33e-02 | -0.431000 | 2.73e-02 |
Base-Excision Repair, AP Site Formation | 18 | 1.73e-03 | -0.426000 | 5.00e-03 |
RNA Polymerase III Transcription Initiation From Type 1 Promoter | 28 | 1.01e-04 | -0.424000 | 4.60e-04 |
Polymerase switching on the C-strand of the telomere | 24 | 3.27e-04 | -0.423000 | 1.22e-03 |
Defective EXT1 causes exostoses 1, TRPS2 and CHDS | 12 | 1.11e-02 | -0.423000 | 2.35e-02 |
Defective EXT2 causes exostoses 2 | 12 | 1.11e-02 | -0.423000 | 2.35e-02 |
Endosomal/Vacuolar pathway | 12 | 1.12e-02 | -0.423000 | 2.37e-02 |
Mitochondrial tRNA aminoacylation | 18 | 2.03e-03 | -0.420000 | 5.65e-03 |
Early Phase of HIV Life Cycle | 14 | 6.61e-03 | -0.419000 | 1.50e-02 |
ERK/MAPK targets | 20 | 1.18e-03 | -0.419000 | 3.60e-03 |
NGF-stimulated transcription | 39 | 5.99e-06 | -0.419000 | 4.77e-05 |
Initiation of Nuclear Envelope (NE) Reformation | 18 | 2.12e-03 | -0.418000 | 5.83e-03 |
tRNA Aminoacylation | 24 | 3.92e-04 | -0.418000 | 1.41e-03 |
YAP1- and WWTR1 (TAZ)-stimulated gene expression | 15 | 5.30e-03 | -0.416000 | 1.24e-02 |
HS-GAG biosynthesis | 28 | 1.42e-04 | -0.415000 | 6.09e-04 |
Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 29 | 1.09e-04 | -0.415000 | 4.90e-04 |
RHO GTPases Activate Formins | 114 | 1.89e-14 | -0.415000 | 7.03e-13 |
Transport of Mature mRNAs Derived from Intronless Transcripts | 41 | 4.29e-06 | -0.415000 | 3.79e-05 |
Expression and translocation of olfactory receptors | 365 | 5.99e-42 | 0.412000 | 1.31e-39 |
Acetylcholine Neurotransmitter Release Cycle | 16 | 4.32e-03 | -0.412000 | 1.05e-02 |
Resolution of Sister Chromatid Cohesion | 98 | 1.86e-12 | -0.411000 | 5.08e-11 |
Signaling by ALK | 26 | 2.84e-04 | -0.411000 | 1.08e-03 |
Association of TriC/CCT with target proteins during biosynthesis | 38 | 1.21e-05 | -0.410000 | 8.33e-05 |
Serotonin Neurotransmitter Release Cycle | 16 | 4.54e-03 | -0.410000 | 1.09e-02 |
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models | 22 | 8.89e-04 | -0.409000 | 2.76e-03 |
Neurodegenerative Diseases | 22 | 8.89e-04 | -0.409000 | 2.76e-03 |
RMTs methylate histone arginines | 29 | 1.38e-04 | -0.409000 | 5.99e-04 |
Activation of HOX genes during differentiation | 61 | 3.54e-08 | -0.408000 | 5.20e-07 |
Activation of anterior HOX genes in hindbrain development during early embryogenesis | 61 | 3.54e-08 | -0.408000 | 5.20e-07 |
DARPP-32 events | 24 | 5.44e-04 | -0.408000 | 1.85e-03 |
RNA Pol II CTD phosphorylation and interaction with CE | 26 | 3.32e-04 | -0.406000 | 1.23e-03 |
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 26 | 3.32e-04 | -0.406000 | 1.23e-03 |
eNOS activation | 11 | 2.01e-02 | -0.405000 | 3.83e-02 |
Transport of Mature mRNA Derived from an Intronless Transcript | 40 | 9.57e-06 | -0.404000 | 7.00e-05 |
EGR2 and SOX10-mediated initiation of Schwann cell myelination | 27 | 2.93e-04 | -0.402000 | 1.11e-03 |
Dopamine Neurotransmitter Release Cycle | 20 | 1.83e-03 | -0.402000 | 5.25e-03 |
Nuclear Events (kinase and transcription factor activation) | 60 | 7.10e-08 | -0.402000 | 9.60e-07 |
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | 89 | 6.02e-11 | -0.401000 | 1.31e-09 |
Amplification of signal from the kinetochores | 89 | 6.02e-11 | -0.401000 | 1.31e-09 |
Signaling by PDGFR in disease | 20 | 1.91e-03 | -0.401000 | 5.42e-03 |
ERKs are inactivated | 13 | 1.24e-02 | -0.400000 | 2.56e-02 |
Cleavage of the damaged pyrimidine | 16 | 5.55e-03 | -0.400000 | 1.29e-02 |
Depyrimidination | 16 | 5.55e-03 | -0.400000 | 1.29e-02 |
Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 16 | 5.55e-03 | -0.400000 | 1.29e-02 |
Leading Strand Synthesis | 13 | 1.25e-02 | -0.400000 | 2.58e-02 |
Polymerase switching | 13 | 1.25e-02 | -0.400000 | 2.58e-02 |
Olfactory Signaling Pathway | 372 | 6.84e-40 | 0.398000 | 1.16e-37 |
Signaling by WNT in cancer | 32 | 9.81e-05 | -0.398000 | 4.51e-04 |
Inhibition of DNA recombination at telomere | 20 | 2.07e-03 | -0.398000 | 5.72e-03 |
EPH-ephrin mediated repulsion of cells | 48 | 2.11e-06 | -0.395000 | 2.02e-05 |
Cyclin A/B1/B2 associated events during G2/M transition | 24 | 8.05e-04 | -0.395000 | 2.54e-03 |
RND1 GTPase cycle | 41 | 1.24e-05 | -0.394000 | 8.53e-05 |
EML4 and NUDC in mitotic spindle formation | 93 | 4.92e-11 | -0.394000 | 1.16e-09 |
Signaling by FGFR2 in disease | 42 | 1.01e-05 | -0.394000 | 7.28e-05 |
Interactions of Vpr with host cellular proteins | 33 | 9.22e-05 | -0.393000 | 4.30e-04 |
RET signaling | 41 | 1.33e-05 | -0.393000 | 9.01e-05 |
Diseases associated with N-glycosylation of proteins | 19 | 3.04e-03 | -0.393000 | 7.87e-03 |
HDMs demethylate histones | 18 | 3.94e-03 | -0.392000 | 9.69e-03 |
PI-3K cascade:FGFR4 | 19 | 3.09e-03 | -0.392000 | 7.97e-03 |
Vpr-mediated nuclear import of PICs | 32 | 1.35e-04 | -0.390000 | 5.88e-04 |
Role of LAT2/NTAL/LAB on calcium mobilization | 13 | 1.50e-02 | -0.389000 | 3.02e-02 |
Sulfur amino acid metabolism | 27 | 4.82e-04 | -0.388000 | 1.67e-03 |
Interleukin-27 signaling | 11 | 2.69e-02 | -0.385000 | 4.90e-02 |
Downstream signaling of activated FGFR4 | 26 | 6.77e-04 | -0.385000 | 2.20e-03 |
Postmitotic nuclear pore complex (NPC) reformation | 26 | 6.80e-04 | -0.385000 | 2.21e-03 |
Purine ribonucleoside monophosphate biosynthesis | 11 | 2.72e-02 | -0.384000 | 4.94e-02 |
ALK mutants bind TKIs | 12 | 2.12e-02 | -0.384000 | 3.99e-02 |
FGFR2 mutant receptor activation | 32 | 1.74e-04 | -0.383000 | 7.15e-04 |
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | 17 | 6.25e-03 | -0.383000 | 1.43e-02 |
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 17 | 6.25e-03 | -0.383000 | 1.43e-02 |
DNA Damage/Telomere Stress Induced Senescence | 28 | 4.51e-04 | -0.383000 | 1.58e-03 |
RNA Polymerase III Abortive And Retractive Initiation | 41 | 2.26e-05 | -0.382000 | 1.36e-04 |
RNA Polymerase III Transcription | 41 | 2.26e-05 | -0.382000 | 1.36e-04 |
Gap junction degradation | 10 | 3.63e-02 | -0.382000 | 6.28e-02 |
Metabolism of folate and pterines | 16 | 8.21e-03 | -0.382000 | 1.82e-02 |
Negative regulation of NMDA receptor-mediated neuronal transmission | 20 | 3.18e-03 | -0.381000 | 8.14e-03 |
cGMP effects | 15 | 1.07e-02 | -0.381000 | 2.27e-02 |
TRAF3-dependent IRF activation pathway | 15 | 1.07e-02 | -0.380000 | 2.27e-02 |
mRNA Editing | 10 | 3.75e-02 | 0.380000 | 6.46e-02 |
MECP2 regulates neuronal receptors and channels | 17 | 6.72e-03 | -0.380000 | 1.52e-02 |
Cytosolic iron-sulfur cluster assembly | 10 | 3.76e-02 | -0.380000 | 6.47e-02 |
Signal attenuation | 10 | 3.79e-02 | -0.379000 | 6.48e-02 |
Fatty acids | 15 | 1.13e-02 | 0.378000 | 2.37e-02 |
Viral Messenger RNA Synthesis | 42 | 2.45e-05 | -0.376000 | 1.45e-04 |
CRMPs in Sema3A signaling | 15 | 1.19e-02 | -0.375000 | 2.46e-02 |
MicroRNA (miRNA) biogenesis | 26 | 9.41e-04 | -0.375000 | 2.91e-03 |
RHO GTPases activate IQGAPs | 11 | 3.14e-02 | -0.375000 | 5.56e-02 |
Degradation of beta-catenin by the destruction complex | 81 | 5.56e-09 | -0.374000 | 9.23e-08 |
Pentose phosphate pathway | 12 | 2.50e-02 | -0.374000 | 4.62e-02 |
mRNA decay by 5’ to 3’ exoribonuclease | 15 | 1.22e-02 | -0.374000 | 2.53e-02 |
Platelet sensitization by LDL | 17 | 7.65e-03 | -0.373000 | 1.71e-02 |
Signaling by NTRK2 (TRKB) | 25 | 1.29e-03 | -0.372000 | 3.86e-03 |
Signaling by ALK fusions and activated point mutants | 51 | 4.54e-06 | -0.371000 | 3.96e-05 |
Signaling by ALK in cancer | 51 | 4.54e-06 | -0.371000 | 3.96e-05 |
Abortive elongation of HIV-1 transcript in the absence of Tat | 23 | 2.08e-03 | -0.371000 | 5.75e-03 |
CREB1 phosphorylation through the activation of Adenylate Cyclase | 11 | 3.33e-02 | -0.370000 | 5.84e-02 |
Formation of the beta-catenin:TCF transactivating complex | 32 | 2.85e-04 | -0.370000 | 1.08e-03 |
PI-3K cascade:FGFR3 | 17 | 8.24e-03 | -0.370000 | 1.82e-02 |
Downstream signaling of activated FGFR3 | 24 | 1.76e-03 | -0.369000 | 5.07e-03 |
Signaling by NOTCH1 | 70 | 1.03e-07 | -0.368000 | 1.33e-06 |
Rev-mediated nuclear export of HIV RNA | 33 | 2.59e-04 | -0.367000 | 1.00e-03 |
Defective pyroptosis | 11 | 3.49e-02 | -0.367000 | 6.09e-02 |
FOXO-mediated transcription of cell death genes | 15 | 1.38e-02 | -0.367000 | 2.83e-02 |
RNA Polymerase III Transcription Initiation | 36 | 1.40e-04 | -0.367000 | 6.04e-04 |
TRAF6 mediated NF-kB activation | 24 | 1.90e-03 | -0.366000 | 5.40e-03 |
Telomere C-strand synthesis initiation | 11 | 3.58e-02 | -0.365000 | 6.21e-02 |
Nitric oxide stimulates guanylate cyclase | 22 | 3.10e-03 | -0.364000 | 7.98e-03 |
Apoptotic cleavage of cell adhesion proteins | 11 | 3.68e-02 | -0.364000 | 6.34e-02 |
Diseases of DNA repair | 49 | 1.09e-05 | -0.363000 | 7.66e-05 |
SCF(Skp2)-mediated degradation of p27/p21 | 58 | 1.73e-06 | -0.363000 | 1.72e-05 |
RND3 GTPase cycle | 41 | 5.86e-05 | -0.362000 | 2.98e-04 |
Export of Viral Ribonucleoproteins from Nucleus | 31 | 4.84e-04 | -0.362000 | 1.68e-03 |
Initial triggering of complement | 21 | 4.10e-03 | 0.362000 | 1.00e-02 |
Downstream signal transduction | 29 | 7.48e-04 | -0.362000 | 2.39e-03 |
Condensation of Prometaphase Chromosomes | 11 | 3.79e-02 | -0.361000 | 6.48e-02 |
ZBP1(DAI) mediated induction of type I IFNs | 20 | 5.21e-03 | -0.361000 | 1.22e-02 |
Digestion of dietary carbohydrate | 10 | 4.85e-02 | 0.360000 | 7.98e-02 |
tRNA processing in the nucleus | 55 | 3.83e-06 | -0.360000 | 3.44e-05 |
Formation of HIV elongation complex in the absence of HIV Tat | 40 | 8.22e-05 | -0.360000 | 3.89e-04 |
Translesion synthesis by POLI | 17 | 1.03e-02 | -0.359000 | 2.19e-02 |
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | 10 | 4.92e-02 | -0.359000 | 8.07e-02 |
Cell-extracellular matrix interactions | 14 | 2.00e-02 | -0.359000 | 3.81e-02 |
Signaling by NTRK1 (TRKA) | 114 | 3.46e-11 | -0.359000 | 8.38e-10 |
Defective Intrinsic Pathway for Apoptosis | 25 | 1.91e-03 | -0.358000 | 5.42e-03 |
Defects in cobalamin (B12) metabolism | 12 | 3.17e-02 | -0.358000 | 5.59e-02 |
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 54 | 5.42e-06 | -0.358000 | 4.50e-05 |
Constitutive Signaling by NOTCH1 PEST Domain Mutants | 54 | 5.42e-06 | -0.358000 | 4.50e-05 |
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 54 | 5.42e-06 | -0.358000 | 4.50e-05 |
Signaling by NOTCH1 PEST Domain Mutants in Cancer | 54 | 5.42e-06 | -0.358000 | 4.50e-05 |
Signaling by NOTCH1 in Cancer | 54 | 5.42e-06 | -0.358000 | 4.50e-05 |
Signaling by NOTCH4 | 79 | 4.00e-08 | -0.357000 | 5.83e-07 |
Transport of Ribonucleoproteins into the Host Nucleus | 30 | 7.66e-04 | -0.355000 | 2.43e-03 |
NEP/NS2 Interacts with the Cellular Export Machinery | 30 | 7.90e-04 | -0.354000 | 2.49e-03 |
Transport of the SLBP Dependant Mature mRNA | 34 | 3.63e-04 | -0.353000 | 1.33e-03 |
Activation of the AP-1 family of transcription factors | 10 | 5.31e-02 | -0.353000 | 8.53e-02 |
Defects in vitamin and cofactor metabolism | 20 | 6.26e-03 | -0.353000 | 1.43e-02 |
Norepinephrine Neurotransmitter Release Cycle | 16 | 1.45e-02 | -0.353000 | 2.94e-02 |
MAPK targets/ Nuclear events mediated by MAP kinases | 29 | 1.01e-03 | -0.353000 | 3.10e-03 |
HIV Transcription Initiation | 43 | 6.27e-05 | -0.353000 | 3.10e-04 |
RNA Polymerase II HIV Promoter Escape | 43 | 6.27e-05 | -0.353000 | 3.10e-04 |
RNA Polymerase II Promoter Escape | 43 | 6.27e-05 | -0.353000 | 3.10e-04 |
RNA Polymerase II Transcription Initiation | 43 | 6.27e-05 | -0.353000 | 3.10e-04 |
RNA Polymerase II Transcription Initiation And Promoter Clearance | 43 | 6.27e-05 | -0.353000 | 3.10e-04 |
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 43 | 6.27e-05 | -0.353000 | 3.10e-04 |
Translocation of SLC2A4 (GLUT4) to the plasma membrane | 51 | 1.37e-05 | -0.352000 | 9.19e-05 |
Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | 11 | 4.34e-02 | -0.352000 | 7.29e-02 |
BMAL1:CLOCK,NPAS2 activates circadian gene expression | 27 | 1.60e-03 | -0.351000 | 4.67e-03 |
Heme biosynthesis | 13 | 2.87e-02 | -0.350000 | 5.15e-02 |
Mitotic Prometaphase | 175 | 1.32e-15 | -0.350000 | 5.47e-14 |
Translation | 263 | 1.38e-22 | -0.350000 | 8.81e-21 |
Constitutive Signaling by NOTCH1 HD Domain Mutants | 15 | 1.94e-02 | -0.349000 | 3.73e-02 |
Signaling by NOTCH1 HD Domain Mutants in Cancer | 15 | 1.94e-02 | -0.349000 | 3.73e-02 |
RND2 GTPase cycle | 42 | 9.34e-05 | -0.348000 | 4.31e-04 |
Formation of the Early Elongation Complex | 32 | 6.49e-04 | -0.348000 | 2.12e-03 |
Formation of the HIV-1 Early Elongation Complex | 32 | 6.49e-04 | -0.348000 | 2.12e-03 |
Interleukin-6 signaling | 11 | 4.55e-02 | -0.348000 | 7.59e-02 |
Metabolism of cofactors | 19 | 8.63e-03 | -0.348000 | 1.89e-02 |
Transcriptional regulation by RUNX2 | 116 | 1.01e-10 | -0.347000 | 2.06e-09 |
HIV elongation arrest and recovery | 29 | 1.22e-03 | -0.347000 | 3.71e-03 |
Pausing and recovery of HIV elongation | 29 | 1.22e-03 | -0.347000 | 3.71e-03 |
VxPx cargo-targeting to cilium | 20 | 7.30e-03 | -0.346000 | 1.64e-02 |
Formation of HIV-1 elongation complex containing HIV-1 Tat | 38 | 2.19e-04 | -0.346000 | 8.61e-04 |
HIV Transcription Elongation | 38 | 2.19e-04 | -0.346000 | 8.61e-04 |
Tat-mediated elongation of the HIV-1 transcript | 38 | 2.19e-04 | -0.346000 | 8.61e-04 |
NOTCH2 Activation and Transmission of Signal to the Nucleus | 22 | 4.92e-03 | -0.346000 | 1.16e-02 |
Transcriptional regulation by small RNAs | 46 | 4.82e-05 | -0.346000 | 2.51e-04 |
HDR through Single Strand Annealing (SSA) | 36 | 3.24e-04 | -0.346000 | 1.21e-03 |
Interactions of Rev with host cellular proteins | 35 | 3.98e-04 | -0.346000 | 1.43e-03 |
Signaling by Activin | 15 | 2.06e-02 | -0.345000 | 3.90e-02 |
Negative regulation of NOTCH4 signaling | 52 | 1.68e-05 | -0.345000 | 1.08e-04 |
EPHB-mediated forward signaling | 34 | 5.08e-04 | -0.344000 | 1.75e-03 |
Activation of AMPK downstream of NMDARs | 10 | 5.93e-02 | -0.344000 | 9.40e-02 |
Translesion synthesis by REV1 | 16 | 1.72e-02 | -0.344000 | 3.37e-02 |
Cyclin E associated events during G1/S transition | 81 | 8.66e-08 | -0.344000 | 1.16e-06 |
CaMK IV-mediated phosphorylation of CREB | 10 | 5.99e-02 | -0.344000 | 9.44e-02 |
Mitotic Spindle Checkpoint | 106 | 9.64e-10 | -0.343000 | 1.78e-08 |
Cyclin A:Cdk2-associated events at S phase entry | 83 | 6.43e-08 | -0.343000 | 8.77e-07 |
Downstream signaling of activated FGFR2 | 29 | 1.38e-03 | -0.343000 | 4.13e-03 |
G0 and Early G1 | 27 | 2.04e-03 | -0.343000 | 5.65e-03 |
RNA polymerase II transcribes snRNA genes | 77 | 2.05e-07 | -0.342000 | 2.45e-06 |
RNA Polymerase III Transcription Initiation From Type 3 Promoter | 28 | 1.76e-03 | -0.341000 | 5.07e-03 |
Regulation of IFNG signaling | 14 | 2.71e-02 | -0.341000 | 4.93e-02 |
TP53 Regulates Transcription of DNA Repair Genes | 57 | 8.77e-06 | -0.340000 | 6.53e-05 |
Asymmetric localization of PCP proteins | 62 | 3.56e-06 | -0.340000 | 3.22e-05 |
Signaling by FGFR4 in disease | 11 | 5.09e-02 | -0.340000 | 8.29e-02 |
Activation of RAC1 | 11 | 5.09e-02 | -0.340000 | 8.29e-02 |
Creation of C4 and C2 activators | 14 | 2.79e-02 | 0.339000 | 5.03e-02 |
Deposition of new CENPA-containing nucleosomes at the centromere | 26 | 2.76e-03 | -0.339000 | 7.25e-03 |
Nucleosome assembly | 26 | 2.76e-03 | -0.339000 | 7.25e-03 |
Mitochondrial protein import | 54 | 1.64e-05 | -0.339000 | 1.07e-04 |
Transport of the SLBP independent Mature mRNA | 33 | 7.55e-04 | -0.339000 | 2.40e-03 |
Transcription of the HIV genome | 62 | 3.96e-06 | -0.339000 | 3.54e-05 |
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 37 | 3.71e-04 | -0.338000 | 1.35e-03 |
GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | 50 | 3.53e-05 | -0.338000 | 1.96e-04 |
Presynaptic nicotinic acetylcholine receptors | 12 | 4.28e-02 | 0.338000 | 7.21e-02 |
Signaling by FGFR3 in disease | 21 | 7.51e-03 | -0.337000 | 1.68e-02 |
Formation of RNA Pol II elongation complex | 53 | 2.20e-05 | -0.337000 | 1.34e-04 |
RNA Polymerase II Transcription Elongation | 53 | 2.20e-05 | -0.337000 | 1.34e-04 |
Impaired BRCA2 binding to RAD51 | 33 | 8.16e-04 | -0.337000 | 2.57e-03 |
Estrogen-dependent gene expression | 91 | 2.87e-08 | -0.336000 | 4.30e-07 |
Separation of Sister Chromatids | 161 | 1.68e-13 | -0.336000 | 5.35e-12 |
Phospholipase C-mediated cascade; FGFR4 | 14 | 2.94e-02 | -0.336000 | 5.26e-02 |
TNFR1-induced proapoptotic signaling | 13 | 3.58e-02 | -0.336000 | 6.21e-02 |
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 44 | 1.15e-04 | -0.336000 | 5.11e-04 |
Transcriptional Regulation by MECP2 | 60 | 6.72e-06 | -0.336000 | 5.15e-05 |
PI-3K cascade:FGFR2 | 22 | 6.40e-03 | -0.336000 | 1.45e-02 |
TCF dependent signaling in response to WNT | 168 | 5.59e-14 | -0.336000 | 1.86e-12 |
Polo-like kinase mediated events | 16 | 2.01e-02 | -0.336000 | 3.82e-02 |
Erythrocytes take up carbon dioxide and release oxygen | 12 | 4.42e-02 | -0.335000 | 7.39e-02 |
O2/CO2 exchange in erythrocytes | 12 | 4.42e-02 | -0.335000 | 7.39e-02 |
Signaling by NTRKs | 133 | 2.34e-11 | -0.335000 | 5.77e-10 |
G1/S Transition | 126 | 8.55e-11 | -0.334000 | 1.81e-09 |
NOTCH1 Intracellular Domain Regulates Transcription | 44 | 1.23e-04 | -0.334000 | 5.45e-04 |
Transcriptional regulation of pluripotent stem cells | 30 | 1.53e-03 | -0.334000 | 4.51e-03 |
Downregulation of SMAD2/3:SMAD4 transcriptional activity | 26 | 3.21e-03 | -0.334000 | 8.20e-03 |
Ca2+ pathway | 62 | 5.46e-06 | -0.334000 | 4.51e-05 |
MET activates RAP1 and RAC1 | 11 | 5.54e-02 | -0.333000 | 8.86e-02 |
Activation of ATR in response to replication stress | 37 | 4.55e-04 | -0.333000 | 1.59e-03 |
NRIF signals cell death from the nucleus | 16 | 2.11e-02 | -0.333000 | 3.99e-02 |
Phase 0 - rapid depolarisation | 31 | 1.47e-03 | -0.330000 | 4.34e-03 |
Signaling by Hippo | 19 | 1.29e-02 | -0.330000 | 2.65e-02 |
RIP-mediated NFkB activation via ZBP1 | 16 | 2.25e-02 | -0.329000 | 4.20e-02 |
Mitochondrial translation | 93 | 4.20e-08 | -0.329000 | 6.05e-07 |
Regulation of TP53 Activity through Association with Co-factors | 14 | 3.34e-02 | -0.328000 | 5.86e-02 |
LDL clearance | 19 | 1.33e-02 | -0.328000 | 2.73e-02 |
Mitochondrial translation initiation | 87 | 1.21e-07 | -0.328000 | 1.51e-06 |
Unblocking of NMDA receptors, glutamate binding and activation | 19 | 1.33e-02 | -0.328000 | 2.73e-02 |
Pausing and recovery of Tat-mediated HIV elongation | 27 | 3.25e-03 | -0.327000 | 8.24e-03 |
Tat-mediated HIV elongation arrest and recovery | 27 | 3.25e-03 | -0.327000 | 8.24e-03 |
XBP1(S) activates chaperone genes | 48 | 9.28e-05 | -0.326000 | 4.31e-04 |
Disassembly of the destruction complex and recruitment of AXIN to the membrane | 30 | 2.00e-03 | -0.326000 | 5.64e-03 |
Retrograde neurotrophin signalling | 14 | 3.48e-02 | -0.326000 | 6.07e-02 |
NOTCH4 Intracellular Domain Regulates Transcription | 19 | 1.39e-02 | -0.326000 | 2.84e-02 |
RNA Polymerase II Pre-transcription Events | 73 | 1.49e-06 | -0.326000 | 1.52e-05 |
Dual incision in TC-NER | 63 | 7.85e-06 | -0.325000 | 5.91e-05 |
RHOC GTPase cycle | 69 | 2.97e-06 | -0.325000 | 2.74e-05 |
Defective B4GALT7 causes EDS, progeroid type | 17 | 2.03e-02 | -0.325000 | 3.86e-02 |
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 13 | 4.26e-02 | -0.325000 | 7.19e-02 |
Mitotic G1 phase and G1/S transition | 144 | 1.70e-11 | -0.324000 | 4.34e-10 |
Mitochondrial translation termination | 87 | 1.66e-07 | -0.324000 | 2.02e-06 |
Degradation of AXIN | 53 | 4.48e-05 | -0.324000 | 2.36e-04 |
Activation of SMO | 17 | 2.09e-02 | -0.324000 | 3.94e-02 |
Incretin synthesis, secretion, and inactivation | 23 | 7.25e-03 | -0.323000 | 1.63e-02 |
VEGFR2 mediated vascular permeability | 26 | 4.36e-03 | -0.323000 | 1.06e-02 |
Retrograde transport at the Trans-Golgi-Network | 47 | 1.28e-04 | -0.323000 | 5.64e-04 |
Anchoring of the basal body to the plasma membrane | 92 | 8.92e-08 | -0.322000 | 1.18e-06 |
HCMV Early Events | 55 | 3.54e-05 | -0.322000 | 1.96e-04 |
Telomere C-strand (Lagging Strand) Synthesis | 32 | 1.62e-03 | -0.322000 | 4.73e-03 |
Activated NOTCH1 Transmits Signal to the Nucleus | 31 | 1.94e-03 | -0.322000 | 5.46e-03 |
Hedgehog ligand biogenesis | 63 | 1.02e-05 | -0.321000 | 7.30e-05 |
Regulation of PTEN stability and activity | 66 | 6.34e-06 | -0.321000 | 4.95e-05 |
Cell Cycle Checkpoints | 248 | 2.86e-18 | -0.321000 | 1.41e-16 |
Defective homologous recombination repair (HRR) due to BRCA2 loss of function | 39 | 5.24e-04 | -0.321000 | 1.79e-03 |
Diseases of DNA Double-Strand Break Repair | 39 | 5.24e-04 | -0.321000 | 1.79e-03 |
Mitochondrial iron-sulfur cluster biogenesis | 12 | 5.43e-02 | -0.321000 | 8.71e-02 |
G1/S-Specific Transcription | 28 | 3.31e-03 | -0.321000 | 8.35e-03 |
FRS-mediated FGFR4 signaling | 21 | 1.10e-02 | -0.320000 | 2.32e-02 |
Diseases of programmed cell death | 41 | 3.84e-04 | -0.320000 | 1.39e-03 |
Presynaptic phase of homologous DNA pairing and strand exchange | 38 | 6.39e-04 | -0.320000 | 2.10e-03 |
Mitotic Telophase/Cytokinesis | 10 | 7.97e-02 | -0.320000 | 1.19e-01 |
Degradation of cysteine and homocysteine | 14 | 3.82e-02 | -0.320000 | 6.52e-02 |
Metabolism of polyamines | 55 | 4.10e-05 | -0.320000 | 2.20e-04 |
RUNX1 regulates transcription of genes involved in differentiation of HSCs | 68 | 5.11e-06 | -0.320000 | 4.39e-05 |
Cargo trafficking to the periciliary membrane | 49 | 1.08e-04 | -0.320000 | 4.89e-04 |
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 50 | 9.22e-05 | -0.319000 | 4.30e-04 |
p53-Independent DNA Damage Response | 50 | 9.22e-05 | -0.319000 | 4.30e-04 |
p53-Independent G1/S DNA damage checkpoint | 50 | 9.22e-05 | -0.319000 | 4.30e-04 |
SUMOylation of DNA replication proteins | 44 | 2.49e-04 | -0.319000 | 9.62e-04 |
Diseases of signal transduction by growth factor receptors and second messengers | 410 | 1.43e-28 | -0.318000 | 1.29e-26 |
Regulation of RAS by GAPs | 66 | 7.69e-06 | -0.318000 | 5.82e-05 |
Transcriptional regulation by RUNX3 | 93 | 1.12e-07 | -0.318000 | 1.42e-06 |
RORA activates gene expression | 17 | 2.33e-02 | -0.318000 | 4.33e-02 |
Chromosome Maintenance | 86 | 3.48e-07 | -0.318000 | 3.91e-06 |
Host Interactions of HIV factors | 122 | 1.33e-09 | -0.317000 | 2.43e-08 |
Interleukin-35 Signalling | 12 | 5.72e-02 | -0.317000 | 9.09e-02 |
Cap-dependent Translation Initiation | 112 | 6.67e-09 | -0.317000 | 1.07e-07 |
Eukaryotic Translation Initiation | 112 | 6.67e-09 | -0.317000 | 1.07e-07 |
Signaling by WNT | 263 | 9.47e-19 | -0.316000 | 4.99e-17 |
Beta-catenin independent WNT signaling | 144 | 5.70e-11 | -0.316000 | 1.28e-09 |
EPH-Ephrin signaling | 90 | 2.23e-07 | -0.316000 | 2.62e-06 |
Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | 20 | 1.45e-02 | -0.316000 | 2.94e-02 |
Ubiquitin-dependent degradation of Cyclin D | 50 | 1.12e-04 | -0.316000 | 5.02e-04 |
Loss of Nlp from mitotic centrosomes | 65 | 1.07e-05 | -0.316000 | 7.57e-05 |
Loss of proteins required for interphase microtubule organization from the centrosome | 65 | 1.07e-05 | -0.316000 | 7.57e-05 |
Activation of NMDA receptors and postsynaptic events | 69 | 5.99e-06 | -0.315000 | 4.77e-05 |
Transcriptional regulation of white adipocyte differentiation | 81 | 9.66e-07 | -0.315000 | 1.01e-05 |
HS-GAG degradation | 18 | 2.08e-02 | -0.315000 | 3.94e-02 |
PCP/CE pathway | 90 | 2.46e-07 | -0.314000 | 2.83e-06 |
Golgi Associated Vesicle Biogenesis | 51 | 1.01e-04 | -0.314000 | 4.62e-04 |
VEGFR2 mediated cell proliferation | 19 | 1.76e-02 | -0.314000 | 3.43e-02 |
Mitochondrial translation elongation | 87 | 3.95e-07 | -0.314000 | 4.34e-06 |
HIV Life Cycle | 139 | 1.54e-10 | -0.314000 | 3.05e-09 |
Nuclear Pore Complex (NPC) Disassembly | 34 | 1.53e-03 | -0.314000 | 4.51e-03 |
GLI3 is processed to GLI3R by the proteasome | 58 | 3.55e-05 | -0.314000 | 1.97e-04 |
DAG and IP3 signaling | 39 | 7.00e-04 | -0.314000 | 2.25e-03 |
Defective B3GAT3 causes JDSSDHD | 17 | 2.52e-02 | -0.313000 | 4.64e-02 |
Metabolism of nitric oxide: NOS3 activation and regulation | 15 | 3.55e-02 | -0.313000 | 6.17e-02 |
Regulation of RUNX2 expression and activity | 71 | 4.87e-06 | -0.313000 | 4.23e-05 |
Signaling by FGFR in disease | 61 | 2.29e-05 | -0.313000 | 1.37e-04 |
Regulation of ornithine decarboxylase (ODC) | 49 | 1.48e-04 | -0.313000 | 6.24e-04 |
DNA Damage Bypass | 46 | 2.42e-04 | -0.313000 | 9.43e-04 |
Keratinization | 214 | 3.10e-15 | 0.312000 | 1.25e-13 |
TNFR1-induced NFkappaB signaling pathway | 22 | 1.12e-02 | -0.312000 | 2.37e-02 |
SUMOylation of SUMOylation proteins | 33 | 1.91e-03 | -0.312000 | 5.42e-03 |
Cilium Assembly | 174 | 1.17e-12 | -0.312000 | 3.38e-11 |
B-WICH complex positively regulates rRNA expression | 29 | 3.63e-03 | -0.312000 | 8.99e-03 |
MAPK3 (ERK1) activation | 10 | 8.75e-02 | -0.312000 | 1.29e-01 |
tRNA processing | 98 | 9.44e-08 | -0.312000 | 1.23e-06 |
Intraflagellar transport | 36 | 1.23e-03 | -0.311000 | 3.73e-03 |
Translocation of ZAP-70 to Immunological synapse | 17 | 2.65e-02 | 0.311000 | 4.83e-02 |
Homologous DNA Pairing and Strand Exchange | 41 | 5.73e-04 | -0.311000 | 1.93e-03 |
Activated NTRK2 signals through FRS2 and FRS3 | 11 | 7.43e-02 | -0.311000 | 1.13e-01 |
SUMOylation of transcription factors | 20 | 1.63e-02 | -0.310000 | 3.24e-02 |
Hh mutants abrogate ligand secretion | 57 | 5.10e-05 | -0.310000 | 2.63e-04 |
Regulation of expression of SLITs and ROBOs | 159 | 1.48e-11 | -0.310000 | 3.83e-10 |
RHO GTPases activate CIT | 19 | 1.94e-02 | -0.310000 | 3.73e-02 |
G2/M DNA damage checkpoint | 58 | 4.44e-05 | -0.310000 | 2.35e-04 |
Regulation of Apoptosis | 51 | 1.29e-04 | -0.310000 | 5.64e-04 |
Metabolism of Angiotensinogen to Angiotensins | 15 | 3.78e-02 | 0.310000 | 6.48e-02 |
Telomere Maintenance | 62 | 2.45e-05 | -0.310000 | 1.45e-04 |
SHC-mediated cascade:FGFR4 | 19 | 1.94e-02 | -0.310000 | 3.73e-02 |
Constitutive Signaling by AKT1 E17K in Cancer | 25 | 7.47e-03 | -0.309000 | 1.68e-02 |
Regulation of pyruvate dehydrogenase (PDH) complex | 14 | 4.53e-02 | -0.309000 | 7.57e-02 |
Recognition of DNA damage by PCNA-containing replication complex | 29 | 3.98e-03 | -0.309000 | 9.78e-03 |
Dermatan sulfate biosynthesis | 10 | 9.08e-02 | -0.309000 | 1.33e-01 |
Nervous system development | 527 | 4.56e-34 | -0.309000 | 6.97e-32 |
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | 30 | 3.42e-03 | -0.309000 | 8.50e-03 |
Regulation of Glucokinase by Glucokinase Regulatory Protein | 30 | 3.42e-03 | -0.309000 | 8.50e-03 |
Activation of BH3-only proteins | 30 | 3.49e-03 | -0.308000 | 8.65e-03 |
CLEC7A (Dectin-1) induces NFAT activation | 11 | 7.70e-02 | -0.308000 | 1.16e-01 |
Purine salvage | 12 | 6.52e-02 | -0.307000 | 1.01e-01 |
Negative epigenetic regulation of rRNA expression | 45 | 3.59e-04 | -0.307000 | 1.32e-03 |
SRP-dependent cotranslational protein targeting to membrane | 105 | 5.27e-08 | -0.307000 | 7.25e-07 |
Signaling by ROBO receptors | 203 | 4.27e-14 | -0.307000 | 1.52e-12 |
Base Excision Repair | 45 | 3.66e-04 | -0.307000 | 1.34e-03 |
FGFR2c ligand binding and activation | 12 | 6.58e-02 | -0.307000 | 1.02e-01 |
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | 62 | 3.00e-05 | -0.306000 | 1.74e-04 |
Organelle biogenesis and maintenance | 243 | 1.79e-16 | -0.306000 | 7.80e-15 |
SARS-CoV-2 modulates autophagy | 11 | 7.89e-02 | -0.306000 | 1.18e-01 |
HIV Infection | 216 | 8.68e-15 | -0.306000 | 3.40e-13 |
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | 12 | 6.66e-02 | -0.306000 | 1.03e-01 |
RHOV GTPase cycle | 36 | 1.50e-03 | -0.306000 | 4.44e-03 |
RNA Polymerase I Promoter Escape | 28 | 5.11e-03 | -0.306000 | 1.20e-02 |
FGFR4 ligand binding and activation | 13 | 5.64e-02 | -0.305000 | 8.99e-02 |
RNA Polymerase II Transcription Termination | 62 | 3.18e-05 | -0.305000 | 1.82e-04 |
Syndecan interactions | 19 | 2.12e-02 | -0.305000 | 3.99e-02 |
Axon guidance | 503 | 6.18e-32 | -0.305000 | 7.86e-30 |
IRE1alpha activates chaperones | 50 | 1.88e-04 | -0.305000 | 7.68e-04 |
Biotin transport and metabolism | 10 | 9.48e-02 | -0.305000 | 1.38e-01 |
Mitochondrial Fatty Acid Beta-Oxidation | 35 | 1.79e-03 | -0.305000 | 5.14e-03 |
Transcriptional regulation of granulopoiesis | 31 | 3.29e-03 | -0.305000 | 8.33e-03 |
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 108 | 4.33e-08 | -0.305000 | 6.12e-07 |
Nonsense-Mediated Decay (NMD) | 108 | 4.33e-08 | -0.305000 | 6.12e-07 |
Response of EIF2AK1 (HRI) to heme deficiency | 14 | 4.83e-02 | -0.305000 | 7.95e-02 |
Ub-specific processing proteases | 157 | 4.21e-11 | -0.305000 | 1.00e-09 |
Ephrin signaling | 17 | 2.96e-02 | -0.305000 | 5.28e-02 |
FGFRL1 modulation of FGFR1 signaling | 13 | 5.71e-02 | -0.305000 | 9.09e-02 |
G1/S DNA Damage Checkpoints | 66 | 1.85e-05 | -0.305000 | 1.17e-04 |
Neurotransmitter release cycle | 47 | 3.04e-04 | -0.304000 | 1.14e-03 |
Deactivation of the beta-catenin transactivating complex | 39 | 9.99e-04 | -0.304000 | 3.08e-03 |
BBSome-mediated cargo-targeting to cilium | 23 | 1.16e-02 | -0.304000 | 2.42e-02 |
Neurexins and neuroligins | 52 | 1.48e-04 | -0.304000 | 6.24e-04 |
Regulation of beta-cell development | 41 | 7.51e-04 | -0.304000 | 2.40e-03 |
Late Phase of HIV Life Cycle | 126 | 3.67e-09 | -0.304000 | 6.16e-08 |
Influenza Viral RNA Transcription and Replication | 129 | 2.45e-09 | -0.304000 | 4.31e-08 |
trans-Golgi Network Vesicle Budding | 67 | 1.72e-05 | -0.304000 | 1.10e-04 |
Highly calcium permeable postsynaptic nicotinic acetylcholine receptors | 11 | 8.17e-02 | 0.303000 | 1.22e-01 |
Assembly and cell surface presentation of NMDA receptors | 23 | 1.18e-02 | -0.303000 | 2.46e-02 |
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | 19 | 2.24e-02 | -0.302000 | 4.19e-02 |
Vpu mediated degradation of CD4 | 50 | 2.14e-04 | -0.302000 | 8.52e-04 |
DNA Double-Strand Break Repair | 130 | 2.51e-09 | -0.302000 | 4.36e-08 |
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | 74 | 6.83e-06 | -0.302000 | 5.19e-05 |
Antigen processing: Ubiquitination & Proteasome degradation | 293 | 4.77e-19 | -0.302000 | 2.60e-17 |
Nuclear import of Rev protein | 32 | 3.12e-03 | -0.302000 | 8.02e-03 |
Regulation of gene expression in beta cells | 21 | 1.66e-02 | -0.302000 | 3.29e-02 |
Influenza Infection | 148 | 2.24e-10 | -0.302000 | 4.33e-09 |
COPI-mediated anterograde transport | 83 | 1.98e-06 | -0.302000 | 1.92e-05 |
Regulation of RUNX3 expression and activity | 53 | 1.44e-04 | -0.302000 | 6.14e-04 |
Protein-protein interactions at synapses | 78 | 4.05e-06 | -0.302000 | 3.59e-05 |
Hh mutants are degraded by ERAD | 54 | 1.29e-04 | -0.301000 | 5.64e-04 |
Transport of Mature Transcript to Cytoplasm | 76 | 5.62e-06 | -0.301000 | 4.62e-05 |
G2/M Checkpoints | 129 | 3.67e-09 | -0.300000 | 6.16e-08 |
p53-Dependent G1 DNA Damage Response | 64 | 3.30e-05 | -0.300000 | 1.86e-04 |
p53-Dependent G1/S DNA damage checkpoint | 64 | 3.30e-05 | -0.300000 | 1.86e-04 |
Defective B3GALT6 causes EDSP2 and SEMDJL1 | 17 | 3.25e-02 | -0.299000 | 5.72e-02 |
Signaling by TGF-beta Receptor Complex | 86 | 1.56e-06 | -0.299000 | 1.59e-05 |
ESR-mediated signaling | 160 | 6.08e-11 | -0.299000 | 1.31e-09 |
Signaling by PDGF | 52 | 1.87e-04 | -0.299000 | 7.66e-04 |
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 32 | 3.38e-03 | -0.299000 | 8.47e-03 |
SUMOylation of RNA binding proteins | 45 | 5.13e-04 | -0.299000 | 1.76e-03 |
PI-3K cascade:FGFR1 | 21 | 1.76e-02 | -0.299000 | 3.43e-02 |
Regulation of FZD by ubiquitination | 21 | 1.77e-02 | -0.299000 | 3.44e-02 |
Energy dependent regulation of mTOR by LKB1-AMPK | 28 | 6.24e-03 | -0.298000 | 1.43e-02 |
Sensory processing of sound by inner hair cells of the cochlea | 62 | 4.84e-05 | -0.298000 | 2.51e-04 |
Processing of DNA double-strand break ends | 61 | 5.59e-05 | -0.298000 | 2.86e-04 |
AURKA Activation by TPX2 | 68 | 2.11e-05 | -0.298000 | 1.31e-04 |
Vif-mediated degradation of APOBEC3G | 50 | 2.66e-04 | -0.298000 | 1.02e-03 |
DNA Repair | 277 | 1.67e-17 | -0.297000 | 7.99e-16 |
GABA synthesis, release, reuptake and degradation | 19 | 2.51e-02 | -0.297000 | 4.63e-02 |
Interaction With Cumulus Cells And The Zona Pellucida | 11 | 8.86e-02 | 0.296000 | 1.30e-01 |
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | 13 | 6.47e-02 | -0.296000 | 1.01e-01 |
Signaling by NOTCH2 | 32 | 3.77e-03 | -0.296000 | 9.30e-03 |
Phospholipase C-mediated cascade; FGFR3 | 12 | 7.60e-02 | -0.296000 | 1.15e-01 |
FOXO-mediated transcription | 65 | 3.81e-05 | -0.295000 | 2.08e-04 |
Reactions specific to the complex N-glycan synthesis pathway | 10 | 1.06e-01 | -0.295000 | 1.52e-01 |
PRC2 methylates histones and DNA | 13 | 6.55e-02 | -0.295000 | 1.02e-01 |
Protein ubiquitination | 61 | 6.76e-05 | -0.295000 | 3.29e-04 |
HATs acetylate histones | 71 | 1.74e-05 | -0.295000 | 1.11e-04 |
TP53 Regulates Transcription of Cell Cycle Genes | 49 | 3.57e-04 | -0.295000 | 1.31e-03 |
Neddylation | 228 | 1.73e-14 | -0.294000 | 6.63e-13 |
MyD88 cascade initiated on plasma membrane | 79 | 6.06e-06 | -0.294000 | 4.77e-05 |
Toll Like Receptor 10 (TLR10) Cascade | 79 | 6.06e-06 | -0.294000 | 4.77e-05 |
Toll Like Receptor 5 (TLR5) Cascade | 79 | 6.06e-06 | -0.294000 | 4.77e-05 |
Long-term potentiation | 22 | 1.69e-02 | -0.294000 | 3.33e-02 |
Degradation of GLI1 by the proteasome | 58 | 1.07e-04 | -0.294000 | 4.87e-04 |
SCF-beta-TrCP mediated degradation of Emi1 | 53 | 2.16e-04 | -0.294000 | 8.57e-04 |
FRS-mediated FGFR3 signaling | 19 | 2.68e-02 | -0.293000 | 4.88e-02 |
Formation of the cornified envelope | 74 | 1.29e-05 | 0.293000 | 8.78e-05 |
GTP hydrolysis and joining of the 60S ribosomal subunit | 105 | 2.09e-07 | -0.293000 | 2.48e-06 |
Sensory processing of sound by outer hair cells of the cochlea | 49 | 3.87e-04 | -0.293000 | 1.40e-03 |
Defective CFTR causes cystic fibrosis | 59 | 9.90e-05 | -0.293000 | 4.54e-04 |
Receptor-type tyrosine-protein phosphatases | 16 | 4.27e-02 | -0.293000 | 7.20e-02 |
SUMOylation of chromatin organization proteins | 54 | 2.01e-04 | -0.292000 | 8.09e-04 |
RHOF GTPase cycle | 40 | 1.39e-03 | -0.292000 | 4.13e-03 |
Formation of the ternary complex, and subsequently, the 43S complex | 47 | 5.43e-04 | -0.291000 | 1.85e-03 |
Gap-filling DNA repair synthesis and ligation in TC-NER | 62 | 7.30e-05 | -0.291000 | 3.51e-04 |
Formation of a pool of free 40S subunits | 95 | 9.61e-07 | -0.291000 | 1.01e-05 |
Acetylcholine binding and downstream events | 14 | 5.98e-02 | 0.290000 | 9.43e-02 |
Postsynaptic nicotinic acetylcholine receptors | 14 | 5.98e-02 | 0.290000 | 9.43e-02 |
NS1 Mediated Effects on Host Pathways | 39 | 1.68e-03 | -0.290000 | 4.90e-03 |
Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 12 | 8.17e-02 | -0.290000 | 1.22e-01 |
Eukaryotic Translation Elongation | 88 | 2.50e-06 | -0.290000 | 2.34e-05 |
TBC/RABGAPs | 42 | 1.14e-03 | -0.290000 | 3.48e-03 |
ISG15 antiviral mechanism | 71 | 2.38e-05 | -0.290000 | 1.41e-04 |
RHO GTPase Effectors | 232 | 3.03e-14 | -0.289000 | 1.10e-12 |
Degradation of GLI2 by the proteasome | 58 | 1.41e-04 | -0.289000 | 6.06e-04 |
STAT5 activation downstream of FLT3 ITD mutants | 10 | 1.14e-01 | -0.289000 | 1.60e-01 |
Ethanol oxidation | 12 | 8.32e-02 | 0.289000 | 1.23e-01 |
Regulation of cholesterol biosynthesis by SREBP (SREBF) | 54 | 2.45e-04 | -0.288000 | 9.52e-04 |
Toll Like Receptor 3 (TLR3) Cascade | 88 | 2.90e-06 | -0.288000 | 2.69e-05 |
Negative regulation of MAPK pathway | 41 | 1.40e-03 | -0.288000 | 4.17e-03 |
Elevation of cytosolic Ca2+ levels | 16 | 4.60e-02 | -0.288000 | 7.66e-02 |
Signaling by KIT in disease | 20 | 2.57e-02 | -0.288000 | 4.71e-02 |
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | 20 | 2.57e-02 | -0.288000 | 4.71e-02 |
Orc1 removal from chromatin | 69 | 3.52e-05 | -0.288000 | 1.96e-04 |
DCC mediated attractive signaling | 14 | 6.22e-02 | -0.288000 | 9.74e-02 |
Signaling by BMP | 27 | 9.62e-03 | -0.288000 | 2.07e-02 |
Chromatin modifying enzymes | 185 | 1.41e-11 | -0.288000 | 3.72e-10 |
Chromatin organization | 185 | 1.41e-11 | -0.288000 | 3.72e-10 |
Mitochondrial biogenesis | 69 | 3.56e-05 | -0.288000 | 1.97e-04 |
Metabolism of non-coding RNA | 50 | 4.41e-04 | -0.287000 | 1.55e-03 |
snRNP Assembly | 50 | 4.41e-04 | -0.287000 | 1.55e-03 |
Phosphorylation of CD3 and TCR zeta chains | 20 | 2.62e-02 | 0.287000 | 4.78e-02 |
RAF activation | 33 | 4.30e-03 | -0.287000 | 1.05e-02 |
Resolution of Abasic Sites (AP sites) | 37 | 2.52e-03 | -0.287000 | 6.67e-03 |
Nuclear events mediated by NFE2L2 | 76 | 1.53e-05 | -0.287000 | 1.01e-04 |
Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 76 | 1.53e-05 | -0.287000 | 1.01e-04 |
Regulation of PLK1 Activity at G2/M Transition | 83 | 6.34e-06 | -0.286000 | 4.95e-05 |
Mitotic Metaphase and Anaphase | 222 | 1.81e-13 | -0.286000 | 5.66e-12 |
Regulation of activated PAK-2p34 by proteasome mediated degradation | 48 | 5.99e-04 | -0.286000 | 1.98e-03 |
Formation of TC-NER Pre-Incision Complex | 51 | 4.08e-04 | -0.286000 | 1.46e-03 |
Post NMDA receptor activation events | 58 | 1.64e-04 | -0.286000 | 6.83e-04 |
Recruitment of NuMA to mitotic centrosomes | 76 | 1.62e-05 | -0.286000 | 1.06e-04 |
Signaling by FGFR2 | 72 | 2.78e-05 | -0.285000 | 1.63e-04 |
Cellular response to hypoxia | 71 | 3.25e-05 | -0.285000 | 1.85e-04 |
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 94 | 1.77e-06 | -0.285000 | 1.75e-05 |
Cytosolic sensors of pathogen-associated DNA | 60 | 1.35e-04 | -0.285000 | 5.88e-04 |
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 55 | 2.60e-04 | -0.285000 | 1.00e-03 |
Antiviral mechanism by IFN-stimulated genes | 78 | 1.41e-05 | -0.284000 | 9.42e-05 |
E3 ubiquitin ligases ubiquitinate target proteins | 43 | 1.26e-03 | -0.284000 | 3.79e-03 |
PCNA-Dependent Long Patch Base Excision Repair | 21 | 2.42e-02 | -0.284000 | 4.48e-02 |
NoRC negatively regulates rRNA expression | 43 | 1.27e-03 | -0.284000 | 3.81e-03 |
Platelet homeostasis | 85 | 5.94e-06 | -0.284000 | 4.77e-05 |
Citric acid cycle (TCA cycle) | 21 | 2.42e-02 | -0.284000 | 4.49e-02 |
MyD88 dependent cascade initiated on endosome | 84 | 6.74e-06 | -0.284000 | 5.15e-05 |
Toll Like Receptor 7/8 (TLR7/8) Cascade | 84 | 6.74e-06 | -0.284000 | 5.15e-05 |
NCAM1 interactions | 36 | 3.19e-03 | -0.284000 | 8.15e-03 |
CD28 dependent PI3K/Akt signaling | 22 | 2.12e-02 | -0.284000 | 3.99e-02 |
RHOU GTPase cycle | 37 | 2.80e-03 | -0.284000 | 7.33e-03 |
Mitotic Anaphase | 221 | 3.33e-13 | -0.284000 | 1.01e-11 |
CaM pathway | 33 | 4.84e-03 | -0.283000 | 1.14e-02 |
Calmodulin induced events | 33 | 4.84e-03 | -0.283000 | 1.14e-02 |
Branched-chain amino acid catabolism | 20 | 2.87e-02 | -0.282000 | 5.15e-02 |
L13a-mediated translational silencing of Ceruloplasmin expression | 104 | 6.39e-07 | -0.282000 | 6.97e-06 |
Voltage gated Potassium channels | 42 | 1.55e-03 | -0.282000 | 4.54e-03 |
FCERI mediated NF-kB activation | 74 | 2.72e-05 | -0.282000 | 1.60e-04 |
Heparan sulfate/heparin (HS-GAG) metabolism | 49 | 6.40e-04 | -0.282000 | 2.10e-03 |
Regulation of MECP2 expression and activity | 30 | 7.54e-03 | -0.282000 | 1.69e-02 |
Interleukin-15 signaling | 13 | 7.86e-02 | -0.282000 | 1.18e-01 |
Signaling by TGFB family members | 114 | 2.01e-07 | -0.282000 | 2.42e-06 |
Ribosomal scanning and start codon recognition | 54 | 3.44e-04 | -0.281000 | 1.27e-03 |
HDACs deacetylate histones | 29 | 8.73e-03 | -0.281000 | 1.91e-02 |
Glutamate Neurotransmitter Release Cycle | 23 | 1.96e-02 | -0.281000 | 3.75e-02 |
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | 38 | 2.71e-03 | -0.281000 | 7.14e-03 |
Synthesis of substrates in N-glycan biosythesis | 60 | 1.66e-04 | -0.281000 | 6.87e-04 |
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 83 | 9.52e-06 | -0.281000 | 7.00e-05 |
mRNA 3’-end processing | 53 | 4.01e-04 | -0.281000 | 1.44e-03 |
Protein methylation | 16 | 5.17e-02 | -0.281000 | 8.37e-02 |
Glucuronidation | 25 | 1.50e-02 | 0.281000 | 3.02e-02 |
Regulation of signaling by CBL | 18 | 3.91e-02 | -0.281000 | 6.64e-02 |
Autodegradation of the E3 ubiquitin ligase COP1 | 50 | 5.93e-04 | -0.281000 | 1.97e-03 |
MyD88-independent TLR4 cascade | 92 | 3.29e-06 | -0.280000 | 3.00e-05 |
TRIF(TICAM1)-mediated TLR4 signaling | 92 | 3.29e-06 | -0.280000 | 3.00e-05 |
Centrosome maturation | 77 | 2.14e-05 | -0.280000 | 1.32e-04 |
Recruitment of mitotic centrosome proteins and complexes | 77 | 2.14e-05 | -0.280000 | 1.32e-04 |
Signaling by FLT3 ITD and TKD mutants | 16 | 5.25e-02 | -0.280000 | 8.46e-02 |
p75NTR signals via NF-kB | 15 | 6.05e-02 | -0.280000 | 9.53e-02 |
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 34 | 4.76e-03 | -0.280000 | 1.13e-02 |
Interleukin-1 signaling | 97 | 1.92e-06 | -0.280000 | 1.87e-05 |
Ketone body metabolism | 10 | 1.26e-01 | -0.279000 | 1.73e-01 |
Extension of Telomeres | 48 | 8.18e-04 | -0.279000 | 2.57e-03 |
G2/M Transition | 176 | 1.64e-10 | -0.279000 | 3.21e-09 |
TNF signaling | 40 | 2.27e-03 | -0.279000 | 6.13e-03 |
Extra-nuclear estrogen signaling | 73 | 3.76e-05 | -0.279000 | 2.06e-04 |
Response of EIF2AK4 (GCN2) to amino acid deficiency | 95 | 2.64e-06 | -0.279000 | 2.46e-05 |
Nuclear Envelope Breakdown | 50 | 6.50e-04 | -0.279000 | 2.12e-03 |
Mitotic G2-G2/M phases | 178 | 1.42e-10 | -0.278000 | 2.86e-09 |
Signaling by FGFR1 in disease | 37 | 3.38e-03 | -0.278000 | 8.47e-03 |
SHC-mediated cascade:FGFR3 | 17 | 4.71e-02 | -0.278000 | 7.80e-02 |
p75 NTR receptor-mediated signalling | 89 | 5.74e-06 | -0.278000 | 4.69e-05 |
FRS-mediated FGFR2 signaling | 24 | 1.84e-02 | -0.278000 | 3.56e-02 |
Hedgehog ‘off’ state | 97 | 2.23e-06 | -0.278000 | 2.12e-05 |
Regulation of KIT signaling | 16 | 5.45e-02 | -0.278000 | 8.72e-02 |
Deubiquitination | 230 | 3.75e-13 | -0.278000 | 1.10e-11 |
Sensory processing of sound | 69 | 6.66e-05 | -0.277000 | 3.27e-04 |
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 42 | 1.87e-03 | -0.277000 | 5.34e-03 |
Mitotic Prophase | 78 | 2.29e-05 | -0.277000 | 1.37e-04 |
Translesion synthesis by POLK | 17 | 4.80e-02 | -0.277000 | 7.92e-02 |
M Phase | 336 | 2.58e-18 | -0.276000 | 1.31e-16 |
Rap1 signalling | 16 | 5.56e-02 | -0.276000 | 8.87e-02 |
Glutamate and glutamine metabolism | 12 | 9.73e-02 | -0.276000 | 1.40e-01 |
Cell Cycle, Mitotic | 477 | 3.53e-25 | -0.276000 | 2.84e-23 |
CTLA4 inhibitory signaling | 21 | 2.84e-02 | -0.276000 | 5.12e-02 |
AUF1 (hnRNP D0) binds and destabilizes mRNA | 53 | 5.14e-04 | -0.276000 | 1.76e-03 |
Synthesis of IP3 and IP4 in the cytosol | 25 | 1.70e-02 | -0.276000 | 3.35e-02 |
mRNA Splicing - Major Pathway | 173 | 3.83e-10 | -0.276000 | 7.31e-09 |
The role of GTSE1 in G2/M progression after G2 checkpoint | 58 | 2.84e-04 | -0.275000 | 1.08e-03 |
Glycosphingolipid metabolism | 40 | 2.59e-03 | -0.275000 | 6.84e-03 |
Ras activation upon Ca2+ influx through NMDA receptor | 19 | 3.78e-02 | -0.275000 | 6.48e-02 |
Signaling by VEGF | 101 | 1.77e-06 | -0.275000 | 1.75e-05 |
Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | 38 | 3.38e-03 | -0.275000 | 8.47e-03 |
NOTCH3 Activation and Transmission of Signal to the Nucleus | 25 | 1.75e-02 | -0.274000 | 3.41e-02 |
Digestion and absorption | 26 | 1.55e-02 | 0.274000 | 3.09e-02 |
APC/C:Cdc20 mediated degradation of mitotic proteins | 74 | 4.52e-05 | -0.274000 | 2.38e-04 |
Translation initiation complex formation | 54 | 4.98e-04 | -0.274000 | 1.72e-03 |
UCH proteinases | 81 | 2.03e-05 | -0.274000 | 1.27e-04 |
RHOJ GTPase cycle | 51 | 7.16e-04 | -0.274000 | 2.29e-03 |
Eukaryotic Translation Termination | 87 | 1.02e-05 | -0.274000 | 7.30e-05 |
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 75 | 4.19e-05 | -0.273000 | 2.23e-04 |
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 53 | 5.76e-04 | -0.273000 | 1.94e-03 |
Phospholipase C-mediated cascade; FGFR2 | 17 | 5.11e-02 | -0.273000 | 8.30e-02 |
Homology Directed Repair | 100 | 2.32e-06 | -0.273000 | 2.19e-05 |
NF-kB is activated and signals survival | 12 | 1.01e-01 | -0.273000 | 1.46e-01 |
Viral mRNA Translation | 84 | 1.52e-05 | -0.273000 | 1.01e-04 |
Platelet calcium homeostasis | 27 | 1.42e-02 | -0.273000 | 2.88e-02 |
Elastic fibre formation | 41 | 2.53e-03 | -0.272000 | 6.68e-03 |
Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 71 | 7.14e-05 | -0.272000 | 3.44e-04 |
Opioid Signalling | 88 | 9.86e-06 | -0.272000 | 7.17e-05 |
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 89 | 8.91e-06 | -0.272000 | 6.58e-05 |
Degradation of DVL | 55 | 4.80e-04 | -0.272000 | 1.67e-03 |
APC/C-mediated degradation of cell cycle proteins | 86 | 1.28e-05 | -0.272000 | 8.76e-05 |
Regulation of mitotic cell cycle | 86 | 1.28e-05 | -0.272000 | 8.76e-05 |
HDR through MMEJ (alt-NHEJ) | 11 | 1.19e-01 | -0.272000 | 1.66e-01 |
Peptide chain elongation | 84 | 1.68e-05 | -0.271000 | 1.09e-04 |
G-protein mediated events | 52 | 7.10e-04 | -0.271000 | 2.28e-03 |
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | 72 | 6.83e-05 | -0.271000 | 3.31e-04 |
Netrin-1 signaling | 49 | 1.03e-03 | -0.271000 | 3.17e-03 |
Activation of NF-kappaB in B cells | 64 | 1.79e-04 | -0.271000 | 7.33e-04 |
TGF-beta receptor signaling activates SMADs | 45 | 1.69e-03 | -0.270000 | 4.91e-03 |
MyD88 deficiency (TLR2/4) | 16 | 6.12e-02 | 0.270000 | 9.61e-02 |
Kinesins | 42 | 2.45e-03 | -0.270000 | 6.56e-03 |
NIK–>noncanonical NF-kB signaling | 57 | 4.24e-04 | -0.270000 | 1.51e-03 |
Nucleotide Excision Repair | 107 | 1.40e-06 | -0.270000 | 1.45e-05 |
FGFR1 mutant receptor activation | 30 | 1.06e-02 | -0.270000 | 2.25e-02 |
Activation of the TFAP2 (AP-2) family of transcription factors | 11 | 1.22e-01 | -0.270000 | 1.69e-01 |
Meiotic recombination | 26 | 1.73e-02 | -0.269000 | 3.39e-02 |
Ca-dependent events | 35 | 5.79e-03 | -0.269000 | 1.34e-02 |
Processing of Capped Intron-Containing Pre-mRNA | 231 | 1.60e-12 | -0.269000 | 4.44e-11 |
Cell Cycle | 602 | 1.02e-29 | -0.269000 | 1.20e-27 |
Signaling by ERBB2 ECD mutants | 15 | 7.11e-02 | -0.269000 | 1.09e-01 |
Complement cascade | 56 | 4.94e-04 | 0.269000 | 1.71e-03 |
RHOB GTPase cycle | 66 | 1.57e-04 | -0.269000 | 6.57e-04 |
Regulation of APC/C activators between G1/S and early anaphase | 79 | 3.60e-05 | -0.269000 | 1.98e-04 |
Nonhomologous End-Joining (NHEJ) | 32 | 8.52e-03 | -0.269000 | 1.87e-02 |
S Phase | 157 | 6.12e-09 | -0.269000 | 1.00e-07 |
Downstream signaling events of B Cell Receptor (BCR) | 78 | 4.09e-05 | -0.268000 | 2.20e-04 |
Dual Incision in GG-NER | 39 | 3.70e-03 | -0.268000 | 9.16e-03 |
Termination of translesion DNA synthesis | 31 | 9.80e-03 | -0.268000 | 2.10e-02 |
MTOR signalling | 40 | 3.39e-03 | -0.268000 | 8.47e-03 |
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | 14 | 8.35e-02 | -0.267000 | 1.24e-01 |
Miscellaneous transport and binding events | 21 | 3.42e-02 | -0.267000 | 5.97e-02 |
RHOBTB1 GTPase cycle | 22 | 3.08e-02 | -0.266000 | 5.46e-02 |
Synthesis of active ubiquitin: roles of E1 and E2 enzymes | 27 | 1.68e-02 | -0.266000 | 3.32e-02 |
Regulation of TP53 Activity through Phosphorylation | 88 | 1.63e-05 | -0.266000 | 1.06e-04 |
ER to Golgi Anterograde Transport | 134 | 1.10e-07 | -0.265000 | 1.41e-06 |
Hormone ligand-binding receptors | 13 | 9.80e-02 | -0.265000 | 1.41e-01 |
Chemokine receptors bind chemokines | 56 | 6.04e-04 | 0.265000 | 1.99e-03 |
SUMO E3 ligases SUMOylate target proteins | 158 | 8.97e-09 | -0.265000 | 1.41e-07 |
SHC-mediated cascade:FGFR2 | 22 | 3.16e-02 | -0.265000 | 5.59e-02 |
Hedgehog ‘on’ state | 83 | 3.06e-05 | -0.265000 | 1.76e-04 |
Digestion | 21 | 3.58e-02 | 0.264000 | 6.21e-02 |
Interaction between L1 and Ankyrins | 28 | 1.54e-02 | -0.264000 | 3.07e-02 |
VEGFA-VEGFR2 Pathway | 93 | 1.04e-05 | -0.264000 | 7.40e-05 |
mRNA Splicing | 183 | 6.71e-10 | -0.264000 | 1.25e-08 |
Signaling by Rho GTPases, Miro GTPases and RHOBTB3 | 604 | 9.57e-29 | -0.264000 | 9.14e-27 |
Nucleotide biosynthesis | 14 | 8.75e-02 | -0.264000 | 1.29e-01 |
Selenocysteine synthesis | 87 | 2.11e-05 | -0.264000 | 1.31e-04 |
RNA Polymerase I Transcription Termination | 27 | 1.78e-02 | -0.263000 | 3.44e-02 |
MAPK6/MAPK4 signaling | 89 | 1.73e-05 | -0.263000 | 1.11e-04 |
COPI-dependent Golgi-to-ER retrograde traffic | 81 | 4.15e-05 | -0.263000 | 2.22e-04 |
Signaling by Leptin | 11 | 1.31e-01 | -0.263000 | 1.79e-01 |
RUNX3 regulates NOTCH signaling | 13 | 1.01e-01 | -0.263000 | 1.45e-01 |
Interleukin-10 signaling | 45 | 2.31e-03 | 0.262000 | 6.23e-03 |
Asparagine N-linked glycosylation | 278 | 4.74e-14 | -0.262000 | 1.61e-12 |
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 15 | 7.91e-02 | -0.262000 | 1.18e-01 |
Laminin interactions | 23 | 3.01e-02 | -0.261000 | 5.35e-02 |
Downstream signaling of activated FGFR1 | 31 | 1.19e-02 | -0.261000 | 2.46e-02 |
SUMOylation of ubiquitinylation proteins | 37 | 6.00e-03 | -0.261000 | 1.38e-02 |
Activation of gene expression by SREBF (SREBP) | 42 | 3.42e-03 | -0.261000 | 8.50e-03 |
DNA Replication Pre-Initiation | 97 | 8.85e-06 | -0.261000 | 6.57e-05 |
Transcriptional activation of mitochondrial biogenesis | 51 | 1.27e-03 | -0.261000 | 3.81e-03 |
Signaling by Rho GTPases | 590 | 1.92e-27 | -0.261000 | 1.63e-25 |
PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases | 14 | 9.14e-02 | -0.260000 | 1.33e-01 |
Regulation of Complement cascade | 45 | 2.51e-03 | 0.260000 | 6.66e-03 |
VLDLR internalisation and degradation | 16 | 7.19e-02 | -0.260000 | 1.10e-01 |
Synaptic adhesion-like molecules | 19 | 4.99e-02 | -0.260000 | 8.17e-02 |
Defective GALNT3 causes HFTC | 18 | 5.66e-02 | 0.259000 | 9.01e-02 |
Formation of Incision Complex in GG-NER | 40 | 4.51e-03 | -0.259000 | 1.08e-02 |
Signaling by NOTCH | 183 | 1.39e-09 | -0.259000 | 2.50e-08 |
HDR through Homologous Recombination (HRR) | 65 | 3.04e-04 | -0.259000 | 1.14e-03 |
Adrenaline,noradrenaline inhibits insulin secretion | 28 | 1.77e-02 | -0.259000 | 3.44e-02 |
Intra-Golgi and retrograde Golgi-to-ER traffic | 181 | 1.82e-09 | -0.259000 | 3.24e-08 |
Death Receptor Signalling | 129 | 3.77e-07 | -0.259000 | 4.18e-06 |
Interleukin-7 signaling | 21 | 4.01e-02 | -0.259000 | 6.80e-02 |
Lagging Strand Synthesis | 19 | 5.10e-02 | -0.259000 | 8.29e-02 |
Cytoprotection by HMOX1 | 58 | 6.56e-04 | -0.258000 | 2.14e-03 |
Signaling by FGFR | 85 | 3.86e-05 | -0.258000 | 2.10e-04 |
PECAM1 interactions | 12 | 1.22e-01 | -0.258000 | 1.69e-01 |
DSCAM interactions | 11 | 1.39e-01 | -0.258000 | 1.88e-01 |
Deadenylation-dependent mRNA decay | 56 | 8.54e-04 | -0.257000 | 2.66e-03 |
Metabolism of RNA | 638 | 8.36e-29 | -0.257000 | 8.51e-27 |
Formation of Senescence-Associated Heterochromatin Foci (SAHF) | 11 | 1.39e-01 | -0.257000 | 1.88e-01 |
Golgi-to-ER retrograde transport | 115 | 1.83e-06 | -0.257000 | 1.79e-05 |
Cell death signalling via NRAGE, NRIF and NADE | 69 | 2.21e-04 | -0.257000 | 8.68e-04 |
Class I MHC mediated antigen processing & presentation | 363 | 3.64e-17 | -0.257000 | 1.68e-15 |
Toll Like Receptor 9 (TLR9) Cascade | 88 | 3.12e-05 | -0.257000 | 1.79e-04 |
Heme signaling | 45 | 2.89e-03 | -0.257000 | 7.50e-03 |
DNA Replication | 125 | 7.24e-07 | -0.256000 | 7.73e-06 |
Assembly of the pre-replicative complex | 82 | 6.00e-05 | -0.256000 | 3.04e-04 |
AKT phosphorylates targets in the cytosol | 14 | 9.71e-02 | -0.256000 | 1.40e-01 |
FGFR3 mutant receptor activation | 11 | 1.42e-01 | -0.256000 | 1.91e-01 |
Signaling by activated point mutants of FGFR3 | 11 | 1.42e-01 | -0.256000 | 1.91e-01 |
SUMOylation of intracellular receptors | 29 | 1.71e-02 | -0.256000 | 3.35e-02 |
Regulation of TNFR1 signaling | 32 | 1.23e-02 | -0.256000 | 2.54e-02 |
SUMOylation of DNA damage response and repair proteins | 71 | 1.93e-04 | -0.256000 | 7.82e-04 |
Fc epsilon receptor (FCERI) signaling | 126 | 7.23e-07 | -0.255000 | 7.73e-06 |
Signaling by Hedgehog | 133 | 3.59e-07 | -0.255000 | 4.00e-06 |
RHOD GTPase cycle | 49 | 2.01e-03 | -0.255000 | 5.64e-03 |
Signaling by Erythropoietin | 25 | 2.76e-02 | -0.254000 | 5.00e-02 |
Oncogenic MAPK signaling | 76 | 1.25e-04 | -0.254000 | 5.53e-04 |
Prefoldin mediated transfer of substrate to CCT/TriC | 27 | 2.22e-02 | -0.254000 | 4.17e-02 |
Signaling by CSF3 (G-CSF) | 28 | 1.99e-02 | -0.254000 | 3.81e-02 |
Signalling to RAS | 20 | 4.93e-02 | -0.254000 | 8.08e-02 |
SUMOylation | 164 | 1.97e-08 | -0.254000 | 2.98e-07 |
MASTL Facilitates Mitotic Progression | 10 | 1.65e-01 | -0.254000 | 2.16e-01 |
Autodegradation of Cdh1 by Cdh1:APC/C | 62 | 5.65e-04 | -0.253000 | 1.91e-03 |
Signaling by Receptor Tyrosine Kinases | 492 | 5.55e-22 | -0.253000 | 3.26e-20 |
CDK-mediated phosphorylation and removal of Cdc6 | 71 | 2.27e-04 | -0.253000 | 8.86e-04 |
Transcriptional Regulation by TP53 | 346 | 5.78e-16 | -0.253000 | 2.45e-14 |
Cross-presentation of soluble exogenous antigens (endosomes) | 48 | 2.49e-03 | -0.252000 | 6.65e-03 |
Activation of the pre-replicative complex | 31 | 1.52e-02 | -0.252000 | 3.04e-02 |
WNT5A-dependent internalization of FZD4 | 15 | 9.12e-02 | -0.252000 | 1.33e-01 |
PI3K Cascade | 43 | 4.28e-03 | -0.252000 | 1.05e-02 |
Regulation of TP53 Expression and Degradation | 37 | 8.28e-03 | -0.251000 | 1.83e-02 |
Intrinsic Pathway for Apoptosis | 52 | 1.76e-03 | -0.251000 | 5.07e-03 |
Protein folding | 96 | 2.24e-05 | -0.250000 | 1.36e-04 |
Stabilization of p53 | 55 | 1.34e-03 | -0.250000 | 4.01e-03 |
Reduction of cytosolic Ca++ levels | 11 | 1.51e-01 | -0.250000 | 2.02e-01 |
Synthesis, secretion, and deacylation of Ghrelin | 19 | 5.94e-02 | -0.250000 | 9.40e-02 |
IGF1R signaling cascade | 51 | 2.03e-03 | -0.250000 | 5.65e-03 |
MAP kinase activation | 58 | 1.01e-03 | -0.250000 | 3.10e-03 |
Non-integrin membrane-ECM interactions | 40 | 6.32e-03 | -0.249000 | 1.44e-02 |
Circadian Clock | 69 | 3.38e-04 | -0.249000 | 1.25e-03 |
tRNA modification in the nucleus and cytosol | 38 | 7.80e-03 | -0.249000 | 1.73e-02 |
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 12 | 1.35e-01 | -0.249000 | 1.84e-01 |
DNA strand elongation | 31 | 1.65e-02 | -0.249000 | 3.26e-02 |
Signaling by NOTCH3 | 48 | 2.87e-03 | -0.249000 | 7.49e-03 |
Transcription of E2F targets under negative control by DREAM complex | 19 | 6.07e-02 | -0.248000 | 9.54e-02 |
Glycogen breakdown (glycogenolysis) | 12 | 1.36e-01 | -0.248000 | 1.85e-01 |
Adenylate cyclase inhibitory pathway | 14 | 1.08e-01 | -0.248000 | 1.53e-01 |
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 13 | 1.21e-01 | -0.248000 | 1.69e-01 |
Aspirin ADME | 44 | 4.38e-03 | 0.248000 | 1.06e-02 |
HCMV Infection | 79 | 1.36e-04 | -0.248000 | 5.92e-04 |
G alpha (z) signalling events | 48 | 2.93e-03 | -0.248000 | 7.60e-03 |
Dectin-2 family | 28 | 2.32e-02 | 0.248000 | 4.33e-02 |
L1CAM interactions | 92 | 4.00e-05 | -0.248000 | 2.17e-04 |
Regulation of TP53 Degradation | 36 | 1.01e-02 | -0.247000 | 2.17e-02 |
Calcitonin-like ligand receptors | 10 | 1.76e-01 | -0.247000 | 2.28e-01 |
Selenoamino acid metabolism | 103 | 1.47e-05 | -0.247000 | 9.81e-05 |
Transport of Mature mRNA derived from an Intron-Containing Transcript | 67 | 4.76e-04 | -0.247000 | 1.66e-03 |
Dissolution of Fibrin Clot | 13 | 1.24e-01 | 0.247000 | 1.71e-01 |
Activation of kainate receptors upon glutamate binding | 29 | 2.15e-02 | -0.247000 | 4.04e-02 |
Respiratory electron transport | 90 | 5.28e-05 | -0.246000 | 2.71e-04 |
Insulin receptor signalling cascade | 53 | 1.92e-03 | -0.246000 | 5.43e-03 |
Killing mechanisms | 11 | 1.57e-01 | -0.246000 | 2.08e-01 |
WNT5:FZD7-mediated leishmania damping | 11 | 1.57e-01 | -0.246000 | 2.08e-01 |
Signaling by NTRK3 (TRKC) | 17 | 7.90e-02 | -0.246000 | 1.18e-01 |
Transport of organic anions | 10 | 1.78e-01 | 0.246000 | 2.30e-01 |
Fertilization | 26 | 2.99e-02 | 0.246000 | 5.33e-02 |
Inositol phosphate metabolism | 45 | 4.37e-03 | -0.245000 | 1.06e-02 |
Epigenetic regulation of gene expression | 83 | 1.13e-04 | -0.245000 | 5.04e-04 |
Defective B3GALTL causes PpS | 36 | 1.09e-02 | -0.245000 | 2.32e-02 |
Regulation of mRNA stability by proteins that bind AU-rich elements | 87 | 7.99e-05 | -0.244000 | 3.80e-04 |
Activated point mutants of FGFR2 | 16 | 9.06e-02 | -0.244000 | 1.33e-01 |
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 52 | 2.30e-03 | -0.244000 | 6.20e-03 |
SUMOylation of transcription cofactors | 43 | 5.64e-03 | -0.244000 | 1.31e-02 |
TICAM1, RIP1-mediated IKK complex recruitment | 18 | 7.33e-02 | -0.244000 | 1.11e-01 |
Signaling by FLT3 fusion proteins | 19 | 6.59e-02 | -0.244000 | 1.02e-01 |
Gene expression (Transcription) | 1407 | 1.05e-53 | -0.244000 | 5.37e-51 |
Dectin-1 mediated noncanonical NF-kB signaling | 60 | 1.11e-03 | -0.243000 | 3.40e-03 |
Switching of origins to a post-replicative state | 90 | 6.73e-05 | -0.243000 | 3.28e-04 |
Unfolded Protein Response (UPR) | 91 | 6.35e-05 | -0.242000 | 3.13e-04 |
FRS-mediated FGFR1 signaling | 23 | 4.45e-02 | -0.242000 | 7.44e-02 |
Major pathway of rRNA processing in the nucleolus and cytosol | 171 | 4.63e-08 | -0.242000 | 6.50e-07 |
Glycolysis | 68 | 5.58e-04 | -0.242000 | 1.89e-03 |
Metal ion SLC transporters | 25 | 3.62e-02 | -0.242000 | 6.27e-02 |
Apoptosis | 164 | 8.92e-08 | -0.242000 | 1.18e-06 |
COPI-independent Golgi-to-ER retrograde traffic | 34 | 1.47e-02 | -0.242000 | 2.97e-02 |
Signaling by cytosolic FGFR1 fusion mutants | 17 | 8.47e-02 | -0.241000 | 1.25e-01 |
APC/C:Cdc20 mediated degradation of Securin | 66 | 6.92e-04 | -0.241000 | 2.24e-03 |
Synthesis of DNA | 118 | 5.95e-06 | -0.241000 | 4.77e-05 |
TP53 Regulates Metabolic Genes | 83 | 1.45e-04 | -0.241000 | 6.17e-04 |
RHO GTPases Activate WASPs and WAVEs | 34 | 1.50e-02 | -0.241000 | 3.02e-02 |
IRS-related events triggered by IGF1R | 50 | 3.23e-03 | -0.241000 | 8.22e-03 |
NRAGE signals death through JNK | 53 | 2.44e-03 | -0.241000 | 6.54e-03 |
ADP signalling through P2Y purinoceptor 12 | 22 | 5.11e-02 | -0.240000 | 8.30e-02 |
Meiosis | 56 | 1.88e-03 | -0.240000 | 5.37e-03 |
Regulation of TP53 Activity | 154 | 2.69e-07 | -0.240000 | 3.06e-06 |
Reversible hydration of carbon dioxide | 11 | 1.69e-01 | -0.240000 | 2.20e-01 |
Transport to the Golgi and subsequent modification | 165 | 1.12e-07 | -0.239000 | 1.42e-06 |
Sensory Perception | 576 | 8.04e-23 | 0.239000 | 5.59e-21 |
Telomere Extension By Telomerase | 22 | 5.24e-02 | -0.239000 | 8.45e-02 |
Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 24 | 4.28e-02 | -0.239000 | 7.21e-02 |
IRS-mediated signalling | 47 | 4.69e-03 | -0.238000 | 1.12e-02 |
RHO GTPase cycle | 421 | 4.25e-17 | -0.238000 | 1.91e-15 |
Neurotoxicity of clostridium toxins | 10 | 1.92e-01 | -0.238000 | 2.47e-01 |
RNA Polymerase II Transcription | 1271 | 1.52e-46 | -0.237000 | 4.64e-44 |
Toll Like Receptor 4 (TLR4) Cascade | 124 | 4.95e-06 | -0.237000 | 4.27e-05 |
Fatty acyl-CoA biosynthesis | 35 | 1.53e-02 | -0.237000 | 3.05e-02 |
Mismatch Repair | 15 | 1.13e-01 | -0.236000 | 1.60e-01 |
PD-1 signaling | 21 | 6.07e-02 | 0.236000 | 9.54e-02 |
RHOBTB GTPase Cycle | 34 | 1.70e-02 | -0.236000 | 3.35e-02 |
Activation of BAD and translocation to mitochondria | 15 | 1.13e-01 | -0.236000 | 1.60e-01 |
SARS-CoV-2 targets host intracellular signalling and regulatory pathways | 12 | 1.57e-01 | -0.236000 | 2.07e-01 |
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | 95 | 6.99e-05 | -0.236000 | 3.38e-04 |
MAPK1/MAPK3 signaling | 271 | 2.21e-11 | -0.236000 | 5.53e-10 |
Chaperonin-mediated protein folding | 90 | 1.10e-04 | -0.236000 | 4.94e-04 |
Signaling by FGFR4 | 40 | 9.90e-03 | -0.236000 | 2.12e-02 |
Glucose metabolism | 87 | 1.44e-04 | -0.236000 | 6.14e-04 |
mRNA Splicing - Minor Pathway | 53 | 3.04e-03 | -0.235000 | 7.87e-03 |
Potential therapeutics for SARS | 83 | 2.13e-04 | -0.235000 | 8.52e-04 |
PLC beta mediated events | 47 | 5.41e-03 | -0.234000 | 1.26e-02 |
Metabolism of proteins | 1774 | 1.52e-61 | -0.234000 | 1.16e-58 |
Global Genome Nucleotide Excision Repair (GG-NER) | 81 | 2.67e-04 | -0.234000 | 1.02e-03 |
Signaling by Nuclear Receptors | 237 | 5.03e-10 | -0.234000 | 9.49e-09 |
RAF/MAP kinase cascade | 265 | 5.07e-11 | -0.234000 | 1.17e-09 |
Negative regulation of TCF-dependent signaling by WNT ligand antagonists | 15 | 1.17e-01 | -0.234000 | 1.64e-01 |
Membrane Trafficking | 586 | 3.48e-22 | -0.233000 | 2.13e-20 |
KEAP1-NFE2L2 pathway | 103 | 4.24e-05 | -0.233000 | 2.25e-04 |
NCAM signaling for neurite out-growth | 57 | 2.32e-03 | -0.233000 | 6.23e-03 |
Presynaptic function of Kainate receptors | 21 | 6.43e-02 | -0.233000 | 1.00e-01 |
MAPK family signaling cascades | 312 | 1.31e-12 | -0.233000 | 3.70e-11 |
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | 16 | 1.07e-01 | -0.233000 | 1.52e-01 |
Unwinding of DNA | 12 | 1.63e-01 | -0.233000 | 2.14e-01 |
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | 21 | 6.48e-02 | -0.233000 | 1.01e-01 |
Translesion Synthesis by POLH | 19 | 7.94e-02 | -0.232000 | 1.19e-01 |
RHOA GTPase cycle | 140 | 2.06e-06 | -0.232000 | 1.98e-05 |
PKA activation | 18 | 8.81e-02 | -0.232000 | 1.30e-01 |
Transcriptional Regulation by E2F6 | 32 | 2.30e-02 | -0.232000 | 4.30e-02 |
SUMOylation of DNA methylation proteins | 16 | 1.08e-01 | -0.232000 | 1.53e-01 |
Generic Transcription Pathway | 1150 | 1.21e-40 | -0.232000 | 2.30e-38 |
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | 14 | 1.33e-01 | -0.232000 | 1.81e-01 |
Eicosanoids | 12 | 1.64e-01 | 0.232000 | 2.15e-01 |
Myogenesis | 29 | 3.10e-02 | -0.231000 | 5.50e-02 |
Uptake and actions of bacterial toxins | 29 | 3.10e-02 | -0.231000 | 5.50e-02 |
Negative regulators of DDX58/IFIH1 signaling | 34 | 1.96e-02 | -0.231000 | 3.75e-02 |
TICAM1-dependent activation of IRF3/IRF7 | 12 | 1.66e-01 | -0.231000 | 2.17e-01 |
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | 72 | 6.95e-04 | -0.231000 | 2.24e-03 |
Molecules associated with elastic fibres | 30 | 2.85e-02 | -0.231000 | 5.13e-02 |
CD28 co-stimulation | 32 | 2.41e-02 | -0.230000 | 4.48e-02 |
PINK1-PRKN Mediated Mitophagy | 21 | 6.80e-02 | -0.230000 | 1.05e-01 |
G beta:gamma signalling through PLC beta | 20 | 7.52e-02 | -0.230000 | 1.14e-01 |
Negative regulation of activity of TFAP2 (AP-2) family transcription factors | 10 | 2.08e-01 | -0.230000 | 2.64e-01 |
Cellular response to starvation | 147 | 1.62e-06 | -0.229000 | 1.63e-05 |
Bicarbonate transporters | 10 | 2.10e-01 | -0.229000 | 2.65e-01 |
Activation of PPARGC1A (PGC-1alpha) by phosphorylation | 10 | 2.10e-01 | -0.229000 | 2.65e-01 |
Sphingolipid metabolism | 81 | 3.77e-04 | -0.228000 | 1.37e-03 |
Cellular responses to stress | 683 | 2.32e-24 | -0.228000 | 1.77e-22 |
POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | 12 | 1.72e-01 | -0.228000 | 2.24e-01 |
PI3K/AKT Signaling in Cancer | 103 | 6.69e-05 | -0.227000 | 3.27e-04 |
Activation of Matrix Metalloproteinases | 31 | 2.85e-02 | 0.227000 | 5.14e-02 |
Disease | 1624 | 4.22e-53 | -0.226000 | 1.61e-50 |
Golgi Cisternae Pericentriolar Stack Reorganization | 14 | 1.43e-01 | -0.226000 | 1.92e-01 |
Complex I biogenesis | 49 | 6.22e-03 | -0.226000 | 1.43e-02 |
Sialic acid metabolism | 33 | 2.54e-02 | -0.225000 | 4.67e-02 |
SHC-mediated cascade:FGFR1 | 21 | 7.46e-02 | -0.225000 | 1.13e-01 |
rRNA processing in the nucleus and cytosol | 180 | 1.98e-07 | -0.225000 | 2.40e-06 |
PKA-mediated phosphorylation of CREB | 19 | 9.02e-02 | -0.224000 | 1.32e-01 |
O-glycosylation of TSR domain-containing proteins | 37 | 1.82e-02 | -0.224000 | 3.52e-02 |
Receptor Mediated Mitophagy | 10 | 2.20e-01 | -0.224000 | 2.75e-01 |
rRNA processing | 186 | 1.32e-07 | -0.224000 | 1.64e-06 |
Post-translational protein modification | 1294 | 3.79e-42 | -0.224000 | 9.65e-40 |
Deadenylation of mRNA | 25 | 5.33e-02 | -0.223000 | 8.55e-02 |
DNA Double Strand Break Response | 42 | 1.23e-02 | -0.223000 | 2.54e-02 |
Infectious disease | 885 | 1.13e-29 | -0.223000 | 1.24e-27 |
Cellular responses to stimuli | 697 | 7.24e-24 | -0.223000 | 5.27e-22 |
Recycling pathway of L1 | 23 | 6.40e-02 | -0.223000 | 1.00e-01 |
Neuronal System | 371 | 1.47e-13 | -0.223000 | 4.78e-12 |
Prolonged ERK activation events | 14 | 1.49e-01 | -0.223000 | 1.99e-01 |
Cellular response to chemical stress | 187 | 1.47e-07 | -0.223000 | 1.81e-06 |
Glycogen synthesis | 15 | 1.36e-01 | -0.222000 | 1.84e-01 |
IRF3-mediated induction of type I IFN | 11 | 2.02e-01 | -0.222000 | 2.58e-01 |
TP53 Regulates Transcription of Death Receptors and Ligands | 12 | 1.82e-01 | -0.222000 | 2.35e-01 |
N-glycan trimming in the ER and Calnexin/Calreticulin cycle | 34 | 2.51e-02 | -0.222000 | 4.63e-02 |
Trafficking and processing of endosomal TLR | 11 | 2.03e-01 | 0.222000 | 2.59e-01 |
Effects of PIP2 hydrolysis | 26 | 5.05e-02 | -0.222000 | 8.24e-02 |
Signaling by the B Cell Receptor (BCR) | 105 | 8.68e-05 | -0.221000 | 4.10e-04 |
Phospholipase C-mediated cascade: FGFR1 | 16 | 1.25e-01 | -0.221000 | 1.73e-01 |
CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 25 | 5.54e-02 | -0.221000 | 8.86e-02 |
IKK complex recruitment mediated by RIP1 | 22 | 7.24e-02 | -0.221000 | 1.10e-01 |
Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 23 | 6.65e-02 | -0.221000 | 1.03e-01 |
Cardiac conduction | 120 | 2.90e-05 | -0.221000 | 1.69e-04 |
Signaling by Non-Receptor Tyrosine Kinases | 55 | 4.61e-03 | -0.221000 | 1.10e-02 |
Signaling by PTK6 | 55 | 4.61e-03 | -0.221000 | 1.10e-02 |
HCMV Late Events | 54 | 5.00e-03 | -0.221000 | 1.17e-02 |
FGFR1c ligand binding and activation | 11 | 2.05e-01 | -0.220000 | 2.61e-01 |
Signaling by activated point mutants of FGFR1 | 11 | 2.05e-01 | -0.220000 | 2.61e-01 |
Cargo recognition for clathrin-mediated endocytosis | 98 | 1.65e-04 | -0.220000 | 6.83e-04 |
Inhibition of replication initiation of damaged DNA by RB1/E2F1 | 11 | 2.06e-01 | -0.220000 | 2.62e-01 |
ER-Phagosome pathway | 87 | 3.91e-04 | -0.220000 | 1.41e-03 |
A tetrasaccharide linker sequence is required for GAG synthesis | 23 | 6.82e-02 | -0.220000 | 1.05e-01 |
Erythropoietin activates RAS | 14 | 1.55e-01 | -0.220000 | 2.05e-01 |
Interleukin-17 signaling | 66 | 2.07e-03 | -0.219000 | 5.72e-03 |
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 120 | 3.39e-05 | 0.219000 | 1.91e-04 |
RAC1 GTPase cycle | 170 | 8.33e-07 | -0.219000 | 8.84e-06 |
Regulation of lipid metabolism by PPARalpha | 116 | 4.74e-05 | -0.218000 | 2.48e-04 |
Listeria monocytogenes entry into host cells | 19 | 9.93e-02 | -0.218000 | 1.43e-01 |
Clathrin-mediated endocytosis | 135 | 1.19e-05 | -0.218000 | 8.24e-05 |
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 41 | 1.58e-02 | -0.218000 | 3.14e-02 |
Constitutive Signaling by EGFRvIII | 15 | 1.44e-01 | -0.218000 | 1.93e-01 |
Signaling by EGFRvIII in Cancer | 15 | 1.44e-01 | -0.218000 | 1.93e-01 |
Apoptotic cleavage of cellular proteins | 35 | 2.57e-02 | -0.218000 | 4.71e-02 |
Collagen biosynthesis and modifying enzymes | 65 | 2.40e-03 | -0.218000 | 6.44e-03 |
Intra-Golgi traffic | 43 | 1.37e-02 | -0.217000 | 2.81e-02 |
Apoptotic execution phase | 43 | 1.39e-02 | -0.217000 | 2.83e-02 |
Collagen formation | 88 | 4.36e-04 | -0.217000 | 1.54e-03 |
Butyrophilin (BTN) family interactions | 12 | 1.93e-01 | 0.217000 | 2.48e-01 |
KSRP (KHSRP) binds and destabilizes mRNA | 17 | 1.22e-01 | -0.217000 | 1.69e-01 |
Synthesis of glycosylphosphatidylinositol (GPI) | 17 | 1.22e-01 | -0.217000 | 1.69e-01 |
Defective HDR through Homologous Recombination (HRR) due to BRCA1 loss-of-function | 23 | 7.21e-02 | -0.217000 | 1.10e-01 |
Defective HDR through Homologous Recombination (HRR) due to PALB2 loss of function | 23 | 7.21e-02 | -0.217000 | 1.10e-01 |
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | 23 | 7.21e-02 | -0.217000 | 1.10e-01 |
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | 23 | 7.21e-02 | -0.217000 | 1.10e-01 |
Impaired BRCA2 binding to PALB2 | 23 | 7.21e-02 | -0.217000 | 1.10e-01 |
Cellular Senescence | 130 | 2.01e-05 | -0.216000 | 1.26e-04 |
Negative regulation of the PI3K/AKT network | 111 | 8.19e-05 | -0.216000 | 3.89e-04 |
Synthesis of PIPs at the plasma membrane | 48 | 9.53e-03 | -0.216000 | 2.06e-02 |
Insulin processing | 26 | 5.64e-02 | -0.216000 | 8.99e-02 |
Regulation of commissural axon pathfinding by SLIT and ROBO | 10 | 2.37e-01 | -0.216000 | 2.95e-01 |
Regulation of PTEN mRNA translation | 25 | 6.16e-02 | 0.216000 | 9.66e-02 |
ABC-family proteins mediated transport | 98 | 2.20e-04 | -0.216000 | 8.63e-04 |
Zinc transporters | 17 | 1.24e-01 | -0.216000 | 1.71e-01 |
Intracellular signaling by second messengers | 313 | 5.38e-11 | -0.215000 | 1.23e-09 |
The citric acid (TCA) cycle and respiratory electron transport | 143 | 8.74e-06 | -0.215000 | 6.53e-05 |
Cyclin D associated events in G1 | 46 | 1.17e-02 | -0.215000 | 2.43e-02 |
G1 Phase | 46 | 1.17e-02 | -0.215000 | 2.43e-02 |
PPARA activates gene expression | 114 | 7.38e-05 | -0.215000 | 3.53e-04 |
Nuclear Envelope (NE) Reassembly | 73 | 1.55e-03 | -0.214000 | 4.54e-03 |
Gene Silencing by RNA | 80 | 9.25e-04 | -0.214000 | 2.87e-03 |
GPER1 signaling | 44 | 1.40e-02 | -0.214000 | 2.85e-02 |
G beta:gamma signalling through BTK | 17 | 1.27e-01 | -0.214000 | 1.74e-01 |
FCERI mediated MAPK activation | 29 | 4.67e-02 | -0.213000 | 7.74e-02 |
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 104 | 1.69e-04 | -0.213000 | 6.98e-04 |
Triglyceride catabolism | 23 | 7.68e-02 | -0.213000 | 1.16e-01 |
Vesicle-mediated transport | 624 | 8.28e-20 | -0.213000 | 4.69e-18 |
Transcriptional regulation by RUNX1 | 183 | 6.90e-07 | -0.213000 | 7.47e-06 |
Signalling to ERKs | 34 | 3.26e-02 | -0.212000 | 5.74e-02 |
Gluconeogenesis | 32 | 3.86e-02 | -0.211000 | 6.57e-02 |
Regulation of TLR by endogenous ligand | 17 | 1.32e-01 | 0.211000 | 1.81e-01 |
Assembly of collagen fibrils and other multimeric structures | 56 | 6.38e-03 | -0.211000 | 1.45e-02 |
Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon | 17 | 1.33e-01 | -0.211000 | 1.81e-01 |
Ovarian tumor domain proteases | 36 | 2.89e-02 | -0.210000 | 5.18e-02 |
RHO GTPases activate PKNs | 34 | 3.38e-02 | -0.210000 | 5.91e-02 |
Signal Transduction | 2408 | 3.33e-65 | -0.210000 | 5.09e-62 |
Signaling by SCF-KIT | 43 | 1.73e-02 | -0.210000 | 3.38e-02 |
Phase 2 - plateau phase | 14 | 1.75e-01 | -0.209000 | 2.27e-01 |
Signaling by ERBB2 KD Mutants | 24 | 7.60e-02 | -0.209000 | 1.15e-01 |
Regulation of PTEN gene transcription | 59 | 5.50e-03 | -0.209000 | 1.28e-02 |
Lysosome Vesicle Biogenesis | 33 | 3.84e-02 | -0.208000 | 6.55e-02 |
Presynaptic depolarization and calcium channel opening | 12 | 2.12e-01 | -0.208000 | 2.67e-01 |
CLEC7A (Dectin-1) signaling | 96 | 4.27e-04 | -0.208000 | 1.51e-03 |
Synthesis of bile acids and bile salts via 24-hydroxycholesterol | 14 | 1.78e-01 | -0.208000 | 2.30e-01 |
Inactivation of CSF3 (G-CSF) signaling | 23 | 8.47e-02 | -0.208000 | 1.25e-01 |
Interleukin-1 family signaling | 134 | 3.30e-05 | -0.208000 | 1.86e-04 |
Frs2-mediated activation | 12 | 2.15e-01 | -0.207000 | 2.70e-01 |
RHOQ GTPase cycle | 57 | 7.14e-03 | -0.206000 | 1.61e-02 |
Oxidative Stress Induced Senescence | 66 | 3.82e-03 | -0.206000 | 9.42e-03 |
RHOH GTPase cycle | 36 | 3.30e-02 | -0.205000 | 5.80e-02 |
ABC transporter disorders | 75 | 2.12e-03 | -0.205000 | 5.83e-03 |
MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 94 | 5.87e-04 | -0.205000 | 1.96e-03 |
Toll Like Receptor 2 (TLR2) Cascade | 94 | 5.87e-04 | -0.205000 | 1.96e-03 |
Toll Like Receptor TLR1:TLR2 Cascade | 94 | 5.87e-04 | -0.205000 | 1.96e-03 |
Toll Like Receptor TLR6:TLR2 Cascade | 94 | 5.87e-04 | -0.205000 | 1.96e-03 |
Transmission across Chemical Synapses | 237 | 5.22e-08 | -0.205000 | 7.25e-07 |
Apoptotic factor-mediated response | 17 | 1.44e-01 | -0.205000 | 1.93e-01 |
Trafficking of GluR2-containing AMPA receptors | 15 | 1.70e-01 | -0.205000 | 2.22e-01 |
SARS-CoV Infections | 339 | 8.94e-11 | -0.205000 | 1.87e-09 |
Constitutive Signaling by Overexpressed ERBB2 | 10 | 2.64e-01 | -0.204000 | 3.24e-01 |
Metabolism of nucleotides | 95 | 5.86e-04 | -0.204000 | 1.96e-03 |
Iron uptake and transport | 57 | 7.76e-03 | -0.204000 | 1.73e-02 |
p75NTR recruits signalling complexes | 12 | 2.22e-01 | -0.204000 | 2.77e-01 |
Recycling of bile acids and salts | 18 | 1.35e-01 | 0.203000 | 1.84e-01 |
Removal of the Flap Intermediate from the C-strand | 17 | 1.46e-01 | -0.203000 | 1.96e-01 |
PKMTs methylate histone lysines | 37 | 3.23e-02 | -0.203000 | 5.70e-02 |
MAP3K8 (TPL2)-dependent MAPK1/3 activation | 15 | 1.73e-01 | -0.203000 | 2.25e-01 |
PKA activation in glucagon signalling | 17 | 1.47e-01 | -0.203000 | 1.97e-01 |
Removal of the Flap Intermediate | 13 | 2.05e-01 | -0.203000 | 2.61e-01 |
MET promotes cell motility | 29 | 5.89e-02 | -0.203000 | 9.34e-02 |
PERK regulates gene expression | 32 | 4.75e-02 | -0.202000 | 7.86e-02 |
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 32 | 4.77e-02 | -0.202000 | 7.87e-02 |
Potassium Channels | 102 | 4.16e-04 | -0.202000 | 1.48e-03 |
CDC42 GTPase cycle | 144 | 2.82e-05 | -0.202000 | 1.65e-04 |
SARS-CoV-2 Infection | 265 | 1.52e-08 | -0.202000 | 2.34e-07 |
FCGR3A-mediated phagocytosis | 57 | 8.49e-03 | -0.201000 | 1.87e-02 |
Leishmania phagocytosis | 57 | 8.49e-03 | -0.201000 | 1.87e-02 |
Parasite infection | 57 | 8.49e-03 | -0.201000 | 1.87e-02 |
RAC2 GTPase cycle | 80 | 1.83e-03 | -0.201000 | 5.25e-03 |
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | 17 | 1.51e-01 | -0.201000 | 2.01e-01 |
Aberrant regulation of mitotic cell cycle due to RB1 defects | 36 | 3.66e-02 | -0.201000 | 6.31e-02 |
mRNA decay by 3’ to 5’ exoribonuclease | 16 | 1.64e-01 | -0.201000 | 2.15e-01 |
Synthesis of PC | 27 | 7.06e-02 | -0.201000 | 1.08e-01 |
Maturation of nucleoprotein | 11 | 2.49e-01 | -0.201000 | 3.07e-01 |
G alpha (12/13) signalling events | 74 | 2.82e-03 | -0.201000 | 7.37e-03 |
Signaling by FGFR1 | 49 | 1.51e-02 | -0.201000 | 3.02e-02 |
Signal amplification | 33 | 4.61e-02 | -0.200000 | 7.68e-02 |
NOTCH3 Intracellular Domain Regulates Transcription | 24 | 8.90e-02 | -0.200000 | 1.31e-01 |
Signaling by Insulin receptor | 76 | 2.51e-03 | -0.200000 | 6.66e-03 |
PIP3 activates AKT signaling | 275 | 1.07e-08 | -0.200000 | 1.67e-07 |
Defective GALNT12 causes CRCS1 | 18 | 1.42e-01 | 0.200000 | 1.91e-01 |
Downregulation of TGF-beta receptor signaling | 26 | 7.74e-02 | -0.200000 | 1.16e-01 |
Diseases of glycosylation | 137 | 5.28e-05 | -0.200000 | 2.71e-04 |
Selective autophagy | 59 | 7.94e-03 | -0.200000 | 1.76e-02 |
IRAK4 deficiency (TLR2/4) | 17 | 1.54e-01 | 0.200000 | 2.04e-01 |
Cellular response to heat stress | 95 | 7.71e-04 | -0.200000 | 2.44e-03 |
Common Pathway of Fibrin Clot Formation | 21 | 1.13e-01 | 0.199000 | 1.60e-01 |
Fcgamma receptor (FCGR) dependent phagocytosis | 82 | 1.81e-03 | -0.199000 | 5.20e-03 |
Meiotic synapsis | 32 | 5.17e-02 | -0.199000 | 8.37e-02 |
Glucagon signaling in metabolic regulation | 33 | 4.87e-02 | -0.198000 | 8.01e-02 |
Downstream TCR signaling | 92 | 1.02e-03 | -0.198000 | 3.12e-03 |
Glutathione synthesis and recycling | 13 | 2.19e-01 | -0.197000 | 2.75e-01 |
Rab regulation of trafficking | 114 | 2.81e-04 | -0.197000 | 1.07e-03 |
Glycogen metabolism | 24 | 9.57e-02 | -0.196000 | 1.39e-01 |
Positive epigenetic regulation of rRNA expression | 43 | 2.59e-02 | -0.196000 | 4.73e-02 |
Signaling by BRAF and RAF1 fusions | 60 | 8.78e-03 | -0.195000 | 1.92e-02 |
ER Quality Control Compartment (ERQC) | 20 | 1.30e-01 | -0.195000 | 1.78e-01 |
Regulation of HSF1-mediated heat shock response | 78 | 2.88e-03 | -0.195000 | 7.49e-03 |
Pyruvate metabolism and Citric Acid (TCA) cycle | 52 | 1.50e-02 | -0.195000 | 3.02e-02 |
Signal regulatory protein family interactions | 13 | 2.24e-01 | 0.195000 | 2.80e-01 |
SARS-CoV-2 modulates host translation machinery | 46 | 2.25e-02 | -0.194000 | 4.20e-02 |
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | 25 | 9.25e-02 | -0.194000 | 1.35e-01 |
TAK1-dependent IKK and NF-kappa-B activation | 25 | 9.26e-02 | -0.194000 | 1.35e-01 |
Chondroitin sulfate/dermatan sulfate metabolism | 45 | 2.41e-02 | -0.194000 | 4.48e-02 |
RNA Polymerase I Transcription Initiation | 42 | 2.93e-02 | -0.194000 | 5.26e-02 |
Protein localization | 147 | 4.75e-05 | -0.194000 | 2.48e-04 |
Prostacyclin signalling through prostacyclin receptor | 19 | 1.43e-01 | -0.194000 | 1.93e-01 |
Activation of GABAB receptors | 43 | 2.79e-02 | -0.194000 | 5.03e-02 |
GABA B receptor activation | 43 | 2.79e-02 | -0.194000 | 5.03e-02 |
Constitutive Signaling by Aberrant PI3K in Cancer | 77 | 3.34e-03 | -0.193000 | 8.41e-03 |
Factors involved in megakaryocyte development and platelet production | 130 | 1.47e-04 | -0.193000 | 6.21e-04 |
Diseases of mitotic cell cycle | 37 | 4.29e-02 | -0.192000 | 7.21e-02 |
FLT3 Signaling | 38 | 4.04e-02 | -0.192000 | 6.84e-02 |
ATF6 (ATF6-alpha) activates chaperones | 11 | 2.70e-01 | -0.192000 | 3.31e-01 |
Resolution of D-loop Structures through Holliday Junction Intermediates | 31 | 6.54e-02 | -0.191000 | 1.02e-01 |
ATF4 activates genes in response to endoplasmic reticulum stress | 28 | 8.00e-02 | -0.191000 | 1.19e-01 |
Signaling by FGFR3 | 39 | 3.94e-02 | -0.191000 | 6.70e-02 |
Interleukin-6 family signaling | 24 | 1.06e-01 | -0.190000 | 1.52e-01 |
Nuclear events stimulated by ALK signaling in cancer | 18 | 1.62e-01 | -0.190000 | 2.14e-01 |
Programmed Cell Death | 192 | 5.41e-06 | -0.190000 | 4.50e-05 |
Response of Mtb to phagocytosis | 22 | 1.23e-01 | -0.190000 | 1.70e-01 |
Nucleotide catabolism | 35 | 5.27e-02 | -0.189000 | 8.47e-02 |
G beta:gamma signalling through CDC42 | 19 | 1.54e-01 | -0.189000 | 2.04e-01 |
mTORC1-mediated signalling | 23 | 1.18e-01 | -0.188000 | 1.65e-01 |
RNA Polymerase I Transcription | 47 | 2.57e-02 | -0.188000 | 4.71e-02 |
Nuclear Receptor transcription pathway | 51 | 2.02e-02 | -0.188000 | 3.85e-02 |
Toll-like Receptor Cascades | 143 | 1.06e-04 | -0.188000 | 4.81e-04 |
SARS-CoV-2-host interactions | 185 | 1.08e-05 | -0.187000 | 7.60e-05 |
Processive synthesis on the C-strand of the telomere | 19 | 1.58e-01 | -0.187000 | 2.08e-01 |
RHOBTB2 GTPase cycle | 22 | 1.29e-01 | -0.187000 | 1.76e-01 |
FGFR1 ligand binding and activation | 15 | 2.10e-01 | -0.187000 | 2.65e-01 |
Zinc influx into cells by the SLC39 gene family | 10 | 3.06e-01 | -0.187000 | 3.68e-01 |
Calnexin/calreticulin cycle | 25 | 1.06e-01 | -0.187000 | 1.52e-01 |
E2F mediated regulation of DNA replication | 20 | 1.49e-01 | -0.186000 | 2.00e-01 |
Resolution of D-Loop Structures | 32 | 6.84e-02 | -0.186000 | 1.05e-01 |
Interconversion of nucleotide di- and triphosphates | 29 | 8.31e-02 | -0.186000 | 1.23e-01 |
Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | 10 | 3.09e-01 | -0.186000 | 3.71e-01 |
Cholesterol biosynthesis | 24 | 1.15e-01 | -0.186000 | 1.63e-01 |
Regulation of signaling by NODAL | 11 | 2.87e-01 | 0.186000 | 3.47e-01 |
ATF6 (ATF6-alpha) activates chaperone genes | 10 | 3.10e-01 | -0.186000 | 3.72e-01 |
Peroxisomal lipid metabolism | 28 | 8.94e-02 | -0.185000 | 1.31e-01 |
FCERI mediated Ca+2 mobilization | 27 | 9.59e-02 | -0.185000 | 1.39e-01 |
COPII-mediated vesicle transport | 66 | 9.35e-03 | -0.185000 | 2.03e-02 |
DAP12 signaling | 28 | 9.08e-02 | -0.185000 | 1.33e-01 |
Mitophagy | 27 | 9.69e-02 | -0.184000 | 1.40e-01 |
Plasma lipoprotein clearance | 37 | 5.23e-02 | -0.184000 | 8.45e-02 |
Role of phospholipids in phagocytosis | 23 | 1.27e-01 | -0.184000 | 1.74e-01 |
Cell-Cell communication | 112 | 7.71e-04 | -0.184000 | 2.44e-03 |
RHO GTPases Activate ROCKs | 19 | 1.67e-01 | -0.183000 | 2.18e-01 |
Sphingolipid de novo biosynthesis | 41 | 4.36e-02 | -0.182000 | 7.31e-02 |
WNT ligand biogenesis and trafficking | 25 | 1.16e-01 | -0.182000 | 1.63e-01 |
Downregulation of ERBB2:ERBB3 signaling | 13 | 2.57e-01 | -0.181000 | 3.17e-01 |
Metabolism of amino acids and derivatives | 345 | 6.70e-09 | -0.181000 | 1.07e-07 |
Metabolism of carbohydrates | 275 | 2.36e-07 | -0.181000 | 2.74e-06 |
IL-6-type cytokine receptor ligand interactions | 17 | 1.97e-01 | -0.181000 | 2.52e-01 |
Developmental Biology | 1020 | 1.35e-22 | -0.180000 | 8.81e-21 |
Glycosaminoglycan metabolism | 116 | 8.25e-04 | -0.180000 | 2.58e-03 |
RNA Polymerase I Promoter Clearance | 46 | 3.53e-02 | -0.179000 | 6.15e-02 |
Notch-HLH transcription pathway | 24 | 1.29e-01 | -0.179000 | 1.76e-01 |
FGFR2 ligand binding and activation | 19 | 1.77e-01 | -0.179000 | 2.29e-01 |
MET activates PTK2 signaling | 18 | 1.89e-01 | -0.179000 | 2.43e-01 |
Senescence-Associated Secretory Phenotype (SASP) | 53 | 2.44e-02 | -0.179000 | 4.51e-02 |
Cytochrome c-mediated apoptotic response | 12 | 2.84e-01 | -0.179000 | 3.45e-01 |
FLT3 signaling in disease | 28 | 1.02e-01 | -0.178000 | 1.46e-01 |
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | 15 | 2.32e-01 | -0.178000 | 2.90e-01 |
Signaling by ERBB2 in Cancer | 25 | 1.24e-01 | -0.178000 | 1.71e-01 |
Regulation of gene expression by Hypoxia-inducible Factor | 11 | 3.08e-01 | -0.178000 | 3.70e-01 |
Vasopressin regulates renal water homeostasis via Aquaporins | 42 | 4.71e-02 | -0.177000 | 7.80e-02 |
Infection with Mycobacterium tuberculosis | 26 | 1.18e-01 | -0.177000 | 1.66e-01 |
G-protein beta:gamma signalling | 30 | 9.36e-02 | -0.177000 | 1.36e-01 |
Growth hormone receptor signaling | 24 | 1.35e-01 | -0.176000 | 1.84e-01 |
mitochondrial fatty acid beta-oxidation of saturated fatty acids | 11 | 3.12e-01 | -0.176000 | 3.74e-01 |
G beta:gamma signalling through PI3Kgamma | 25 | 1.29e-01 | -0.175000 | 1.77e-01 |
Glutamate binding, activation of AMPA receptors and synaptic plasticity | 29 | 1.02e-01 | -0.175000 | 1.46e-01 |
Trafficking of AMPA receptors | 29 | 1.02e-01 | -0.175000 | 1.46e-01 |
Fatty acid metabolism | 167 | 9.32e-05 | -0.175000 | 4.31e-04 |
Semaphorin interactions | 61 | 1.81e-02 | -0.175000 | 3.51e-02 |
TNFR2 non-canonical NF-kB pathway | 94 | 3.42e-03 | -0.175000 | 8.50e-03 |
PTEN Regulation | 150 | 2.25e-04 | -0.174000 | 8.78e-04 |
Mitochondrial calcium ion transport | 22 | 1.57e-01 | -0.174000 | 2.07e-01 |
The role of Nef in HIV-1 replication and disease pathogenesis | 27 | 1.17e-01 | -0.174000 | 1.64e-01 |
Collagen chain trimerization | 42 | 5.17e-02 | -0.173000 | 8.37e-02 |
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | 37 | 6.80e-02 | -0.173000 | 1.05e-01 |
Integrin cell surface interactions | 66 | 1.50e-02 | -0.173000 | 3.02e-02 |
Diseases associated with glycosaminoglycan metabolism | 38 | 6.50e-02 | -0.173000 | 1.01e-01 |
DNA Damage Recognition in GG-NER | 36 | 7.48e-02 | -0.172000 | 1.13e-01 |
Signaling by ERBB2 | 49 | 3.78e-02 | -0.171000 | 6.48e-02 |
Purine catabolism | 17 | 2.21e-01 | -0.171000 | 2.77e-01 |
STING mediated induction of host immune responses | 13 | 2.90e-01 | -0.170000 | 3.51e-01 |
Disorders of transmembrane transporters | 167 | 1.55e-04 | -0.170000 | 6.49e-04 |
Neurotransmitter receptors and postsynaptic signal transmission | 175 | 1.10e-04 | -0.169000 | 4.94e-04 |
Signal transduction by L1 | 20 | 1.90e-01 | -0.169000 | 2.44e-01 |
Class B/2 (Secretin family receptors) | 94 | 4.66e-03 | -0.169000 | 1.11e-02 |
Interleukin-37 signaling | 21 | 1.81e-01 | -0.169000 | 2.33e-01 |
PI Metabolism | 79 | 9.54e-03 | -0.169000 | 2.06e-02 |
Smooth Muscle Contraction | 39 | 6.87e-02 | -0.168000 | 1.05e-01 |
Regulation of insulin secretion | 77 | 1.09e-02 | -0.168000 | 2.32e-02 |
Negative regulation of FGFR4 signaling | 30 | 1.13e-01 | -0.167000 | 1.60e-01 |
RHOG GTPase cycle | 69 | 1.63e-02 | -0.167000 | 3.23e-02 |
Activation of G protein gated Potassium channels | 29 | 1.19e-01 | -0.167000 | 1.66e-01 |
G protein gated Potassium channels | 29 | 1.19e-01 | -0.167000 | 1.66e-01 |
Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | 29 | 1.19e-01 | -0.167000 | 1.66e-01 |
Metabolism of lipids | 696 | 4.74e-14 | -0.167000 | 1.61e-12 |
Depolymerisation of the Nuclear Lamina | 14 | 2.80e-01 | -0.167000 | 3.42e-01 |
GABA receptor activation | 57 | 2.96e-02 | -0.167000 | 5.28e-02 |
Signaling by MET | 66 | 1.96e-02 | -0.166000 | 3.75e-02 |
InlB-mediated entry of Listeria monocytogenes into host cell | 14 | 2.83e-01 | -0.166000 | 3.45e-01 |
Azathioprine ADME | 22 | 1.79e-01 | -0.165000 | 2.31e-01 |
Gap-filling DNA repair synthesis and ligation in GG-NER | 25 | 1.53e-01 | -0.165000 | 2.03e-01 |
FGFR3 ligand binding and activation | 12 | 3.22e-01 | -0.165000 | 3.84e-01 |
FGFR3c ligand binding and activation | 12 | 3.22e-01 | -0.165000 | 3.84e-01 |
SHC1 events in ERBB4 signaling | 14 | 2.85e-01 | -0.165000 | 3.46e-01 |
Defective C1GALT1C1 causes TNPS | 18 | 2.26e-01 | 0.165000 | 2.82e-01 |
Acetylcholine regulates insulin secretion | 10 | 3.68e-01 | 0.164000 | 4.31e-01 |
Cell junction organization | 79 | 1.15e-02 | -0.164000 | 2.41e-02 |
Signaling by EGFR | 49 | 4.65e-02 | -0.164000 | 7.73e-02 |
MET activates RAS signaling | 11 | 3.46e-01 | -0.164000 | 4.07e-01 |
Interleukin receptor SHC signaling | 24 | 1.65e-01 | -0.164000 | 2.16e-01 |
Class I peroxisomal membrane protein import | 19 | 2.17e-01 | -0.163000 | 2.73e-01 |
Metabolism | 1967 | 1.31e-33 | -0.163000 | 1.82e-31 |
RAB GEFs exchange GTP for GDP on RABs | 83 | 1.02e-02 | -0.163000 | 2.18e-02 |
HuR (ELAVL1) binds and stabilizes mRNA | 10 | 3.74e-01 | -0.162000 | 4.36e-01 |
SARS-CoV-2 activates/modulates innate and adaptive immune responses | 112 | 3.19e-03 | -0.161000 | 8.15e-03 |
PI3K events in ERBB4 signaling | 10 | 3.77e-01 | -0.161000 | 4.39e-01 |
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 20 | 2.13e-01 | -0.161000 | 2.68e-01 |
Gamma carboxylation, hypusine formation and arylsulfatase activation | 34 | 1.05e-01 | -0.161000 | 1.50e-01 |
Muscle contraction | 186 | 1.70e-04 | -0.160000 | 7.02e-04 |
Integration of energy metabolism | 106 | 4.78e-03 | -0.159000 | 1.13e-02 |
Suppression of phagosomal maturation | 13 | 3.24e-01 | -0.158000 | 3.85e-01 |
ADP signalling through P2Y purinoceptor 1 | 25 | 1.72e-01 | -0.158000 | 2.24e-01 |
Regulation of actin dynamics for phagocytic cup formation | 59 | 3.69e-02 | -0.157000 | 6.35e-02 |
HDL remodeling | 10 | 3.91e-01 | -0.157000 | 4.53e-01 |
PI3K events in ERBB2 signaling | 16 | 2.81e-01 | -0.156000 | 3.43e-01 |
Integrin signaling | 27 | 1.63e-01 | -0.155000 | 2.14e-01 |
Nuclear signaling by ERBB4 | 32 | 1.30e-01 | -0.155000 | 1.78e-01 |
TCR signaling | 112 | 4.70e-03 | -0.154000 | 1.12e-02 |
Adherens junctions interactions | 26 | 1.73e-01 | -0.154000 | 2.25e-01 |
Transport of inorganic cations/anions and amino acids/oligopeptides | 101 | 7.58e-03 | -0.154000 | 1.69e-02 |
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 29 | 1.52e-01 | -0.154000 | 2.02e-01 |
Triglyceride metabolism | 36 | 1.12e-01 | -0.153000 | 1.59e-01 |
Processing of SMDT1 | 15 | 3.06e-01 | -0.153000 | 3.68e-01 |
Josephin domain DUBs | 11 | 3.81e-01 | -0.152000 | 4.43e-01 |
Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 17 | 2.78e-01 | -0.152000 | 3.40e-01 |
Macroautophagy | 111 | 5.73e-03 | -0.152000 | 1.33e-02 |
Signaling by ERBB2 TMD/JMD mutants | 21 | 2.30e-01 | -0.151000 | 2.87e-01 |
Synthesis of very long-chain fatty acyl-CoAs | 23 | 2.10e-01 | -0.151000 | 2.65e-01 |
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 18 | 2.69e-01 | -0.150000 | 3.31e-01 |
Negative regulation of FGFR2 signaling | 33 | 1.35e-01 | -0.150000 | 1.84e-01 |
TP53 Regulates Transcription of Cell Death Genes | 42 | 9.24e-02 | -0.150000 | 1.35e-01 |
Aggrephagy | 23 | 2.13e-01 | -0.150000 | 2.68e-01 |
Antigen processing-Cross presentation | 102 | 8.94e-03 | -0.150000 | 1.95e-02 |
Formation of tubulin folding intermediates by CCT/TriC | 26 | 1.87e-01 | -0.150000 | 2.40e-01 |
CS/DS degradation | 12 | 3.71e-01 | -0.149000 | 4.34e-01 |
Signaling by ERBB4 | 57 | 5.20e-02 | -0.149000 | 8.40e-02 |
Pyrimidine catabolism | 12 | 3.72e-01 | -0.149000 | 4.35e-01 |
Vitamin D (calciferol) metabolism | 12 | 3.73e-01 | -0.148000 | 4.36e-01 |
Tryptophan catabolism | 12 | 3.74e-01 | 0.148000 | 4.36e-01 |
Interleukin-12 family signaling | 54 | 6.06e-02 | -0.148000 | 9.53e-02 |
SARS-CoV-1 Infection | 51 | 6.85e-02 | -0.147000 | 1.05e-01 |
Processive synthesis on the lagging strand | 14 | 3.41e-01 | -0.147000 | 4.02e-01 |
Generation of second messenger molecules | 30 | 1.65e-01 | 0.146000 | 2.16e-01 |
Pyruvate metabolism | 29 | 1.73e-01 | -0.146000 | 2.25e-01 |
Assembly of the ORC complex at the origin of replication | 10 | 4.24e-01 | -0.146000 | 4.88e-01 |
Inwardly rectifying K+ channels | 35 | 1.37e-01 | -0.145000 | 1.86e-01 |
Sema4D in semaphorin signaling | 24 | 2.19e-01 | -0.145000 | 2.75e-01 |
Transport of small molecules | 689 | 9.40e-11 | -0.144000 | 1.94e-09 |
Diseases of metabolism | 234 | 1.42e-04 | -0.144000 | 6.09e-04 |
Metabolism of vitamins and cofactors | 181 | 8.29e-04 | -0.144000 | 2.59e-03 |
Ion transport by P-type ATPases | 51 | 7.78e-02 | -0.143000 | 1.17e-01 |
p38MAPK events | 13 | 3.74e-01 | -0.142000 | 4.36e-01 |
Ion homeostasis | 50 | 8.27e-02 | -0.142000 | 1.23e-01 |
Interleukin-3, Interleukin-5 and GM-CSF signaling | 41 | 1.16e-01 | -0.142000 | 1.64e-01 |
Metabolism of water-soluble vitamins and cofactors | 118 | 7.88e-03 | -0.141000 | 1.75e-02 |
Miscellaneous substrates | 12 | 3.96e-01 | 0.141000 | 4.59e-01 |
Autophagy | 125 | 6.59e-03 | -0.141000 | 1.50e-02 |
Abacavir ADME | 10 | 4.42e-01 | -0.140000 | 5.05e-01 |
Signaling by Retinoic Acid | 41 | 1.21e-01 | -0.140000 | 1.69e-01 |
SLC transporter disorders | 92 | 2.07e-02 | -0.139000 | 3.91e-02 |
Budding and maturation of HIV virion | 28 | 2.01e-01 | -0.139000 | 2.57e-01 |
Lysine catabolism | 12 | 4.04e-01 | -0.139000 | 4.67e-01 |
Thromboxane signalling through TP receptor | 24 | 2.38e-01 | -0.139000 | 2.96e-01 |
Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | 36 | 1.51e-01 | -0.138000 | 2.01e-01 |
Assembly Of The HIV Virion | 16 | 3.39e-01 | -0.138000 | 4.01e-01 |
EPHA-mediated growth cone collapse | 15 | 3.55e-01 | -0.138000 | 4.17e-01 |
Negative regulation of FGFR3 signaling | 28 | 2.07e-01 | -0.138000 | 2.62e-01 |
Inactivation of APC/C via direct inhibition of the APC/C complex | 21 | 2.78e-01 | -0.137000 | 3.40e-01 |
Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | 21 | 2.78e-01 | -0.137000 | 3.40e-01 |
Amino acids regulate mTORC1 | 52 | 8.81e-02 | -0.137000 | 1.30e-01 |
Sema4D induced cell migration and growth-cone collapse | 20 | 2.90e-01 | -0.137000 | 3.51e-01 |
Nucleotide salvage | 21 | 2.80e-01 | -0.136000 | 3.42e-01 |
Post-translational protein phosphorylation | 100 | 1.92e-02 | -0.135000 | 3.71e-02 |
Carnitine metabolism | 11 | 4.37e-01 | -0.135000 | 5.01e-01 |
Peroxisomal protein import | 62 | 6.57e-02 | -0.135000 | 1.02e-01 |
Sensory perception of taste | 47 | 1.10e-01 | 0.135000 | 1.56e-01 |
RHO GTPases activate PAKs | 19 | 3.13e-01 | -0.134000 | 3.75e-01 |
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 19 | 3.14e-01 | -0.133000 | 3.75e-01 |
Signaling by Ligand-Responsive EGFR Variants in Cancer | 19 | 3.14e-01 | -0.133000 | 3.75e-01 |
Phospholipid metabolism | 192 | 1.42e-03 | -0.133000 | 4.21e-03 |
Synthesis of IP2, IP, and Ins in the cytosol | 13 | 4.06e-01 | -0.133000 | 4.69e-01 |
The NLRP3 inflammasome | 16 | 3.58e-01 | -0.133000 | 4.20e-01 |
Aquaporin-mediated transport | 51 | 1.01e-01 | -0.133000 | 1.46e-01 |
Pexophagy | 11 | 4.48e-01 | -0.132000 | 5.12e-01 |
Regulation of RUNX1 Expression and Activity | 25 | 2.54e-01 | -0.132000 | 3.13e-01 |
Adaptive Immune System | 711 | 2.69e-09 | -0.131000 | 4.62e-08 |
Sensory perception of sweet, bitter, and umami (glutamate) taste | 41 | 1.51e-01 | 0.129000 | 2.02e-01 |
Synthesis of PIPs at the early endosome membrane | 15 | 3.85e-01 | -0.129000 | 4.47e-01 |
Aspartate and asparagine metabolism | 12 | 4.38e-01 | -0.129000 | 5.02e-01 |
Interleukin-12 signaling | 44 | 1.39e-01 | -0.129000 | 1.88e-01 |
Plasma lipoprotein assembly, remodeling, and clearance | 73 | 5.80e-02 | -0.128000 | 9.20e-02 |
Stimuli-sensing channels | 96 | 2.99e-02 | -0.128000 | 5.33e-02 |
Biosynthesis of specialized proresolving mediators (SPMs) | 19 | 3.34e-01 | -0.128000 | 3.95e-01 |
Sodium/Calcium exchangers | 11 | 4.63e-01 | -0.128000 | 5.25e-01 |
Extracellular matrix organization | 288 | 1.93e-04 | -0.127000 | 7.82e-04 |
Organic cation transport | 10 | 4.86e-01 | -0.127000 | 5.48e-01 |
Signaling by Interleukins | 426 | 6.60e-06 | -0.127000 | 5.12e-05 |
Transferrin endocytosis and recycling | 30 | 2.32e-01 | -0.126000 | 2.90e-01 |
Cobalamin (Cbl, vitamin B12) transport and metabolism | 20 | 3.30e-01 | -0.126000 | 3.91e-01 |
N-glycan antennae elongation in the medial/trans-Golgi | 26 | 2.67e-01 | -0.126000 | 3.29e-01 |
activated TAK1 mediates p38 MAPK activation | 16 | 3.84e-01 | -0.126000 | 4.46e-01 |
Translation of Structural Proteins | 29 | 2.42e-01 | -0.126000 | 3.00e-01 |
RAC3 GTPase cycle | 84 | 4.67e-02 | -0.125000 | 7.74e-02 |
Fanconi Anemia Pathway | 37 | 1.91e-01 | -0.124000 | 2.45e-01 |
Negative regulation of MET activity | 20 | 3.39e-01 | -0.123000 | 4.01e-01 |
Synthesis of PIPs at the late endosome membrane | 10 | 5.03e-01 | -0.122000 | 5.63e-01 |
FCGR3A-mediated IL10 synthesis | 37 | 1.99e-01 | -0.122000 | 2.54e-01 |
Adenylate cyclase activating pathway | 10 | 5.04e-01 | -0.122000 | 5.64e-01 |
CD209 (DC-SIGN) signaling | 20 | 3.46e-01 | -0.122000 | 4.07e-01 |
Tie2 Signaling | 18 | 3.72e-01 | -0.121000 | 4.35e-01 |
Biosynthesis of DHA-derived SPMs | 17 | 3.88e-01 | -0.121000 | 4.49e-01 |
Ion channel transport | 168 | 6.96e-03 | -0.121000 | 1.57e-02 |
Negative regulation of FGFR1 signaling | 32 | 2.39e-01 | -0.120000 | 2.97e-01 |
NOTCH2 intracellular domain regulates transcription | 11 | 4.90e-01 | -0.120000 | 5.51e-01 |
Passive transport by Aquaporins | 13 | 4.54e-01 | 0.120000 | 5.16e-01 |
Interferon alpha/beta signaling | 71 | 8.04e-02 | -0.120000 | 1.20e-01 |
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | 16 | 4.06e-01 | -0.120000 | 4.69e-01 |
Cell-cell junction organization | 56 | 1.22e-01 | -0.119000 | 1.69e-01 |
Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | 14 | 4.40e-01 | 0.119000 | 5.04e-01 |
Diseases of hemostasis | 14 | 4.40e-01 | 0.119000 | 5.04e-01 |
Peptide hormone metabolism | 83 | 6.24e-02 | -0.118000 | 9.76e-02 |
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | 16 | 4.14e-01 | -0.118000 | 4.77e-01 |
Scavenging of heme from plasma | 12 | 4.81e-01 | 0.117000 | 5.42e-01 |
Organic anion transporters | 10 | 5.22e-01 | -0.117000 | 5.82e-01 |
Regulation of BACH1 activity | 15 | 4.36e-01 | 0.116000 | 5.01e-01 |
Cytokine Signaling in Immune system | 667 | 3.26e-07 | -0.116000 | 3.68e-06 |
Gap junction trafficking | 27 | 3.00e-01 | -0.115000 | 3.62e-01 |
Glycerophospholipid biosynthesis | 114 | 3.35e-02 | -0.115000 | 5.87e-02 |
Synthesis of bile acids and bile salts | 34 | 2.47e-01 | -0.115000 | 3.05e-01 |
RHO GTPases activate KTN1 | 11 | 5.12e-01 | -0.114000 | 5.72e-01 |
Metabolism of steroids | 148 | 1.65e-02 | -0.114000 | 3.26e-02 |
Insulin receptor recycling | 25 | 3.23e-01 | -0.114000 | 3.85e-01 |
Processing and activation of SUMO | 10 | 5.33e-01 | -0.114000 | 5.92e-01 |
Gap junction trafficking and regulation | 29 | 2.88e-01 | -0.114000 | 3.49e-01 |
Leishmania infection | 245 | 2.20e-03 | -0.113000 | 5.96e-03 |
Sema3A PAK dependent Axon repulsion | 14 | 4.63e-01 | -0.113000 | 5.25e-01 |
Detoxification of Reactive Oxygen Species | 35 | 2.53e-01 | -0.111000 | 3.13e-01 |
Regulation of TP53 Activity through Acetylation | 29 | 2.99e-01 | -0.111000 | 3.61e-01 |
Synthesis of Leukotrienes (LT) and Eoxins (EX) | 21 | 3.78e-01 | 0.111000 | 4.39e-01 |
Competing endogenous RNAs (ceRNAs) regulate PTEN translation | 16 | 4.42e-01 | 0.111000 | 5.06e-01 |
Costimulation by the CD28 family | 65 | 1.23e-01 | -0.111000 | 1.70e-01 |
Heme degradation | 16 | 4.45e-01 | 0.110000 | 5.08e-01 |
Surfactant metabolism | 29 | 3.09e-01 | 0.109000 | 3.71e-01 |
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 28 | 3.17e-01 | -0.109000 | 3.79e-01 |
Cargo concentration in the ER | 32 | 2.85e-01 | -0.109000 | 3.46e-01 |
Platelet activation, signaling and aggregation | 246 | 3.27e-03 | -0.109000 | 8.28e-03 |
Peptide ligand-binding receptors | 190 | 9.79e-03 | 0.109000 | 2.10e-02 |
O-linked glycosylation | 107 | 5.27e-02 | -0.108000 | 8.47e-02 |
Serotonin receptors | 11 | 5.35e-01 | -0.108000 | 5.93e-01 |
TP53 Regulates Transcription of Caspase Activators and Caspases | 12 | 5.22e-01 | -0.107000 | 5.82e-01 |
Vitamin B5 (pantothenate) metabolism | 16 | 4.61e-01 | -0.106000 | 5.23e-01 |
Drug ADME | 98 | 6.91e-02 | 0.106000 | 1.06e-01 |
RAS processing | 19 | 4.24e-01 | -0.106000 | 4.88e-01 |
Signaling by NODAL | 22 | 3.90e-01 | -0.106000 | 4.52e-01 |
Paradoxical activation of RAF signaling by kinase inactive BRAF | 41 | 2.44e-01 | -0.105000 | 3.02e-01 |
Signaling by RAS mutants | 41 | 2.44e-01 | -0.105000 | 3.02e-01 |
Signaling by moderate kinase activity BRAF mutants | 41 | 2.44e-01 | -0.105000 | 3.02e-01 |
Signaling downstream of RAS mutants | 41 | 2.44e-01 | -0.105000 | 3.02e-01 |
Methylation | 14 | 5.02e-01 | -0.104000 | 5.63e-01 |
p130Cas linkage to MAPK signaling for integrins | 15 | 4.93e-01 | -0.102000 | 5.54e-01 |
Advanced glycosylation endproduct receptor signaling | 13 | 5.26e-01 | -0.102000 | 5.85e-01 |
GPVI-mediated activation cascade | 32 | 3.20e-01 | -0.102000 | 3.82e-01 |
Interferon Signaling | 194 | 1.51e-02 | -0.101000 | 3.03e-02 |
C-type lectin receptors (CLRs) | 137 | 4.11e-02 | -0.101000 | 6.94e-02 |
Keratan sulfate/keratin metabolism | 33 | 3.16e-01 | -0.101000 | 3.78e-01 |
Caspase-mediated cleavage of cytoskeletal proteins | 12 | 5.47e-01 | -0.100000 | 6.05e-01 |
Metalloprotease DUBs | 19 | 4.54e-01 | -0.099100 | 5.16e-01 |
Hemostasis | 560 | 6.23e-05 | -0.098700 | 3.10e-04 |
Synthesis of PE | 12 | 5.56e-01 | -0.098000 | 6.13e-01 |
RAB geranylgeranylation | 57 | 2.03e-01 | -0.097300 | 2.59e-01 |
Interleukin-4 and Interleukin-13 signaling | 104 | 8.93e-02 | -0.096400 | 1.31e-01 |
Inflammasomes | 21 | 4.52e-01 | -0.094700 | 5.15e-01 |
Pregnenolone biosynthesis | 10 | 6.08e-01 | 0.093600 | 6.62e-01 |
Endogenous sterols | 26 | 4.11e-01 | -0.093000 | 4.74e-01 |
DDX58/IFIH1-mediated induction of interferon-alpha/beta | 77 | 1.58e-01 | -0.093000 | 2.09e-01 |
G alpha (s) signalling events | 153 | 4.80e-02 | -0.092500 | 7.92e-02 |
Endosomal Sorting Complex Required For Transport (ESCRT) | 31 | 3.74e-01 | -0.092200 | 4.36e-01 |
RHO GTPases Activate NADPH Oxidases | 22 | 4.54e-01 | 0.092100 | 5.16e-01 |
HSF1-dependent transactivation | 35 | 3.45e-01 | -0.092100 | 4.07e-01 |
Metabolism of fat-soluble vitamins | 46 | 2.83e-01 | -0.091400 | 3.45e-01 |
Negative regulation of FLT3 | 15 | 5.42e-01 | -0.090900 | 6.00e-01 |
Response to elevated platelet cytosolic Ca2+ | 121 | 8.56e-02 | -0.090400 | 1.26e-01 |
Platelet Aggregation (Plug Formation) | 37 | 3.43e-01 | -0.090000 | 4.05e-01 |
Class C/3 (Metabotropic glutamate/pheromone receptors) | 39 | 3.33e-01 | 0.089500 | 3.94e-01 |
APC-Cdc20 mediated degradation of Nek2A | 26 | 4.30e-01 | -0.089500 | 4.93e-01 |
Transcriptional Regulation by VENTX | 41 | 3.24e-01 | -0.088900 | 3.85e-01 |
Amine ligand-binding receptors | 41 | 3.24e-01 | -0.088900 | 3.85e-01 |
Formation of apoptosome | 10 | 6.26e-01 | -0.088900 | 6.78e-01 |
Regulation of the apoptosome activity | 10 | 6.26e-01 | -0.088900 | 6.78e-01 |
Chylomicron assembly | 10 | 6.27e-01 | 0.088700 | 6.78e-01 |
Anti-inflammatory response favouring Leishmania parasite infection | 164 | 5.04e-02 | -0.088500 | 8.23e-02 |
Leishmania parasite growth and survival | 164 | 5.04e-02 | -0.088500 | 8.23e-02 |
Phosphorylation of the APC/C | 20 | 4.97e-01 | -0.087700 | 5.58e-01 |
MHC class II antigen presentation | 104 | 1.22e-01 | -0.087700 | 1.69e-01 |
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | 20 | 5.01e-01 | -0.086800 | 5.62e-01 |
Signaling by RAF1 mutants | 37 | 3.65e-01 | -0.086000 | 4.28e-01 |
Platelet degranulation | 116 | 1.10e-01 | -0.085900 | 1.56e-01 |
Reproduction | 82 | 1.78e-01 | -0.085900 | 2.30e-01 |
rRNA modification in the nucleus and cytosol | 55 | 2.73e-01 | -0.085400 | 3.35e-01 |
ECM proteoglycans | 55 | 2.74e-01 | -0.085300 | 3.35e-01 |
Prolactin receptor signaling | 15 | 5.68e-01 | 0.085200 | 6.24e-01 |
Signaling by EGFR in Cancer | 25 | 4.65e-01 | -0.084400 | 5.25e-01 |
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 49 | 3.07e-01 | -0.084400 | 3.69e-01 |
Regulation of localization of FOXO transcription factors | 11 | 6.28e-01 | -0.084400 | 6.78e-01 |
Pre-NOTCH Transcription and Translation | 45 | 3.27e-01 | -0.084300 | 3.88e-01 |
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | 38 | 3.68e-01 | -0.084300 | 4.31e-01 |
Other semaphorin interactions | 18 | 5.36e-01 | -0.084300 | 5.93e-01 |
Diseases associated with visual transduction | 11 | 6.32e-01 | -0.083300 | 6.81e-01 |
Diseases of the neuronal system | 11 | 6.32e-01 | -0.083300 | 6.81e-01 |
Retinoid cycle disease events | 11 | 6.32e-01 | -0.083300 | 6.81e-01 |
Pre-NOTCH Expression and Processing | 61 | 2.63e-01 | -0.082900 | 3.23e-01 |
Diseases associated with O-glycosylation of proteins | 66 | 2.44e-01 | -0.082900 | 3.02e-01 |
Chondroitin sulfate biosynthesis | 18 | 5.44e-01 | -0.082600 | 6.01e-01 |
Cell surface interactions at the vascular wall | 129 | 1.07e-01 | 0.082200 | 1.52e-01 |
Pyroptosis | 26 | 4.69e-01 | 0.082000 | 5.30e-01 |
Metabolism of steroid hormones | 33 | 4.17e-01 | 0.081700 | 4.80e-01 |
Regulation of IFNA/IFNB signaling | 24 | 4.90e-01 | 0.081300 | 5.51e-01 |
Glycogen storage diseases | 14 | 6.01e-01 | -0.080800 | 6.56e-01 |
Termination of O-glycan biosynthesis | 25 | 4.88e-01 | 0.080100 | 5.49e-01 |
Other interleukin signaling | 24 | 4.98e-01 | -0.079800 | 5.59e-01 |
SLC-mediated transmembrane transport | 238 | 3.83e-02 | -0.077900 | 6.53e-02 |
Phase II - Conjugation of compounds | 109 | 1.62e-01 | 0.077500 | 2.13e-01 |
Androgen biosynthesis | 11 | 6.58e-01 | 0.077100 | 7.03e-01 |
SHC1 events in ERBB2 signaling | 22 | 5.32e-01 | -0.077000 | 5.91e-01 |
TRP channels | 24 | 5.23e-01 | -0.075200 | 5.83e-01 |
Hyaluronan uptake and degradation | 12 | 6.53e-01 | -0.074900 | 6.99e-01 |
Nicotinamide salvaging | 17 | 5.93e-01 | -0.074800 | 6.49e-01 |
Striated Muscle Contraction | 33 | 4.64e-01 | 0.073600 | 5.25e-01 |
Membrane binding and targetting of GAG proteins | 14 | 6.34e-01 | -0.073500 | 6.81e-01 |
Synthesis And Processing Of GAG, GAGPOL Polyproteins | 14 | 6.34e-01 | -0.073500 | 6.81e-01 |
GRB2:SOS provides linkage to MAPK signaling for Integrins | 15 | 6.23e-01 | -0.073300 | 6.75e-01 |
Xenobiotics | 24 | 5.35e-01 | 0.073200 | 5.93e-01 |
Phase I - Functionalization of compounds | 100 | 2.08e-01 | 0.072800 | 2.64e-01 |
Beta-oxidation of very long chain fatty acids | 10 | 6.90e-01 | -0.072700 | 7.34e-01 |
Platelet Adhesion to exposed collagen | 13 | 6.51e-01 | 0.072400 | 6.98e-01 |
ERBB2 Regulates Cell Motility | 15 | 6.31e-01 | -0.071700 | 6.81e-01 |
Oncogene Induced Senescence | 35 | 4.64e-01 | -0.071500 | 5.25e-01 |
Hyaluronan metabolism | 17 | 6.11e-01 | -0.071300 | 6.64e-01 |
O-linked glycosylation of mucins | 62 | 3.32e-01 | -0.071300 | 3.93e-01 |
Organic cation/anion/zwitterion transport | 15 | 6.36e-01 | 0.070700 | 6.83e-01 |
Class A/1 (Rhodopsin-like receptors) | 312 | 3.19e-02 | 0.070500 | 5.63e-02 |
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 16 | 6.27e-01 | -0.070100 | 6.78e-01 |
Scavenging by Class A Receptors | 19 | 6.02e-01 | -0.069000 | 6.57e-01 |
FGFR2b ligand binding and activation | 10 | 7.07e-01 | -0.068700 | 7.49e-01 |
Basigin interactions | 24 | 5.65e-01 | -0.067900 | 6.21e-01 |
Immune System | 1877 | 9.93e-07 | -0.067600 | 1.03e-05 |
Phenylalanine and tyrosine metabolism | 10 | 7.11e-01 | 0.067600 | 7.53e-01 |
Interleukin-2 family signaling | 40 | 4.60e-01 | -0.067500 | 5.22e-01 |
CYP2E1 reactions | 11 | 6.99e-01 | 0.067300 | 7.42e-01 |
Retinoid metabolism and transport | 42 | 4.52e-01 | -0.067000 | 5.15e-01 |
ADORA2B mediated anti-inflammatory cytokines production | 132 | 1.85e-01 | -0.066700 | 2.39e-01 |
Aberrant regulation of mitotic exit in cancer due to RB1 defects | 20 | 6.07e-01 | -0.066400 | 6.61e-01 |
Chylomicron remodeling | 10 | 7.17e-01 | 0.066200 | 7.58e-01 |
G-protein activation | 24 | 5.75e-01 | -0.066200 | 6.30e-01 |
Metabolism of porphyrins | 27 | 5.54e-01 | -0.065700 | 6.11e-01 |
Blood group systems biosynthesis | 22 | 5.95e-01 | 0.065500 | 6.50e-01 |
RIPK1-mediated regulated necrosis | 27 | 5.57e-01 | -0.065300 | 6.13e-01 |
Regulation of necroptotic cell death | 27 | 5.57e-01 | -0.065300 | 6.13e-01 |
Thyroxine biosynthesis | 10 | 7.23e-01 | -0.064800 | 7.62e-01 |
Glucagon-type ligand receptors | 33 | 5.20e-01 | -0.064700 | 5.80e-01 |
Paracetamol ADME | 30 | 5.42e-01 | 0.064400 | 6.00e-01 |
Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | 14 | 6.80e-01 | -0.063700 | 7.25e-01 |
Pre-NOTCH Processing in Golgi | 18 | 6.44e-01 | -0.062900 | 6.91e-01 |
Formation of Fibrin Clot (Clotting Cascade) | 37 | 5.09e-01 | 0.062700 | 5.69e-01 |
Interferon gamma signaling | 90 | 3.13e-01 | -0.061500 | 3.75e-01 |
NOD1/2 Signaling Pathway | 29 | 5.70e-01 | -0.060900 | 6.26e-01 |
Acyl chain remodelling of PE | 24 | 6.06e-01 | -0.060800 | 6.61e-01 |
FCGR activation | 12 | 7.19e-01 | 0.060100 | 7.59e-01 |
Degradation of the extracellular matrix | 108 | 2.85e-01 | -0.059500 | 3.46e-01 |
Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | 18 | 6.65e-01 | -0.058900 | 7.11e-01 |
Diseases of carbohydrate metabolism | 30 | 5.77e-01 | -0.058900 | 6.32e-01 |
Synthesis of PA | 35 | 5.48e-01 | -0.058600 | 6.05e-01 |
Biological oxidations | 216 | 1.44e-01 | 0.057600 | 1.93e-01 |
GAB1 signalosome | 17 | 6.82e-01 | -0.057400 | 7.27e-01 |
Signaling by GPCR | 671 | 1.13e-02 | -0.057200 | 2.38e-02 |
Nucleotide-like (purinergic) receptors | 13 | 7.21e-01 | 0.057100 | 7.61e-01 |
Activation of the phototransduction cascade | 11 | 7.43e-01 | 0.057000 | 7.82e-01 |
Regulation of TP53 Activity through Methylation | 18 | 6.77e-01 | 0.056700 | 7.23e-01 |
HSF1 activation | 27 | 6.11e-01 | -0.056600 | 6.64e-01 |
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 117 | 2.96e-01 | -0.055900 | 3.58e-01 |
APC/C:Cdc20 mediated degradation of Cyclin B | 24 | 6.36e-01 | -0.055800 | 6.83e-01 |
The phototransduction cascade | 32 | 5.91e-01 | 0.054800 | 6.48e-01 |
Na+/Cl- dependent neurotransmitter transporters | 18 | 6.87e-01 | 0.054800 | 7.32e-01 |
CD28 dependent Vav1 pathway | 11 | 7.54e-01 | -0.054500 | 7.91e-01 |
Tight junction interactions | 28 | 6.19e-01 | -0.054200 | 6.73e-01 |
Eicosanoid ligand-binding receptors | 14 | 7.32e-01 | -0.052800 | 7.72e-01 |
Peptide hormone biosynthesis | 11 | 7.65e-01 | -0.052100 | 7.99e-01 |
Amino acid transport across the plasma membrane | 30 | 6.23e-01 | -0.051900 | 6.75e-01 |
TNFs bind their physiological receptors | 25 | 6.54e-01 | 0.051800 | 7.00e-01 |
Amyloid fiber formation | 53 | 5.19e-01 | -0.051200 | 5.79e-01 |
G alpha (q) signalling events | 206 | 2.13e-01 | -0.050200 | 2.69e-01 |
ERBB2 Activates PTK6 Signaling | 13 | 7.55e-01 | 0.050000 | 7.91e-01 |
Inactivation, recovery and regulation of the phototransduction cascade | 31 | 6.38e-01 | 0.048800 | 6.85e-01 |
GPCR downstream signalling | 604 | 4.10e-02 | -0.048600 | 6.94e-02 |
DAP12 interactions | 40 | 6.00e-01 | -0.047900 | 6.55e-01 |
N-Glycan antennae elongation | 15 | 7.50e-01 | -0.047500 | 7.87e-01 |
Triglyceride biosynthesis | 13 | 7.72e-01 | -0.046300 | 8.05e-01 |
NR1H2 and NR1H3-mediated signaling | 53 | 5.65e-01 | -0.045700 | 6.21e-01 |
ABC transporters in lipid homeostasis | 17 | 7.47e-01 | 0.045200 | 7.85e-01 |
Regulation of innate immune responses to cytosolic DNA | 14 | 7.70e-01 | -0.045100 | 8.04e-01 |
Neutrophil degranulation | 458 | 9.73e-02 | -0.045100 | 1.40e-01 |
Binding and Uptake of Ligands by Scavenger Receptors | 41 | 6.20e-01 | 0.044700 | 6.73e-01 |
Assembly of active LPL and LIPC lipase complexes | 17 | 7.50e-01 | -0.044500 | 7.88e-01 |
Gastrin-CREB signalling pathway via PKC and MAPK | 17 | 7.60e-01 | -0.042800 | 7.95e-01 |
Translation of Replicase and Assembly of the Replication Transcription Complex | 13 | 7.91e-01 | -0.042400 | 8.24e-01 |
EGFR downregulation | 30 | 6.89e-01 | -0.042200 | 7.33e-01 |
Arachidonic acid metabolism | 56 | 6.02e-01 | -0.040300 | 6.57e-01 |
Metabolic disorders of biological oxidation enzymes | 32 | 6.99e-01 | -0.039500 | 7.42e-01 |
Post-chaperonin tubulin folding pathway | 23 | 7.44e-01 | -0.039400 | 7.82e-01 |
Downregulation of ERBB2 signaling | 28 | 7.21e-01 | -0.039000 | 7.61e-01 |
Collagen degradation | 39 | 6.88e-01 | -0.037200 | 7.32e-01 |
Carboxyterminal post-translational modifications of tubulin | 40 | 6.86e-01 | 0.036900 | 7.31e-01 |
LGI-ADAM interactions | 14 | 8.13e-01 | -0.036400 | 8.45e-01 |
Spry regulation of FGF signaling | 16 | 8.03e-01 | -0.036100 | 8.34e-01 |
Free fatty acids regulate insulin secretion | 10 | 8.46e-01 | 0.035400 | 8.74e-01 |
Caspase activation via extrinsic apoptotic signalling pathway | 25 | 7.60e-01 | -0.035200 | 7.95e-01 |
Interleukin-2 signaling | 11 | 8.42e-01 | -0.034600 | 8.72e-01 |
Alpha-protein kinase 1 signaling pathway | 10 | 8.52e-01 | -0.034100 | 8.78e-01 |
TRAF6 mediated IRF7 activation | 28 | 7.55e-01 | -0.034000 | 7.91e-01 |
Phase 4 - resting membrane potential | 19 | 8.00e-01 | -0.033500 | 8.32e-01 |
NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 43 | 7.10e-01 | -0.032800 | 7.52e-01 |
CASP8 activity is inhibited | 11 | 8.53e-01 | 0.032200 | 8.78e-01 |
Dimerization of procaspase-8 | 11 | 8.53e-01 | 0.032200 | 8.78e-01 |
Regulation by c-FLIP | 11 | 8.53e-01 | 0.032200 | 8.78e-01 |
Bile acid and bile salt metabolism | 45 | 7.09e-01 | -0.032100 | 7.51e-01 |
Signaling by high-kinase activity BRAF mutants | 32 | 7.58e-01 | -0.031400 | 7.94e-01 |
Metallothioneins bind metals | 11 | 8.65e-01 | 0.029700 | 8.87e-01 |
Innate Immune System | 999 | 1.21e-01 | -0.028900 | 1.68e-01 |
Lewis blood group biosynthesis | 18 | 8.32e-01 | 0.028900 | 8.63e-01 |
Acyl chain remodelling of PI | 16 | 8.43e-01 | -0.028500 | 8.72e-01 |
GRB2 events in EGFR signaling | 13 | 8.60e-01 | 0.028300 | 8.83e-01 |
Keratan sulfate degradation | 12 | 8.67e-01 | 0.028000 | 8.88e-01 |
GRB2 events in ERBB2 signaling | 16 | 8.50e-01 | -0.027300 | 8.77e-01 |
Gap junction assembly | 18 | 8.45e-01 | 0.026700 | 8.73e-01 |
Glutathione conjugation | 37 | 7.84e-01 | 0.026000 | 8.17e-01 |
G alpha (i) signalling events | 306 | 4.50e-01 | -0.025100 | 5.14e-01 |
Cytochrome P450 - arranged by substrate type | 64 | 7.40e-01 | 0.024000 | 7.79e-01 |
SHC1 events in EGFR signaling | 14 | 8.79e-01 | -0.023500 | 8.99e-01 |
Synthesis of PIPs at the Golgi membrane | 17 | 8.70e-01 | 0.023000 | 8.91e-01 |
Cytosolic sulfonation of small molecules | 23 | 8.49e-01 | -0.022900 | 8.77e-01 |
Keratan sulfate biosynthesis | 28 | 8.37e-01 | -0.022500 | 8.67e-01 |
Plasma lipoprotein assembly | 19 | 8.67e-01 | -0.022200 | 8.88e-01 |
Plasma lipoprotein remodeling | 32 | 8.29e-01 | -0.022100 | 8.60e-01 |
Intrinsic Pathway of Fibrin Clot Formation | 21 | 8.62e-01 | 0.022000 | 8.85e-01 |
Synthesis of bile acids and bile salts via 27-hydroxycholesterol | 15 | 8.87e-01 | -0.021200 | 9.06e-01 |
Attenuation phase | 25 | 8.58e-01 | -0.020700 | 8.82e-01 |
GPCR ligand binding | 444 | 4.79e-01 | 0.019600 | 5.40e-01 |
Chaperone Mediated Autophagy | 19 | 8.87e-01 | 0.018800 | 9.06e-01 |
Transport of bile salts and organic acids, metal ions and amine compounds | 84 | 7.73e-01 | -0.018200 | 8.05e-01 |
Acyl chain remodelling of PC | 26 | 8.77e-01 | -0.017600 | 8.97e-01 |
Cell recruitment (pro-inflammatory response) | 25 | 8.89e-01 | 0.016100 | 9.07e-01 |
Purinergic signaling in leishmaniasis infection | 25 | 8.89e-01 | 0.016100 | 9.07e-01 |
Mucopolysaccharidoses | 10 | 9.31e-01 | -0.015900 | 9.40e-01 |
Aflatoxin activation and detoxification | 20 | 9.05e-01 | -0.015400 | 9.20e-01 |
The canonical retinoid cycle in rods (twilight vision) | 23 | 9.01e-01 | 0.015000 | 9.16e-01 |
PIWI-interacting RNA (piRNA) biogenesis | 29 | 8.90e-01 | -0.014800 | 9.07e-01 |
Tandem pore domain potassium channels | 12 | 9.30e-01 | -0.014700 | 9.40e-01 |
TRAF6-mediated induction of TAK1 complex within TLR4 complex | 15 | 9.23e-01 | -0.014300 | 9.35e-01 |
Post-translational modification: synthesis of GPI-anchored proteins | 90 | 8.19e-01 | -0.014000 | 8.50e-01 |
Diseases associated with the TLR signaling cascade | 29 | 8.99e-01 | 0.013600 | 9.15e-01 |
Diseases of Immune System | 29 | 8.99e-01 | 0.013600 | 9.15e-01 |
Acyl chain remodelling of PS | 21 | 9.14e-01 | 0.013600 | 9.27e-01 |
Cellular hexose transport | 21 | 9.22e-01 | 0.012400 | 9.34e-01 |
Response to metal ions | 14 | 9.37e-01 | 0.012100 | 9.47e-01 |
IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | 14 | 9.38e-01 | 0.012000 | 9.47e-01 |
Sealing of the nuclear envelope (NE) by ESCRT-III | 31 | 9.13e-01 | 0.011300 | 9.27e-01 |
Late endosomal microautophagy | 32 | 9.13e-01 | 0.011200 | 9.27e-01 |
RA biosynthesis pathway | 22 | 9.45e-01 | -0.008490 | 9.53e-01 |
Thrombin signalling through proteinase activated receptors (PARs) | 32 | 9.40e-01 | -0.007750 | 9.48e-01 |
Regulated Necrosis | 53 | 9.30e-01 | 0.006980 | 9.40e-01 |
Visual phototransduction | 93 | 9.16e-01 | 0.006300 | 9.29e-01 |
Nicotinate metabolism | 29 | 9.58e-01 | 0.005680 | 9.65e-01 |
Caspase activation via Death Receptors in the presence of ligand | 16 | 9.71e-01 | 0.005260 | 9.76e-01 |
TICAM1,TRAF6-dependent induction of TAK1 complex | 10 | 9.78e-01 | -0.005030 | 9.83e-01 |
Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | 24 | 9.70e-01 | 0.004470 | 9.76e-01 |
Interleukin-20 family signaling | 25 | 9.70e-01 | 0.004290 | 9.76e-01 |
Glyoxylate metabolism and glycine degradation | 30 | 9.83e-01 | 0.002190 | 9.87e-01 |
ROS and RNS production in phagocytes | 35 | 9.86e-01 | 0.001710 | 9.89e-01 |
Metabolism of amine-derived hormones | 17 | 9.91e-01 | 0.001660 | 9.93e-01 |
Pyrimidine salvage | 10 | 9.96e-01 | -0.000903 | 9.97e-01 |
MAP2K and MAPK activation | 36 | 9.94e-01 | -0.000723 | 9.96e-01 |
Acyl chain remodelling of PG | 18 | 9.96e-01 | 0.000668 | 9.97e-01 |
Transport of vitamins, nucleosides, and related molecules | 38 | 9.98e-01 | 0.000179 | 9.98e-01 |
Folding of actin by CCT/TriC
441 | |
---|---|
set | Folding of actin by CCT/TriC |
setSize | 10 |
pANOVA | 0.000212 |
s.dist | -0.676 |
p.adjustANOVA | 0.000852 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ACTB | -21952.5 |
CCT7 | -21406.5 |
CCT6A | -20888.5 |
CCT8 | -20835.5 |
CCT6B | -18632.5 |
TCP1 | -16726.5 |
CCT4 | -16427.5 |
CCT5 | -15859.5 |
CCT2 | -14332.5 |
CCT3 | -11795.5 |
GeneID | Gene Rank |
---|---|
ACTB | -21952.5 |
CCT7 | -21406.5 |
CCT6A | -20888.5 |
CCT8 | -20835.5 |
CCT6B | -18632.5 |
TCP1 | -16726.5 |
CCT4 | -16427.5 |
CCT5 | -15859.5 |
CCT2 | -14332.5 |
CCT3 | -11795.5 |
FOXO-mediated transcription of cell cycle genes
426 | |
---|---|
set | FOXO-mediated transcription of cell cycle genes |
setSize | 16 |
pANOVA | 1.18e-05 |
s.dist | -0.632 |
p.adjustANOVA | 8.23e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
BTG1 | -21718.5 |
KLF4 | -21404.5 |
SMAD4 | -20586.5 |
FOXO3 | -19624.5 |
CAV1 | -19555.5 |
FOXG1 | -19268.5 |
CDKN1B | -19220.5 |
PCBP4 | -18630.5 |
SMAD2 | -17580.5 |
RBL2 | -17219.5 |
CCNG2 | -16510.5 |
MSTN | -15995.5 |
GADD45A | -15001.5 |
CDKN1A | -14105.5 |
SMAD3 | -13045.5 |
FOXO1 | -7497.5 |
GeneID | Gene Rank |
---|---|
BTG1 | -21718.5 |
KLF4 | -21404.5 |
SMAD4 | -20586.5 |
FOXO3 | -19624.5 |
CAV1 | -19555.5 |
FOXG1 | -19268.5 |
CDKN1B | -19220.5 |
PCBP4 | -18630.5 |
SMAD2 | -17580.5 |
RBL2 | -17219.5 |
CCNG2 | -16510.5 |
MSTN | -15995.5 |
GADD45A | -15001.5 |
CDKN1A | -14105.5 |
SMAD3 | -13045.5 |
FOXO1 | -7497.5 |
NOTCH4 Activation and Transmission of Signal to the Nucleus
781 | |
---|---|
set | NOTCH4 Activation and Transmission of Signal to the Nucleus |
setSize | 11 |
pANOVA | 6e-04 |
s.dist | -0.597 |
p.adjustANOVA | 0.00199 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NOTCH4 | -21359.5 |
NCSTN | -20839.5 |
JAG1 | -19940.5 |
ADAM10 | -19689.5 |
DLL4 | -19060.5 |
PSENEN | -18441.5 |
PSEN1 | -18288.5 |
PSEN2 | -17761.5 |
YWHAZ | -17474.5 |
APH1B | -6959.5 |
APH1A | -5574.5 |
GeneID | Gene Rank |
---|---|
NOTCH4 | -21359.5 |
NCSTN | -20839.5 |
JAG1 | -19940.5 |
ADAM10 | -19689.5 |
DLL4 | -19060.5 |
PSENEN | -18441.5 |
PSEN1 | -18288.5 |
PSEN2 | -17761.5 |
YWHAZ | -17474.5 |
APH1B | -6959.5 |
APH1A | -5574.5 |
Repression of WNT target genes
1124 | |
---|---|
set | Repression of WNT target genes |
setSize | 13 |
pANOVA | 0.00032 |
s.dist | -0.576 |
p.adjustANOVA | 0.0012 |
Top enriched genes
GeneID | Gene Rank |
---|---|
TCF7 | -22074.5 |
AXIN2 | -20162.5 |
MYC | -19668.5 |
TLE1 | -18877.5 |
CTBP2 | -18822.5 |
TLE3 | -18435.5 |
TLE4 | -18212.5 |
LEF1 | -18002.5 |
TCF7L1 | -16813.5 |
TLE2 | -13046.5 |
HDAC1 | -12954.5 |
TCF7L2 | -12880.5 |
CTBP1 | -5544.5 |
GeneID | Gene Rank |
---|---|
TCF7 | -22074.5 |
AXIN2 | -20162.5 |
MYC | -19668.5 |
TLE1 | -18877.5 |
CTBP2 | -18822.5 |
TLE3 | -18435.5 |
TLE4 | -18212.5 |
LEF1 | -18002.5 |
TCF7L1 | -16813.5 |
TLE2 | -13046.5 |
HDAC1 | -12954.5 |
TCF7L2 | -12880.5 |
CTBP1 | -5544.5 |
Crosslinking of collagen fibrils
243 | |
---|---|
set | Crosslinking of collagen fibrils |
setSize | 10 |
pANOVA | 0.00215 |
s.dist | -0.56 |
p.adjustANOVA | 0.00589 |
Top enriched genes
GeneID | Gene Rank |
---|---|
LOXL3 | -21905.5 |
TLL1 | -21683.5 |
TLL2 | -21277.5 |
PCOLCE | -18008.5 |
LOX | -17263.5 |
LOXL1 | -16120.5 |
PXDN | -15419.5 |
LOXL2 | -12814.5 |
LOXL4 | -12576.5 |
BMP1 | -6631.5 |
GeneID | Gene Rank |
---|---|
LOXL3 | -21905.5 |
TLL1 | -21683.5 |
TLL2 | -21277.5 |
PCOLCE | -18008.5 |
LOX | -17263.5 |
LOXL1 | -16120.5 |
PXDN | -15419.5 |
LOXL2 | -12814.5 |
LOXL4 | -12576.5 |
BMP1 | -6631.5 |
Processing of Intronless Pre-mRNAs
955 | |
---|---|
set | Processing of Intronless Pre-mRNAs |
setSize | 19 |
pANOVA | 2.36e-05 |
s.dist | -0.56 |
p.adjustANOVA | 0.000141 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NCBP1 | -21980.5 |
PAPOLA | -21384.5 |
FIP1L1 | -21233.5 |
CPSF3 | -20988.5 |
CPSF2 | -20751.5 |
CPSF4 | -20320.5 |
CLP1 | -20138.5 |
CSTF1 | -19976.5 |
WDR33 | -19593.5 |
NCBP2 | -18428.5 |
NUDT21 | -18270.5 |
CSTF3 | -16705.5 |
SYMPK | -16007.5 |
PCF11 | -15073.5 |
CPSF7 | -12935.5 |
CPSF6 | -12106.5 |
CPSF1 | -9582.5 |
CSTF2T | -7070.5 |
PABPN1 | 1646.5 |
GeneID | Gene Rank |
---|---|
NCBP1 | -21980.5 |
PAPOLA | -21384.5 |
FIP1L1 | -21233.5 |
CPSF3 | -20988.5 |
CPSF2 | -20751.5 |
CPSF4 | -20320.5 |
CLP1 | -20138.5 |
CSTF1 | -19976.5 |
WDR33 | -19593.5 |
NCBP2 | -18428.5 |
NUDT21 | -18270.5 |
CSTF3 | -16705.5 |
SYMPK | -16007.5 |
PCF11 | -15073.5 |
CPSF7 | -12935.5 |
CPSF6 | -12106.5 |
CPSF1 | -9582.5 |
CSTF2T | -7070.5 |
PABPN1 | 1646.5 |
Disorders of Developmental Biology
339 | |
---|---|
set | Disorders of Developmental Biology |
setSize | 11 |
pANOVA | 0.00204 |
s.dist | -0.537 |
p.adjustANOVA | 0.00565 |
Top enriched genes
GeneID | Gene Rank |
---|---|
SIN3A | -20791.5 |
CAMK4 | -20762.5 |
BDNF | -19343.5 |
CALM1 | -19082.5 |
HDAC3 | -17766.5 |
TBL1XR1 | -17032.5 |
GPS2 | -16994.5 |
PRKACA | -16613.5 |
NCOR1 | -13722.5 |
HDAC1 | -12954.5 |
NCOR2 | -1658.5 |
GeneID | Gene Rank |
---|---|
SIN3A | -20791.5 |
CAMK4 | -20762.5 |
BDNF | -19343.5 |
CALM1 | -19082.5 |
HDAC3 | -17766.5 |
TBL1XR1 | -17032.5 |
GPS2 | -16994.5 |
PRKACA | -16613.5 |
NCOR1 | -13722.5 |
HDAC1 | -12954.5 |
NCOR2 | -1658.5 |
Disorders of Nervous System Development
340 | |
---|---|
set | Disorders of Nervous System Development |
setSize | 11 |
pANOVA | 0.00204 |
s.dist | -0.537 |
p.adjustANOVA | 0.00565 |
Top enriched genes
GeneID | Gene Rank |
---|---|
SIN3A | -20791.5 |
CAMK4 | -20762.5 |
BDNF | -19343.5 |
CALM1 | -19082.5 |
HDAC3 | -17766.5 |
TBL1XR1 | -17032.5 |
GPS2 | -16994.5 |
PRKACA | -16613.5 |
NCOR1 | -13722.5 |
HDAC1 | -12954.5 |
NCOR2 | -1658.5 |
GeneID | Gene Rank |
---|---|
SIN3A | -20791.5 |
CAMK4 | -20762.5 |
BDNF | -19343.5 |
CALM1 | -19082.5 |
HDAC3 | -17766.5 |
TBL1XR1 | -17032.5 |
GPS2 | -16994.5 |
PRKACA | -16613.5 |
NCOR1 | -13722.5 |
HDAC1 | -12954.5 |
NCOR2 | -1658.5 |
Loss of function of MECP2 in Rett syndrome
676 | |
---|---|
set | Loss of function of MECP2 in Rett syndrome |
setSize | 11 |
pANOVA | 0.00204 |
s.dist | -0.537 |
p.adjustANOVA | 0.00565 |
Top enriched genes
GeneID | Gene Rank |
---|---|
SIN3A | -20791.5 |
CAMK4 | -20762.5 |
BDNF | -19343.5 |
CALM1 | -19082.5 |
HDAC3 | -17766.5 |
TBL1XR1 | -17032.5 |
GPS2 | -16994.5 |
PRKACA | -16613.5 |
NCOR1 | -13722.5 |
HDAC1 | -12954.5 |
NCOR2 | -1658.5 |
GeneID | Gene Rank |
---|---|
SIN3A | -20791.5 |
CAMK4 | -20762.5 |
BDNF | -19343.5 |
CALM1 | -19082.5 |
HDAC3 | -17766.5 |
TBL1XR1 | -17032.5 |
GPS2 | -16994.5 |
PRKACA | -16613.5 |
NCOR1 | -13722.5 |
HDAC1 | -12954.5 |
NCOR2 | -1658.5 |
Pervasive developmental disorders
902 | |
---|---|
set | Pervasive developmental disorders |
setSize | 11 |
pANOVA | 0.00204 |
s.dist | -0.537 |
p.adjustANOVA | 0.00565 |
Top enriched genes
GeneID | Gene Rank |
---|---|
SIN3A | -20791.5 |
CAMK4 | -20762.5 |
BDNF | -19343.5 |
CALM1 | -19082.5 |
HDAC3 | -17766.5 |
TBL1XR1 | -17032.5 |
GPS2 | -16994.5 |
PRKACA | -16613.5 |
NCOR1 | -13722.5 |
HDAC1 | -12954.5 |
NCOR2 | -1658.5 |
GeneID | Gene Rank |
---|---|
SIN3A | -20791.5 |
CAMK4 | -20762.5 |
BDNF | -19343.5 |
CALM1 | -19082.5 |
HDAC3 | -17766.5 |
TBL1XR1 | -17032.5 |
GPS2 | -16994.5 |
PRKACA | -16613.5 |
NCOR1 | -13722.5 |
HDAC1 | -12954.5 |
NCOR2 | -1658.5 |
POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation
884 | |
---|---|
set | POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation |
setSize | 10 |
pANOVA | 0.00331 |
s.dist | -0.536 |
p.adjustANOVA | 0.00835 |
Top enriched genes
GeneID | Gene Rank |
---|---|
GSC | -21580.5 |
GATA6 | -20885.5 |
CDX2 | -20629.5 |
SOX2 | -17376.5 |
EOMES | -17246.5 |
TSC22D1 | -16794.5 |
DKK1 | -14601.5 |
NANOG | -10973.5 |
POU5F1 | -10570.5 |
HHEX | -9901.5 |
GeneID | Gene Rank |
---|---|
GSC | -21580.5 |
GATA6 | -20885.5 |
CDX2 | -20629.5 |
SOX2 | -17376.5 |
EOMES | -17246.5 |
TSC22D1 | -16794.5 |
DKK1 | -14601.5 |
NANOG | -10973.5 |
POU5F1 | -10570.5 |
HHEX | -9901.5 |
Transcriptional regulation of testis differentiation
1426 | |
---|---|
set | Transcriptional regulation of testis differentiation |
setSize | 12 |
pANOVA | 0.00152 |
s.dist | -0.529 |
p.adjustANOVA | 0.00447 |
Top enriched genes
GeneID | Gene Rank |
---|---|
FOXL2 | -22097.5 |
WT1 | -21974.5 |
GATA4 | -21358.5 |
FGF9 | -19688.5 |
SOX9 | -19384.5 |
DHH | -19175.5 |
ZFPM2 | -16001.5 |
AMH | -15831.5 |
PTGDS | -11740.5 |
DMRT1 | -10832.5 |
WNT4 | -10808.5 |
NR5A1 | -2564.5 |
GeneID | Gene Rank |
---|---|
FOXL2 | -22097.5 |
WT1 | -21974.5 |
GATA4 | -21358.5 |
FGF9 | -19688.5 |
SOX9 | -19384.5 |
DHH | -19175.5 |
ZFPM2 | -16001.5 |
AMH | -15831.5 |
PTGDS | -11740.5 |
DMRT1 | -10832.5 |
WNT4 | -10808.5 |
NR5A1 | -2564.5 |
Beta defensins
117 | |
---|---|
set | Beta defensins |
setSize | 32 |
pANOVA | 2.31e-07 |
s.dist | 0.528 |
p.adjustANOVA | 2.7e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
DEFB123 | 3904.5 |
DEFB118 | 3684.5 |
DEFB133 | 3577.5 |
DEFB125 | 3572.5 |
DEFB119 | 3366.5 |
DEFB107A | 3338.0 |
TLR1 | 3265.5 |
DEFB108B | 3259.5 |
CCR2 | 3178.5 |
DEFB1 | 0.5 |
DEFB105A | 0.5 |
DEFB103A | 0.5 |
DEFB110 | 0.5 |
DEFB132 | -1109.5 |
DEFB131 | -1481.5 |
DEFB127 | -1528.5 |
CCR6 | -1547.5 |
DEFB135 | -1567.5 |
DEFB124 | -1714.5 |
DEFB115 | -2207.5 |
GeneID | Gene Rank |
---|---|
DEFB123 | 3904.5 |
DEFB118 | 3684.5 |
DEFB133 | 3577.5 |
DEFB125 | 3572.5 |
DEFB119 | 3366.5 |
DEFB107A | 3338.0 |
TLR1 | 3265.5 |
DEFB108B | 3259.5 |
CCR2 | 3178.5 |
DEFB1 | 0.5 |
DEFB105A | 0.5 |
DEFB103A | 0.5 |
DEFB110 | 0.5 |
DEFB132 | -1109.5 |
DEFB131 | -1481.5 |
DEFB127 | -1528.5 |
CCR6 | -1547.5 |
DEFB135 | -1567.5 |
DEFB124 | -1714.5 |
DEFB115 | -2207.5 |
DEFB116 | -2448.5 |
DEFB121 | -3234.5 |
DEFB128 | -4019.5 |
DEFB126 | -5150.5 |
DEFB113 | -6447.5 |
DEFB114 | -7523.5 |
DEFB106A | -7838.0 |
DEFB136 | -8037.5 |
DEFB134 | -8491.5 |
DEFB104A | -8764.0 |
DEFB129 | -9184.5 |
TLR2 | -17767.5 |
Regulated proteolysis of p75NTR
1069 | |
---|---|
set | Regulated proteolysis of p75NTR |
setSize | 11 |
pANOVA | 0.0025 |
s.dist | -0.526 |
p.adjustANOVA | 0.00665 |
Top enriched genes
GeneID | Gene Rank |
---|---|
TRAF6 | -21294.5 |
ADAM17 | -21224.5 |
NCSTN | -20839.5 |
PSENEN | -18441.5 |
PSEN1 | -18288.5 |
PSEN2 | -17761.5 |
NFKB1 | -16140.5 |
NGFR | -14853.5 |
RELA | -13808.5 |
APH1B | -6959.5 |
APH1A | -5574.5 |
GeneID | Gene Rank |
---|---|
TRAF6 | -21294.5 |
ADAM17 | -21224.5 |
NCSTN | -20839.5 |
PSENEN | -18441.5 |
PSEN1 | -18288.5 |
PSEN2 | -17761.5 |
NFKB1 | -16140.5 |
NGFR | -14853.5 |
RELA | -13808.5 |
APH1B | -6959.5 |
APH1A | -5574.5 |
Diseases associated with glycosylation precursor biosynthesis
325 | |
---|---|
set | Diseases associated with glycosylation precursor biosynthesis |
setSize | 15 |
pANOVA | 0.000433 |
s.dist | -0.525 |
p.adjustANOVA | 0.00153 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PGM1 | -21936.5 |
GALE | -21873.5 |
DOLK | -20285.5 |
DPM3 | -20160.5 |
SRD5A3 | -19374.5 |
GFPT1 | -18453.5 |
MPI | -18324.5 |
GALK1 | -18190.5 |
GNE | -17746.5 |
DPM1 | -17482.5 |
DHDDS | -16076.5 |
NUS1 | -12517.5 |
PMM2 | -9496.5 |
GALT | -4110.5 |
DPM2 | -2510.5 |
GeneID | Gene Rank |
---|---|
PGM1 | -21936.5 |
GALE | -21873.5 |
DOLK | -20285.5 |
DPM3 | -20160.5 |
SRD5A3 | -19374.5 |
GFPT1 | -18453.5 |
MPI | -18324.5 |
GALK1 | -18190.5 |
GNE | -17746.5 |
DPM1 | -17482.5 |
DHDDS | -16076.5 |
NUS1 | -12517.5 |
PMM2 | -9496.5 |
GALT | -4110.5 |
DPM2 | -2510.5 |
Processing of Capped Intronless Pre-mRNA
953 | |
---|---|
set | Processing of Capped Intronless Pre-mRNA |
setSize | 28 |
pANOVA | 1.57e-06 |
s.dist | -0.524 |
p.adjustANOVA | 1.59e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NCBP1 | -21980.5 |
PAPOLA | -21384.5 |
LSM11 | -21355.5 |
FIP1L1 | -21233.5 |
CPSF3 | -20988.5 |
CPSF2 | -20751.5 |
LSM10 | -20335.5 |
CPSF4 | -20320.5 |
CLP1 | -20138.5 |
CSTF1 | -19976.5 |
SLBP | -19880.5 |
WDR33 | -19593.5 |
SNRPD3 | -19465.5 |
SNRPG | -19279.5 |
NCBP2 | -18428.5 |
NUDT21 | -18270.5 |
CSTF3 | -16705.5 |
SNRPF | -16209.5 |
SYMPK | -16007.5 |
PCF11 | -15073.5 |
GeneID | Gene Rank |
---|---|
NCBP1 | -21980.5 |
PAPOLA | -21384.5 |
LSM11 | -21355.5 |
FIP1L1 | -21233.5 |
CPSF3 | -20988.5 |
CPSF2 | -20751.5 |
LSM10 | -20335.5 |
CPSF4 | -20320.5 |
CLP1 | -20138.5 |
CSTF1 | -19976.5 |
SLBP | -19880.5 |
WDR33 | -19593.5 |
SNRPD3 | -19465.5 |
SNRPG | -19279.5 |
NCBP2 | -18428.5 |
NUDT21 | -18270.5 |
CSTF3 | -16705.5 |
SNRPF | -16209.5 |
SYMPK | -16007.5 |
PCF11 | -15073.5 |
CPSF7 | -12935.5 |
CPSF6 | -12106.5 |
ZNF473 | -12032.5 |
CPSF1 | -9582.5 |
CSTF2T | -7070.5 |
SNRPE | -3211.5 |
SNRPB | -2288.5 |
PABPN1 | 1646.5 |
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
1364 | |
---|---|
set | TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest |
setSize | 14 |
pANOVA | 7e-04 |
s.dist | -0.523 |
p.adjustANOVA | 0.00225 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CCNE1 | -21436.5 |
CCNA1 | -21140.5 |
E2F8 | -20938.5 |
E2F1 | -19632.5 |
CDKN1B | -19220.5 |
CCNA2 | -19061.5 |
PCBP4 | -18630.5 |
CDK2 | -16367.5 |
E2F7 | -15412.5 |
CDKN1A | -14105.5 |
CCNE2 | -11345.5 |
ZNF385A | -11096.5 |
TP53 | -8022.5 |
ARID3A | -5938.5 |
GeneID | Gene Rank |
---|---|
CCNE1 | -21436.5 |
CCNA1 | -21140.5 |
E2F8 | -20938.5 |
E2F1 | -19632.5 |
CDKN1B | -19220.5 |
CCNA2 | -19061.5 |
PCBP4 | -18630.5 |
CDK2 | -16367.5 |
E2F7 | -15412.5 |
CDKN1A | -14105.5 |
CCNE2 | -11345.5 |
ZNF385A | -11096.5 |
TP53 | -8022.5 |
ARID3A | -5938.5 |
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs
1167 | |
---|---|
set | SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs |
setSize | 11 |
pANOVA | 0.00275 |
s.dist | -0.521 |
p.adjustANOVA | 0.00722 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NCBP1 | -21980.5 |
LSM11 | -21355.5 |
LSM10 | -20335.5 |
SLBP | -19880.5 |
SNRPD3 | -19465.5 |
SNRPG | -19279.5 |
NCBP2 | -18428.5 |
SNRPF | -16209.5 |
ZNF473 | -12032.5 |
SNRPE | -3211.5 |
SNRPB | -2288.5 |
GeneID | Gene Rank |
---|---|
NCBP1 | -21980.5 |
LSM11 | -21355.5 |
LSM10 | -20335.5 |
SLBP | -19880.5 |
SNRPD3 | -19465.5 |
SNRPG | -19279.5 |
NCBP2 | -18428.5 |
SNRPF | -16209.5 |
ZNF473 | -12032.5 |
SNRPE | -3211.5 |
SNRPB | -2288.5 |
Beta-catenin phosphorylation cascade
119 | |
---|---|
set | Beta-catenin phosphorylation cascade |
setSize | 16 |
pANOVA | 0.00033 |
s.dist | -0.518 |
p.adjustANOVA | 0.00123 |
Top enriched genes
GeneID | Gene Rank |
---|---|
APC | -21266.5 |
PPP2R5D | -20498.5 |
FRAT2 | -19999.5 |
FRAT1 | -19954.5 |
PPP2R1A | -19916.5 |
PPP2R5B | -19700.5 |
PPP2R5E | -18559.5 |
CTNNB1 | -18143.5 |
CSNK1A1 | -17637.5 |
PPP2CA | -17300.5 |
PPP2R5C | -15192.5 |
PPP2R1B | -15087.5 |
GSK3B | -12908.5 |
PPP2R5A | -9471.5 |
AXIN1 | -8669.5 |
PPP2CB | 1209.5 |
GeneID | Gene Rank |
---|---|
APC | -21266.5 |
PPP2R5D | -20498.5 |
FRAT2 | -19999.5 |
FRAT1 | -19954.5 |
PPP2R1A | -19916.5 |
PPP2R5B | -19700.5 |
PPP2R5E | -18559.5 |
CTNNB1 | -18143.5 |
CSNK1A1 | -17637.5 |
PPP2CA | -17300.5 |
PPP2R5C | -15192.5 |
PPP2R1B | -15087.5 |
GSK3B | -12908.5 |
PPP2R5A | -9471.5 |
AXIN1 | -8669.5 |
PPP2CB | 1209.5 |
Defensins
299 | |
---|---|
set | Defensins |
setSize | 40 |
pANOVA | 1.96e-08 |
s.dist | 0.513 |
p.adjustANOVA | 2.98e-07 |
Top enriched genes
GeneID | Gene Rank |
---|---|
DEFB123 | 3904.5 |
DEFA1 | 3897.0 |
DEFB118 | 3684.5 |
DEFA3 | 3618.5 |
DEFB133 | 3577.5 |
DEFB125 | 3572.5 |
DEFB119 | 3366.5 |
DEFB107A | 3338.0 |
TLR1 | 3265.5 |
DEFB108B | 3259.5 |
CCR2 | 3178.5 |
DEFA4 | 1631.5 |
DEFB1 | 0.5 |
DEFB105A | 0.5 |
DEFB103A | 0.5 |
DEFB110 | 0.5 |
DEFB132 | -1109.5 |
DEFB131 | -1481.5 |
DEFB127 | -1528.5 |
CCR6 | -1547.5 |
GeneID | Gene Rank |
---|---|
DEFB123 | 3904.5 |
DEFA1 | 3897.0 |
DEFB118 | 3684.5 |
DEFA3 | 3618.5 |
DEFB133 | 3577.5 |
DEFB125 | 3572.5 |
DEFB119 | 3366.5 |
DEFB107A | 3338.0 |
TLR1 | 3265.5 |
DEFB108B | 3259.5 |
CCR2 | 3178.5 |
DEFA4 | 1631.5 |
DEFB1 | 0.5 |
DEFB105A | 0.5 |
DEFB103A | 0.5 |
DEFB110 | 0.5 |
DEFB132 | -1109.5 |
DEFB131 | -1481.5 |
DEFB127 | -1528.5 |
CCR6 | -1547.5 |
DEFB135 | -1567.5 |
DEFB124 | -1714.5 |
DEFB115 | -2207.5 |
DEFB116 | -2448.5 |
PRSS3 | -2915.5 |
DEFA6 | -3030.5 |
DEFB121 | -3234.5 |
DEFB128 | -4019.5 |
DEFB126 | -5150.5 |
DEFB113 | -6447.5 |
CD4 | -6767.5 |
DEFB114 | -7523.5 |
DEFB106A | -7838.0 |
DEFB136 | -8037.5 |
DEFB134 | -8491.5 |
DEFB104A | -8764.0 |
DEFA5 | -9006.5 |
DEFB129 | -9184.5 |
ART1 | -12699.5 |
TLR2 | -17767.5 |
Physiological factors
917 | |
---|---|
set | Physiological factors |
setSize | 12 |
pANOVA | 0.00249 |
s.dist | -0.504 |
p.adjustANOVA | 0.00664 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NKX2-5 | -21746.5 |
TBX5 | -21422.5 |
GATA4 | -21358.5 |
WWTR1 | -20496.5 |
NPPA | -20069.5 |
NPR1 | -19685.5 |
NPPC | -17475.5 |
CORIN | -17396.5 |
KAT2B | -10519.5 |
HIPK2 | -9029.5 |
NPR2 | -6668.5 |
HIPK1 | -1764.5 |
GeneID | Gene Rank |
---|---|
NKX2-5 | -21746.5 |
TBX5 | -21422.5 |
GATA4 | -21358.5 |
WWTR1 | -20496.5 |
NPPA | -20069.5 |
NPR1 | -19685.5 |
NPPC | -17475.5 |
CORIN | -17396.5 |
KAT2B | -10519.5 |
HIPK2 | -9029.5 |
NPR2 | -6668.5 |
HIPK1 | -1764.5 |
SLBP independent Processing of Histone Pre-mRNAs
1168 | |
---|---|
set | SLBP independent Processing of Histone Pre-mRNAs |
setSize | 10 |
pANOVA | 0.00721 |
s.dist | -0.491 |
p.adjustANOVA | 0.0162 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NCBP1 | -21980.5 |
LSM11 | -21355.5 |
LSM10 | -20335.5 |
SNRPD3 | -19465.5 |
SNRPG | -19279.5 |
NCBP2 | -18428.5 |
SNRPF | -16209.5 |
ZNF473 | -12032.5 |
SNRPE | -3211.5 |
SNRPB | -2288.5 |
GeneID | Gene Rank |
---|---|
NCBP1 | -21980.5 |
LSM11 | -21355.5 |
LSM10 | -20335.5 |
SNRPD3 | -19465.5 |
SNRPG | -19279.5 |
NCBP2 | -18428.5 |
SNRPF | -16209.5 |
ZNF473 | -12032.5 |
SNRPE | -3211.5 |
SNRPB | -2288.5 |
Signaling by FGFR2 IIIa TM
1240 | |
---|---|
set | Signaling by FGFR2 IIIa TM |
setSize | 19 |
pANOVA | 0.000214 |
s.dist | -0.49 |
p.adjustANOVA | 0.000852 |
Top enriched genes
GeneID | Gene Rank |
---|---|
POLR2D | -22060.5 |
NCBP1 | -21980.5 |
GTF2F1 | -21038.5 |
POLR2L | -21029.5 |
POLR2A | -20617.5 |
POLR2F | -19650.5 |
POLR2C | -19178.5 |
POLR2I | -19009.5 |
NCBP2 | -18428.5 |
FGFR2 | -17537.5 |
POLR2G | -17424.5 |
GTF2F2 | -16893.5 |
POLR2B | -16136.5 |
FGF1 | -15290.5 |
POLR2H | -12642.5 |
FGF2 | -6956.5 |
POLR2E | -6942.5 |
POLR2J | -2815.5 |
POLR2K | 2010.5 |
GeneID | Gene Rank |
---|---|
POLR2D | -22060.5 |
NCBP1 | -21980.5 |
GTF2F1 | -21038.5 |
POLR2L | -21029.5 |
POLR2A | -20617.5 |
POLR2F | -19650.5 |
POLR2C | -19178.5 |
POLR2I | -19009.5 |
NCBP2 | -18428.5 |
FGFR2 | -17537.5 |
POLR2G | -17424.5 |
GTF2F2 | -16893.5 |
POLR2B | -16136.5 |
FGF1 | -15290.5 |
POLR2H | -12642.5 |
FGF2 | -6956.5 |
POLR2E | -6942.5 |
POLR2J | -2815.5 |
POLR2K | 2010.5 |
Signaling by PDGFRA extracellular domain mutants
1276 | |
---|---|
set | Signaling by PDGFRA extracellular domain mutants |
setSize | 12 |
pANOVA | 0.004 |
s.dist | -0.48 |
p.adjustANOVA | 0.00979 |
Top enriched genes
GeneID | Gene Rank |
---|---|
KRAS | -21833.5 |
PIK3CB | -21815.5 |
PIK3CA | -20323.5 |
GRB2 | -19995.5 |
PDGFRA | -19525.5 |
STAT1 | -17869.5 |
STAT3 | -15518.5 |
PIK3R2 | -14009.5 |
PIK3R1 | -13634.5 |
SOS1 | -10230.5 |
HRAS | -7215.5 |
NRAS | -1825.5 |
GeneID | Gene Rank |
---|---|
KRAS | -21833.5 |
PIK3CB | -21815.5 |
PIK3CA | -20323.5 |
GRB2 | -19995.5 |
PDGFRA | -19525.5 |
STAT1 | -17869.5 |
STAT3 | -15518.5 |
PIK3R2 | -14009.5 |
PIK3R1 | -13634.5 |
SOS1 | -10230.5 |
HRAS | -7215.5 |
NRAS | -1825.5 |
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
1277 | |
---|---|
set | Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants |
setSize | 12 |
pANOVA | 0.004 |
s.dist | -0.48 |
p.adjustANOVA | 0.00979 |
Top enriched genes
GeneID | Gene Rank |
---|---|
KRAS | -21833.5 |
PIK3CB | -21815.5 |
PIK3CA | -20323.5 |
GRB2 | -19995.5 |
PDGFRA | -19525.5 |
STAT1 | -17869.5 |
STAT3 | -15518.5 |
PIK3R2 | -14009.5 |
PIK3R1 | -13634.5 |
SOS1 | -10230.5 |
HRAS | -7215.5 |
NRAS | -1825.5 |
GeneID | Gene Rank |
---|---|
KRAS | -21833.5 |
PIK3CB | -21815.5 |
PIK3CA | -20323.5 |
GRB2 | -19995.5 |
PDGFRA | -19525.5 |
STAT1 | -17869.5 |
STAT3 | -15518.5 |
PIK3R2 | -14009.5 |
PIK3R1 | -13634.5 |
SOS1 | -10230.5 |
HRAS | -7215.5 |
NRAS | -1825.5 |
MET receptor recycling
695 | |
---|---|
set | MET receptor recycling |
setSize | 10 |
pANOVA | 0.00946 |
s.dist | -0.474 |
p.adjustANOVA | 0.0205 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ARF6 | -21769.5 |
GRB2 | -19995.5 |
MET | -19397.5 |
GGA3 | -17472.5 |
CRKL | -17305.5 |
GAB1 | -17270.5 |
RAB4A | -17100.5 |
CRK | -14328.5 |
RAB4B | -5573.5 |
HGF | -2176.5 |
GeneID | Gene Rank |
---|---|
ARF6 | -21769.5 |
GRB2 | -19995.5 |
MET | -19397.5 |
GGA3 | -17472.5 |
CRKL | -17305.5 |
GAB1 | -17270.5 |
RAB4A | -17100.5 |
CRK | -14328.5 |
RAB4B | -5573.5 |
HGF | -2176.5 |
WNT5A-dependent internalization of FZD2, FZD5 and ROR2
1488 | |
---|---|
set | WNT5A-dependent internalization of FZD2, FZD5 and ROR2 |
setSize | 13 |
pANOVA | 0.00313 |
s.dist | -0.473 |
p.adjustANOVA | 0.00803 |
Top enriched genes
GeneID | Gene Rank |
---|---|
FZD2 | -20397.5 |
CLTC | -18977.5 |
WNT5A | -18860.5 |
ROR1 | -18603.5 |
CLTB | -17987.5 |
AP2B1 | -16861.5 |
CLTA | -15443.5 |
ROR2 | -15124.5 |
FZD5 | -14696.5 |
AP2M1 | -13420.5 |
AP2S1 | -13057.5 |
AP2A1 | -11961.5 |
AP2A2 | -2607.5 |
GeneID | Gene Rank |
---|---|
FZD2 | -20397.5 |
CLTC | -18977.5 |
WNT5A | -18860.5 |
ROR1 | -18603.5 |
CLTB | -17987.5 |
AP2B1 | -16861.5 |
CLTA | -15443.5 |
ROR2 | -15124.5 |
FZD5 | -14696.5 |
AP2M1 | -13420.5 |
AP2S1 | -13057.5 |
AP2A1 | -11961.5 |
AP2A2 | -2607.5 |
CTNNB1 S33 mutants aren’t phosphorylated
153 | |
---|---|
set | CTNNB1 S33 mutants aren’t phosphorylated |
setSize | 14 |
pANOVA | 0.00219 |
s.dist | -0.473 |
p.adjustANOVA | 0.00594 |
Top enriched genes
GeneID | Gene Rank |
---|---|
APC | -21266.5 |
PPP2R5D | -20498.5 |
PPP2R1A | -19916.5 |
PPP2R5B | -19700.5 |
PPP2R5E | -18559.5 |
CTNNB1 | -18143.5 |
CSNK1A1 | -17637.5 |
PPP2CA | -17300.5 |
PPP2R5C | -15192.5 |
PPP2R1B | -15087.5 |
GSK3B | -12908.5 |
PPP2R5A | -9471.5 |
AXIN1 | -8669.5 |
PPP2CB | 1209.5 |
GeneID | Gene Rank |
---|---|
APC | -21266.5 |
PPP2R5D | -20498.5 |
PPP2R1A | -19916.5 |
PPP2R5B | -19700.5 |
PPP2R5E | -18559.5 |
CTNNB1 | -18143.5 |
CSNK1A1 | -17637.5 |
PPP2CA | -17300.5 |
PPP2R5C | -15192.5 |
PPP2R1B | -15087.5 |
GSK3B | -12908.5 |
PPP2R5A | -9471.5 |
AXIN1 | -8669.5 |
PPP2CB | 1209.5 |
CTNNB1 S37 mutants aren’t phosphorylated
154 | |
---|---|
set | CTNNB1 S37 mutants aren’t phosphorylated |
setSize | 14 |
pANOVA | 0.00219 |
s.dist | -0.473 |
p.adjustANOVA | 0.00594 |
Top enriched genes
GeneID | Gene Rank |
---|---|
APC | -21266.5 |
PPP2R5D | -20498.5 |
PPP2R1A | -19916.5 |
PPP2R5B | -19700.5 |
PPP2R5E | -18559.5 |
CTNNB1 | -18143.5 |
CSNK1A1 | -17637.5 |
PPP2CA | -17300.5 |
PPP2R5C | -15192.5 |
PPP2R1B | -15087.5 |
GSK3B | -12908.5 |
PPP2R5A | -9471.5 |
AXIN1 | -8669.5 |
PPP2CB | 1209.5 |
GeneID | Gene Rank |
---|---|
APC | -21266.5 |
PPP2R5D | -20498.5 |
PPP2R1A | -19916.5 |
PPP2R5B | -19700.5 |
PPP2R5E | -18559.5 |
CTNNB1 | -18143.5 |
CSNK1A1 | -17637.5 |
PPP2CA | -17300.5 |
PPP2R5C | -15192.5 |
PPP2R1B | -15087.5 |
GSK3B | -12908.5 |
PPP2R5A | -9471.5 |
AXIN1 | -8669.5 |
PPP2CB | 1209.5 |
CTNNB1 S45 mutants aren’t phosphorylated
155 | |
---|---|
set | CTNNB1 S45 mutants aren’t phosphorylated |
setSize | 14 |
pANOVA | 0.00219 |
s.dist | -0.473 |
p.adjustANOVA | 0.00594 |
Top enriched genes
GeneID | Gene Rank |
---|---|
APC | -21266.5 |
PPP2R5D | -20498.5 |
PPP2R1A | -19916.5 |
PPP2R5B | -19700.5 |
PPP2R5E | -18559.5 |
CTNNB1 | -18143.5 |
CSNK1A1 | -17637.5 |
PPP2CA | -17300.5 |
PPP2R5C | -15192.5 |
PPP2R1B | -15087.5 |
GSK3B | -12908.5 |
PPP2R5A | -9471.5 |
AXIN1 | -8669.5 |
PPP2CB | 1209.5 |
GeneID | Gene Rank |
---|---|
APC | -21266.5 |
PPP2R5D | -20498.5 |
PPP2R1A | -19916.5 |
PPP2R5B | -19700.5 |
PPP2R5E | -18559.5 |
CTNNB1 | -18143.5 |
CSNK1A1 | -17637.5 |
PPP2CA | -17300.5 |
PPP2R5C | -15192.5 |
PPP2R1B | -15087.5 |
GSK3B | -12908.5 |
PPP2R5A | -9471.5 |
AXIN1 | -8669.5 |
PPP2CB | 1209.5 |
CTNNB1 T41 mutants aren’t phosphorylated
156 | |
---|---|
set | CTNNB1 T41 mutants aren’t phosphorylated |
setSize | 14 |
pANOVA | 0.00219 |
s.dist | -0.473 |
p.adjustANOVA | 0.00594 |
Top enriched genes
GeneID | Gene Rank |
---|---|
APC | -21266.5 |
PPP2R5D | -20498.5 |
PPP2R1A | -19916.5 |
PPP2R5B | -19700.5 |
PPP2R5E | -18559.5 |
CTNNB1 | -18143.5 |
CSNK1A1 | -17637.5 |
PPP2CA | -17300.5 |
PPP2R5C | -15192.5 |
PPP2R1B | -15087.5 |
GSK3B | -12908.5 |
PPP2R5A | -9471.5 |
AXIN1 | -8669.5 |
PPP2CB | 1209.5 |
GeneID | Gene Rank |
---|---|
APC | -21266.5 |
PPP2R5D | -20498.5 |
PPP2R1A | -19916.5 |
PPP2R5B | -19700.5 |
PPP2R5E | -18559.5 |
CTNNB1 | -18143.5 |
CSNK1A1 | -17637.5 |
PPP2CA | -17300.5 |
PPP2R5C | -15192.5 |
PPP2R1B | -15087.5 |
GSK3B | -12908.5 |
PPP2R5A | -9471.5 |
AXIN1 | -8669.5 |
PPP2CB | 1209.5 |
Signaling by CTNNB1 phospho-site mutants
1224 | |
---|---|
set | Signaling by CTNNB1 phospho-site mutants |
setSize | 14 |
pANOVA | 0.00219 |
s.dist | -0.473 |
p.adjustANOVA | 0.00594 |
Top enriched genes
GeneID | Gene Rank |
---|---|
APC | -21266.5 |
PPP2R5D | -20498.5 |
PPP2R1A | -19916.5 |
PPP2R5B | -19700.5 |
PPP2R5E | -18559.5 |
CTNNB1 | -18143.5 |
CSNK1A1 | -17637.5 |
PPP2CA | -17300.5 |
PPP2R5C | -15192.5 |
PPP2R1B | -15087.5 |
GSK3B | -12908.5 |
PPP2R5A | -9471.5 |
AXIN1 | -8669.5 |
PPP2CB | 1209.5 |
GeneID | Gene Rank |
---|---|
APC | -21266.5 |
PPP2R5D | -20498.5 |
PPP2R1A | -19916.5 |
PPP2R5B | -19700.5 |
PPP2R5E | -18559.5 |
CTNNB1 | -18143.5 |
CSNK1A1 | -17637.5 |
PPP2CA | -17300.5 |
PPP2R5C | -15192.5 |
PPP2R1B | -15087.5 |
GSK3B | -12908.5 |
PPP2R5A | -9471.5 |
AXIN1 | -8669.5 |
PPP2CB | 1209.5 |
Signaling by GSK3beta mutants
1249 | |
---|---|
set | Signaling by GSK3beta mutants |
setSize | 14 |
pANOVA | 0.00219 |
s.dist | -0.473 |
p.adjustANOVA | 0.00594 |
Top enriched genes
GeneID | Gene Rank |
---|---|
APC | -21266.5 |
PPP2R5D | -20498.5 |
PPP2R1A | -19916.5 |
PPP2R5B | -19700.5 |
PPP2R5E | -18559.5 |
CTNNB1 | -18143.5 |
CSNK1A1 | -17637.5 |
PPP2CA | -17300.5 |
PPP2R5C | -15192.5 |
PPP2R1B | -15087.5 |
GSK3B | -12908.5 |
PPP2R5A | -9471.5 |
AXIN1 | -8669.5 |
PPP2CB | 1209.5 |
GeneID | Gene Rank |
---|---|
APC | -21266.5 |
PPP2R5D | -20498.5 |
PPP2R1A | -19916.5 |
PPP2R5B | -19700.5 |
PPP2R5E | -18559.5 |
CTNNB1 | -18143.5 |
CSNK1A1 | -17637.5 |
PPP2CA | -17300.5 |
PPP2R5C | -15192.5 |
PPP2R1B | -15087.5 |
GSK3B | -12908.5 |
PPP2R5A | -9471.5 |
AXIN1 | -8669.5 |
PPP2CB | 1209.5 |
Antimicrobial peptides
85 | |
---|---|
set | Antimicrobial peptides |
setSize | 82 |
pANOVA | 3.37e-13 |
s.dist | 0.464 |
p.adjustANOVA | 1.01e-11 |
Top enriched genes
GeneID | Gene Rank |
---|---|
DEFB123 | 3904.5 |
DEFA1 | 3897.0 |
LYZ | 3836.5 |
DEFB118 | 3684.5 |
DEFA3 | 3618.5 |
HTN1 | 3587.5 |
DEFB133 | 3577.5 |
DEFB125 | 3572.5 |
PRTN3 | 3486.5 |
DEFB119 | 3366.5 |
RNASE7 | 3351.5 |
DEFB107A | 3338.0 |
TLR1 | 3265.5 |
DEFB108B | 3259.5 |
CTSG | 3211.5 |
CCR2 | 3178.5 |
PI3 | 3162.5 |
BPIFB6 | 3112.5 |
ELANE | 2540.5 |
S100A9 | 2428.5 |
GeneID | Gene Rank |
---|---|
DEFB123 | 3904.5 |
DEFA1 | 3897.0 |
LYZ | 3836.5 |
DEFB118 | 3684.5 |
DEFA3 | 3618.5 |
HTN1 | 3587.5 |
DEFB133 | 3577.5 |
DEFB125 | 3572.5 |
PRTN3 | 3486.5 |
DEFB119 | 3366.5 |
RNASE7 | 3351.5 |
DEFB107A | 3338.0 |
TLR1 | 3265.5 |
DEFB108B | 3259.5 |
CTSG | 3211.5 |
CCR2 | 3178.5 |
PI3 | 3162.5 |
BPIFB6 | 3112.5 |
ELANE | 2540.5 |
S100A9 | 2428.5 |
REG3G | 2364.5 |
PLA2G2A | 1976.5 |
BPI | 1701.5 |
DEFA4 | 1631.5 |
DCD | 1378.5 |
BPIFA2 | 0.5 |
SEMG1 | 0.5 |
S100A8 | 0.5 |
BPIFA1 | 0.5 |
GNLY | 0.5 |
DEFB1 | 0.5 |
DEFB105A | 0.5 |
DEFB103A | 0.5 |
RNASE3 | 0.5 |
LCN2 | 0.5 |
DEFB110 | 0.5 |
DEFB132 | -1109.5 |
SLC11A1 | -1303.5 |
DEFB131 | -1481.5 |
DEFB127 | -1528.5 |
CCR6 | -1547.5 |
DEFB135 | -1567.5 |
DEFB124 | -1714.5 |
ITLN1 | -1797.5 |
BPIFB4 | -1810.5 |
CAMP | -2043.5 |
DEFB115 | -2207.5 |
S100A7A | -2400.5 |
DEFB116 | -2448.5 |
REG3A | -2713.5 |
PRSS3 | -2915.5 |
DEFA6 | -3030.5 |
DEFB121 | -3234.5 |
PGLYRP2 | -3295.5 |
DEFB128 | -4019.5 |
RNASE6 | -4266.5 |
DEFB126 | -5150.5 |
EPPIN | -5322.5 |
PGLYRP4 | -5675.5 |
DEFB113 | -6447.5 |
S100A7 | -6490.5 |
CD4 | -6767.5 |
RNASE8 | -6848.5 |
PGLYRP3 | -7254.5 |
DEFB114 | -7523.5 |
DEFB106A | -7838.0 |
DEFB136 | -8037.5 |
DEFB134 | -8491.5 |
BPIFB2 | -8740.5 |
DEFB104A | -8764.0 |
DEFA5 | -9006.5 |
DEFB129 | -9184.5 |
BPIFB1 | -9296.5 |
HTN3 | -11424.5 |
ART1 | -12699.5 |
CLU | -14608.5 |
ATOX1 | -16699.5 |
TLR2 | -17767.5 |
LTF | -18268.5 |
LEAP2 | -18403.5 |
CHGA | -19032.5 |
PGLYRP1 | -19820.5 |
RAF-independent MAPK1/3 activation
984 | |
---|---|
set | RAF-independent MAPK1/3 activation |
setSize | 22 |
pANOVA | 0.000165 |
s.dist | -0.464 |
p.adjustANOVA | 0.000683 |
Top enriched genes
GeneID | Gene Rank |
---|---|
JAK1 | -21183.5 |
DUSP6 | -20489.5 |
DUSP4 | -20217.5 |
DUSP16 | -20055.5 |
DUSP2 | -19867.5 |
DUSP1 | -19414.5 |
DUSP7 | -19254.5 |
IL6ST | -18503.5 |
CDK1 | -16471.5 |
DUSP10 | -16460.5 |
PEA15 | -16372.5 |
MAP2K1 | -16196.5 |
IL6R | -15462.5 |
TYK2 | -14619.5 |
DUSP8 | -14085.5 |
DUSP5 | -13826.5 |
PTPN11 | -13336.5 |
JAK2 | -12393.5 |
MAP2K2 | -11136.5 |
MAPK1 | -9933.5 |
GeneID | Gene Rank |
---|---|
JAK1 | -21183.5 |
DUSP6 | -20489.5 |
DUSP4 | -20217.5 |
DUSP16 | -20055.5 |
DUSP2 | -19867.5 |
DUSP1 | -19414.5 |
DUSP7 | -19254.5 |
IL6ST | -18503.5 |
CDK1 | -16471.5 |
DUSP10 | -16460.5 |
PEA15 | -16372.5 |
MAP2K1 | -16196.5 |
IL6R | -15462.5 |
TYK2 | -14619.5 |
DUSP8 | -14085.5 |
DUSP5 | -13826.5 |
PTPN11 | -13336.5 |
JAK2 | -12393.5 |
MAP2K2 | -11136.5 |
MAPK1 | -9933.5 |
MAPK3 | -3079.5 |
IL6 | 0.5 |
RUNX3 regulates p14-ARF
1052 | |
---|---|
set | RUNX3 regulates p14-ARF |
setSize | 10 |
pANOVA | 0.0115 |
s.dist | -0.461 |
p.adjustANOVA | 0.0241 |
Top enriched genes
GeneID | Gene Rank |
---|---|
BRD2 | -21879.5 |
KRAS | -21833.5 |
RUNX3 | -19897.5 |
CBFB | -19675.5 |
CCND1 | -19110.5 |
HDAC4 | -14651.5 |
EP300 | -10926.5 |
TGFB1 | -10577.5 |
RUNX1 | -10285.5 |
CDKN2A | -1930.5 |
GeneID | Gene Rank |
---|---|
BRD2 | -21879.5 |
KRAS | -21833.5 |
RUNX3 | -19897.5 |
CBFB | -19675.5 |
CCND1 | -19110.5 |
HDAC4 | -14651.5 |
EP300 | -10926.5 |
TGFB1 | -10577.5 |
RUNX1 | -10285.5 |
CDKN2A | -1930.5 |
RUNX2 regulates bone development
1049 | |
---|---|
set | RUNX2 regulates bone development |
setSize | 29 |
pANOVA | 1.96e-05 |
s.dist | -0.458 |
p.adjustANOVA | 0.000124 |
Top enriched genes
GeneID | Gene Rank |
---|---|
HEY1 | -21716.5 |
SATB2 | -21708.5 |
HES1 | -21328.5 |
YES1 | -21017.5 |
MAF | -20992.5 |
GLI3 | -20691.5 |
SMAD4 | -20586.5 |
SMAD6 | -20523.5 |
WWTR1 | -20496.5 |
RBM14 | -20353.5 |
CBFB | -19675.5 |
HDAC3 | -17766.5 |
RB1 | -16862.5 |
HEY2 | -16750.5 |
RUNX2 | -16321.5 |
ZNF521 | -16201.5 |
COL1A1 | -15705.5 |
HDAC4 | -14651.5 |
SMAD1 | -14513.5 |
IHH | -13261.5 |
GeneID | Gene Rank |
---|---|
HEY1 | -21716.5 |
SATB2 | -21708.5 |
HES1 | -21328.5 |
YES1 | -21017.5 |
MAF | -20992.5 |
GLI3 | -20691.5 |
SMAD4 | -20586.5 |
SMAD6 | -20523.5 |
WWTR1 | -20496.5 |
RBM14 | -20353.5 |
CBFB | -19675.5 |
HDAC3 | -17766.5 |
RB1 | -16862.5 |
HEY2 | -16750.5 |
RUNX2 | -16321.5 |
ZNF521 | -16201.5 |
COL1A1 | -15705.5 |
HDAC4 | -14651.5 |
SMAD1 | -14513.5 |
IHH | -13261.5 |
BGLAP | -10681.5 |
YAP1 | -10314.5 |
MAPK1 | -9933.5 |
SP7 | -9895.5 |
SRC | -6832.5 |
ABL1 | -6737.5 |
UCMA | -5331.5 |
MAPK3 | -3079.5 |
GLI2 | -1860.5 |
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism
1497 | |
---|---|
set | alpha-linolenic (omega3) and linoleic (omega6) acid metabolism |
setSize | 12 |
pANOVA | 0.00609 |
s.dist | -0.457 |
p.adjustANOVA | 0.014 |
Top enriched genes
GeneID | Gene Rank |
---|---|
FADS1 | -20574.5 |
ELOVL2 | -19945.5 |
ACOX1 | -19896.5 |
ELOVL5 | -19201.5 |
ACSL1 | -18473.5 |
ELOVL1 | -17675.5 |
ACOT8 | -15932.5 |
SCP2 | -15636.5 |
FADS2 | -13079.5 |
ACAA1 | -8759.5 |
ELOVL3 | -7600.5 |
HSD17B4 | -3478.5 |
GeneID | Gene Rank |
---|---|
FADS1 | -20574.5 |
ELOVL2 | -19945.5 |
ACOX1 | -19896.5 |
ELOVL5 | -19201.5 |
ACSL1 | -18473.5 |
ELOVL1 | -17675.5 |
ACOT8 | -15932.5 |
SCP2 | -15636.5 |
FADS2 | -13079.5 |
ACAA1 | -8759.5 |
ELOVL3 | -7600.5 |
HSD17B4 | -3478.5 |
alpha-linolenic acid (ALA) metabolism
1498 | |
---|---|
set | alpha-linolenic acid (ALA) metabolism |
setSize | 12 |
pANOVA | 0.00609 |
s.dist | -0.457 |
p.adjustANOVA | 0.014 |
Top enriched genes
GeneID | Gene Rank |
---|---|
FADS1 | -20574.5 |
ELOVL2 | -19945.5 |
ACOX1 | -19896.5 |
ELOVL5 | -19201.5 |
ACSL1 | -18473.5 |
ELOVL1 | -17675.5 |
ACOT8 | -15932.5 |
SCP2 | -15636.5 |
FADS2 | -13079.5 |
ACAA1 | -8759.5 |
ELOVL3 | -7600.5 |
HSD17B4 | -3478.5 |
GeneID | Gene Rank |
---|---|
FADS1 | -20574.5 |
ELOVL2 | -19945.5 |
ACOX1 | -19896.5 |
ELOVL5 | -19201.5 |
ACSL1 | -18473.5 |
ELOVL1 | -17675.5 |
ACOT8 | -15932.5 |
SCP2 | -15636.5 |
FADS2 | -13079.5 |
ACAA1 | -8759.5 |
ELOVL3 | -7600.5 |
HSD17B4 | -3478.5 |
RUNX2 regulates osteoblast differentiation
1050 | |
---|---|
set | RUNX2 regulates osteoblast differentiation |
setSize | 22 |
pANOVA | 0.000213 |
s.dist | -0.456 |
p.adjustANOVA | 0.000852 |
Top enriched genes
GeneID | Gene Rank |
---|---|
HEY1 | -21716.5 |
SATB2 | -21708.5 |
HES1 | -21328.5 |
YES1 | -21017.5 |
MAF | -20992.5 |
GLI3 | -20691.5 |
WWTR1 | -20496.5 |
CBFB | -19675.5 |
HDAC3 | -17766.5 |
RB1 | -16862.5 |
HEY2 | -16750.5 |
RUNX2 | -16321.5 |
ZNF521 | -16201.5 |
COL1A1 | -15705.5 |
BGLAP | -10681.5 |
YAP1 | -10314.5 |
MAPK1 | -9933.5 |
SP7 | -9895.5 |
SRC | -6832.5 |
ABL1 | -6737.5 |
GeneID | Gene Rank |
---|---|
HEY1 | -21716.5 |
SATB2 | -21708.5 |
HES1 | -21328.5 |
YES1 | -21017.5 |
MAF | -20992.5 |
GLI3 | -20691.5 |
WWTR1 | -20496.5 |
CBFB | -19675.5 |
HDAC3 | -17766.5 |
RB1 | -16862.5 |
HEY2 | -16750.5 |
RUNX2 | -16321.5 |
ZNF521 | -16201.5 |
COL1A1 | -15705.5 |
BGLAP | -10681.5 |
YAP1 | -10314.5 |
MAPK1 | -9933.5 |
SP7 | -9895.5 |
SRC | -6832.5 |
ABL1 | -6737.5 |
UCMA | -5331.5 |
MAPK3 | -3079.5 |
APC truncation mutants have impaired AXIN binding
10 | |
---|---|
set | APC truncation mutants have impaired AXIN binding |
setSize | 13 |
pANOVA | 0.00445 |
s.dist | -0.455 |
p.adjustANOVA | 0.0107 |
Top enriched genes
GeneID | Gene Rank |
---|---|
APC | -21266.5 |
PPP2R5D | -20498.5 |
PPP2R1A | -19916.5 |
PPP2R5B | -19700.5 |
PPP2R5E | -18559.5 |
CSNK1A1 | -17637.5 |
PPP2CA | -17300.5 |
PPP2R5C | -15192.5 |
PPP2R1B | -15087.5 |
GSK3B | -12908.5 |
PPP2R5A | -9471.5 |
AXIN1 | -8669.5 |
PPP2CB | 1209.5 |
GeneID | Gene Rank |
---|---|
APC | -21266.5 |
PPP2R5D | -20498.5 |
PPP2R1A | -19916.5 |
PPP2R5B | -19700.5 |
PPP2R5E | -18559.5 |
CSNK1A1 | -17637.5 |
PPP2CA | -17300.5 |
PPP2R5C | -15192.5 |
PPP2R1B | -15087.5 |
GSK3B | -12908.5 |
PPP2R5A | -9471.5 |
AXIN1 | -8669.5 |
PPP2CB | 1209.5 |
AXIN missense mutants destabilize the destruction complex
23 | |
---|---|
set | AXIN missense mutants destabilize the destruction complex |
setSize | 13 |
pANOVA | 0.00445 |
s.dist | -0.455 |
p.adjustANOVA | 0.0107 |
Top enriched genes
GeneID | Gene Rank |
---|---|
APC | -21266.5 |
PPP2R5D | -20498.5 |
PPP2R1A | -19916.5 |
PPP2R5B | -19700.5 |
PPP2R5E | -18559.5 |
CSNK1A1 | -17637.5 |
PPP2CA | -17300.5 |
PPP2R5C | -15192.5 |
PPP2R1B | -15087.5 |
GSK3B | -12908.5 |
PPP2R5A | -9471.5 |
AXIN1 | -8669.5 |
PPP2CB | 1209.5 |
GeneID | Gene Rank |
---|---|
APC | -21266.5 |
PPP2R5D | -20498.5 |
PPP2R1A | -19916.5 |
PPP2R5B | -19700.5 |
PPP2R5E | -18559.5 |
CSNK1A1 | -17637.5 |
PPP2CA | -17300.5 |
PPP2R5C | -15192.5 |
PPP2R1B | -15087.5 |
GSK3B | -12908.5 |
PPP2R5A | -9471.5 |
AXIN1 | -8669.5 |
PPP2CB | 1209.5 |
Signaling by AMER1 mutants
1217 | |
---|---|
set | Signaling by AMER1 mutants |
setSize | 13 |
pANOVA | 0.00445 |
s.dist | -0.455 |
p.adjustANOVA | 0.0107 |
Top enriched genes
GeneID | Gene Rank |
---|---|
APC | -21266.5 |
PPP2R5D | -20498.5 |
PPP2R1A | -19916.5 |
PPP2R5B | -19700.5 |
PPP2R5E | -18559.5 |
CSNK1A1 | -17637.5 |
PPP2CA | -17300.5 |
PPP2R5C | -15192.5 |
PPP2R1B | -15087.5 |
GSK3B | -12908.5 |
PPP2R5A | -9471.5 |
AXIN1 | -8669.5 |
PPP2CB | 1209.5 |
GeneID | Gene Rank |
---|---|
APC | -21266.5 |
PPP2R5D | -20498.5 |
PPP2R1A | -19916.5 |
PPP2R5B | -19700.5 |
PPP2R5E | -18559.5 |
CSNK1A1 | -17637.5 |
PPP2CA | -17300.5 |
PPP2R5C | -15192.5 |
PPP2R1B | -15087.5 |
GSK3B | -12908.5 |
PPP2R5A | -9471.5 |
AXIN1 | -8669.5 |
PPP2CB | 1209.5 |
Signaling by APC mutants
1218 | |
---|---|
set | Signaling by APC mutants |
setSize | 13 |
pANOVA | 0.00445 |
s.dist | -0.455 |
p.adjustANOVA | 0.0107 |
Top enriched genes
GeneID | Gene Rank |
---|---|
APC | -21266.5 |
PPP2R5D | -20498.5 |
PPP2R1A | -19916.5 |
PPP2R5B | -19700.5 |
PPP2R5E | -18559.5 |
CSNK1A1 | -17637.5 |
PPP2CA | -17300.5 |
PPP2R5C | -15192.5 |
PPP2R1B | -15087.5 |
GSK3B | -12908.5 |
PPP2R5A | -9471.5 |
AXIN1 | -8669.5 |
PPP2CB | 1209.5 |
GeneID | Gene Rank |
---|---|
APC | -21266.5 |
PPP2R5D | -20498.5 |
PPP2R1A | -19916.5 |
PPP2R5B | -19700.5 |
PPP2R5E | -18559.5 |
CSNK1A1 | -17637.5 |
PPP2CA | -17300.5 |
PPP2R5C | -15192.5 |
PPP2R1B | -15087.5 |
GSK3B | -12908.5 |
PPP2R5A | -9471.5 |
AXIN1 | -8669.5 |
PPP2CB | 1209.5 |
Signaling by AXIN mutants
1219 | |
---|---|
set | Signaling by AXIN mutants |
setSize | 13 |
pANOVA | 0.00445 |
s.dist | -0.455 |
p.adjustANOVA | 0.0107 |
Top enriched genes
GeneID | Gene Rank |
---|---|
APC | -21266.5 |
PPP2R5D | -20498.5 |
PPP2R1A | -19916.5 |
PPP2R5B | -19700.5 |
PPP2R5E | -18559.5 |
CSNK1A1 | -17637.5 |
PPP2CA | -17300.5 |
PPP2R5C | -15192.5 |
PPP2R1B | -15087.5 |
GSK3B | -12908.5 |
PPP2R5A | -9471.5 |
AXIN1 | -8669.5 |
PPP2CB | 1209.5 |
GeneID | Gene Rank |
---|---|
APC | -21266.5 |
PPP2R5D | -20498.5 |
PPP2R1A | -19916.5 |
PPP2R5B | -19700.5 |
PPP2R5E | -18559.5 |
CSNK1A1 | -17637.5 |
PPP2CA | -17300.5 |
PPP2R5C | -15192.5 |
PPP2R1B | -15087.5 |
GSK3B | -12908.5 |
PPP2R5A | -9471.5 |
AXIN1 | -8669.5 |
PPP2CB | 1209.5 |
Truncations of AMER1 destabilize the destruction complex
1459 | |
---|---|
set | Truncations of AMER1 destabilize the destruction complex |
setSize | 13 |
pANOVA | 0.00445 |
s.dist | -0.455 |
p.adjustANOVA | 0.0107 |
Top enriched genes
GeneID | Gene Rank |
---|---|
APC | -21266.5 |
PPP2R5D | -20498.5 |
PPP2R1A | -19916.5 |
PPP2R5B | -19700.5 |
PPP2R5E | -18559.5 |
CSNK1A1 | -17637.5 |
PPP2CA | -17300.5 |
PPP2R5C | -15192.5 |
PPP2R1B | -15087.5 |
GSK3B | -12908.5 |
PPP2R5A | -9471.5 |
AXIN1 | -8669.5 |
PPP2CB | 1209.5 |
GeneID | Gene Rank |
---|---|
APC | -21266.5 |
PPP2R5D | -20498.5 |
PPP2R1A | -19916.5 |
PPP2R5B | -19700.5 |
PPP2R5E | -18559.5 |
CSNK1A1 | -17637.5 |
PPP2CA | -17300.5 |
PPP2R5C | -15192.5 |
PPP2R1B | -15087.5 |
GSK3B | -12908.5 |
PPP2R5A | -9471.5 |
AXIN1 | -8669.5 |
PPP2CB | 1209.5 |
RNA Polymerase III Transcription Initiation From Type 2 Promoter
1037 | |
---|---|
set | RNA Polymerase III Transcription Initiation From Type 2 Promoter |
setSize | 27 |
pANOVA | 4.18e-05 |
s.dist | -0.455 |
p.adjustANOVA | 0.000223 |
Top enriched genes
GeneID | Gene Rank |
---|---|
POLR1D | -22069.5 |
GTF3C4 | -21636.5 |
GTF3C5 | -21507.5 |
POLR3C | -21172.5 |
POLR2L | -21029.5 |
TBP | -20975.5 |
POLR3G | -20575.5 |
POLR2F | -19650.5 |
POLR3F | -19387.5 |
POLR3A | -18155.5 |
BRF1 | -17876.5 |
POLR3B | -17796.5 |
POLR3GL | -17541.5 |
POLR3E | -17398.5 |
GTF3C2 | -16806.5 |
POLR3D | -15907.5 |
GTF3C6 | -13777.5 |
GTF3C3 | -13676.5 |
POLR3K | -13612.5 |
POLR2H | -12642.5 |
GeneID | Gene Rank |
---|---|
POLR1D | -22069.5 |
GTF3C4 | -21636.5 |
GTF3C5 | -21507.5 |
POLR3C | -21172.5 |
POLR2L | -21029.5 |
TBP | -20975.5 |
POLR3G | -20575.5 |
POLR2F | -19650.5 |
POLR3F | -19387.5 |
POLR3A | -18155.5 |
BRF1 | -17876.5 |
POLR3B | -17796.5 |
POLR3GL | -17541.5 |
POLR3E | -17398.5 |
GTF3C2 | -16806.5 |
POLR3D | -15907.5 |
GTF3C6 | -13777.5 |
GTF3C3 | -13676.5 |
POLR3K | -13612.5 |
POLR2H | -12642.5 |
POLR1C | -11111.5 |
GTF3C1 | -10860.5 |
POLR3H | -8931.5 |
POLR2E | -6942.5 |
CRCP | -3591.5 |
BDP1 | -2231.5 |
POLR2K | 2010.5 |
Nephrin family interactions
805 | |
---|---|
set | Nephrin family interactions |
setSize | 21 |
pANOVA | 0.000331 |
s.dist | -0.452 |
p.adjustANOVA | 0.00123 |
Top enriched genes
GeneID | Gene Rank |
---|---|
FYN | -21951.5 |
WASL | -21834.5 |
PIK3CB | -21815.5 |
PIK3CA | -20323.5 |
MAGI2 | -20244.5 |
CD2AP | -19679.5 |
SPTBN1 | -19454.5 |
ACTN3 | -19142.5 |
KIRREL3 | -19031.5 |
NPHS1 | -18484.5 |
IQGAP1 | -16749.5 |
PIK3R2 | -14009.5 |
KIRREL2 | -14004.5 |
PIK3R1 | -13634.5 |
ACTN4 | -13002.5 |
NCK1 | -11715.5 |
NCK2 | -10484.5 |
SPTAN1 | -7766.5 |
KIRREL | -7307.5 |
ACTN2 | -2173.5 |
GeneID | Gene Rank |
---|---|
FYN | -21951.5 |
WASL | -21834.5 |
PIK3CB | -21815.5 |
PIK3CA | -20323.5 |
MAGI2 | -20244.5 |
CD2AP | -19679.5 |
SPTBN1 | -19454.5 |
ACTN3 | -19142.5 |
KIRREL3 | -19031.5 |
NPHS1 | -18484.5 |
IQGAP1 | -16749.5 |
PIK3R2 | -14009.5 |
KIRREL2 | -14004.5 |
PIK3R1 | -13634.5 |
ACTN4 | -13002.5 |
NCK1 | -11715.5 |
NCK2 | -10484.5 |
SPTAN1 | -7766.5 |
KIRREL | -7307.5 |
ACTN2 | -2173.5 |
ACTN1 | -1265.5 |
Cleavage of the damaged purine
216 | |
---|---|
set | Cleavage of the damaged purine |
setSize | 11 |
pANOVA | 0.00951 |
s.dist | -0.451 |
p.adjustANOVA | 0.0206 |
Top enriched genes
GeneID | Gene Rank |
---|---|
H2AFX | -19427.5 |
TERF1 | -19003.5 |
TERF2IP | -18747.5 |
MUTYH | -18425.5 |
MPG | -16274.5 |
OGG1 | -15696.5 |
ACD | -13964.0 |
TINF2 | -13631.5 |
POT1 | -12498.5 |
NEIL3 | -11997.5 |
TERF2 | -4746.5 |
GeneID | Gene Rank |
---|---|
H2AFX | -19427.5 |
TERF1 | -19003.5 |
TERF2IP | -18747.5 |
MUTYH | -18425.5 |
MPG | -16274.5 |
OGG1 | -15696.5 |
ACD | -13964.0 |
TINF2 | -13631.5 |
POT1 | -12498.5 |
NEIL3 | -11997.5 |
TERF2 | -4746.5 |
Depurination
309 | |
---|---|
set | Depurination |
setSize | 11 |
pANOVA | 0.00951 |
s.dist | -0.451 |
p.adjustANOVA | 0.0206 |
Top enriched genes
GeneID | Gene Rank |
---|---|
H2AFX | -19427.5 |
TERF1 | -19003.5 |
TERF2IP | -18747.5 |
MUTYH | -18425.5 |
MPG | -16274.5 |
OGG1 | -15696.5 |
ACD | -13964.0 |
TINF2 | -13631.5 |
POT1 | -12498.5 |
NEIL3 | -11997.5 |
TERF2 | -4746.5 |
GeneID | Gene Rank |
---|---|
H2AFX | -19427.5 |
TERF1 | -19003.5 |
TERF2IP | -18747.5 |
MUTYH | -18425.5 |
MPG | -16274.5 |
OGG1 | -15696.5 |
ACD | -13964.0 |
TINF2 | -13631.5 |
POT1 | -12498.5 |
NEIL3 | -11997.5 |
TERF2 | -4746.5 |
Here is the session info with all the versions of packages used.
sessionInfo()
## R version 4.2.0 (2022-04-22)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 20.04.4 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.9.0
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.9.0
##
## locale:
## [1] LC_CTYPE=en_US.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_US.UTF-8 LC_COLLATE=en_US.UTF-8
## [5] LC_MONETARY=en_US.UTF-8 LC_MESSAGES=en_US.UTF-8
## [7] LC_PAPER=en_US.UTF-8 LC_NAME=C
## [9] LC_ADDRESS=C LC_TELEPHONE=C
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C
##
## attached base packages:
## [1] grid stats4 parallel stats graphics grDevices utils
## [8] datasets methods base
##
## other attached packages:
## [1] pkgload_1.2.4
## [2] GGally_2.1.2
## [3] ggplot2_3.3.6
## [4] gtools_3.9.2
## [5] tibble_3.1.7
## [6] echarts4r_0.4.3
## [7] ENmix_1.32.0
## [8] doParallel_1.0.17
## [9] qqman_0.1.8
## [10] RCircos_1.2.2
## [11] beeswarm_0.4.0
## [12] forestplot_2.0.1
## [13] checkmate_2.1.0
## [14] magrittr_2.0.3
## [15] reshape2_1.4.4
## [16] gplots_3.1.3
## [17] GEOquery_2.64.2
## [18] RColorBrewer_1.1-3
## [19] IlluminaHumanMethylation450kmanifest_0.4.0
## [20] topconfects_1.12.0
## [21] DMRcatedata_2.14.0
## [22] ExperimentHub_2.4.0
## [23] AnnotationHub_3.4.0
## [24] BiocFileCache_2.4.0
## [25] dbplyr_2.1.1
## [26] DMRcate_2.10.0
## [27] limma_3.52.1
## [28] missMethyl_1.30.0
## [29] IlluminaHumanMethylationEPICanno.ilm10b4.hg19_0.6.0
## [30] IlluminaHumanMethylation450kanno.ilmn12.hg19_0.6.1
## [31] minfi_1.42.0
## [32] bumphunter_1.38.0
## [33] locfit_1.5-9.5
## [34] iterators_1.0.14
## [35] foreach_1.5.2
## [36] Biostrings_2.64.0
## [37] XVector_0.36.0
## [38] SummarizedExperiment_1.26.1
## [39] Biobase_2.56.0
## [40] MatrixGenerics_1.8.0
## [41] matrixStats_0.62.0
## [42] GenomicRanges_1.48.0
## [43] GenomeInfoDb_1.32.2
## [44] IRanges_2.30.0
## [45] S4Vectors_0.34.0
## [46] BiocGenerics_0.42.0
## [47] R.utils_2.11.0
## [48] R.oo_1.24.0
## [49] R.methodsS3_1.8.1
## [50] plyr_1.8.7
## [51] tictoc_1.0.1
## [52] mitch_1.8.0
## [53] eulerr_6.1.1
## [54] kableExtra_1.3.4
## [55] dplyr_1.0.9
##
## loaded via a namespace (and not attached):
## [1] rappdirs_0.3.3 rtracklayer_1.56.0
## [3] tidyr_1.2.0 bit64_4.0.5
## [5] knitr_1.39 DelayedArray_0.22.0
## [7] data.table_1.14.2 rpart_4.1.16
## [9] KEGGREST_1.36.0 RCurl_1.98-1.6
## [11] AnnotationFilter_1.20.0 generics_0.1.2
## [13] GenomicFeatures_1.48.1 preprocessCore_1.58.0
## [15] RSQLite_2.2.14 bit_4.0.4
## [17] tzdb_0.3.0 webshot_0.5.3
## [19] xml2_1.3.3 httpuv_1.6.5
## [21] assertthat_0.2.1 xfun_0.31
## [23] hms_1.1.1 jquerylib_0.1.4
## [25] evaluate_0.15 promises_1.2.0.1
## [27] fansi_1.0.3 restfulr_0.0.13
## [29] scrime_1.3.5 progress_1.2.2
## [31] caTools_1.18.2 readxl_1.4.0
## [33] DBI_1.1.2 geneplotter_1.74.0
## [35] htmlwidgets_1.5.4 reshape_0.8.9
## [37] purrr_0.3.4 ellipsis_0.3.2
## [39] backports_1.4.1 permute_0.9-7
## [41] calibrate_1.7.7 annotate_1.74.0
## [43] biomaRt_2.52.0 sparseMatrixStats_1.8.0
## [45] vctrs_0.4.1 ensembldb_2.20.1
## [47] withr_2.5.0 cachem_1.0.6
## [49] Gviz_1.40.1 BSgenome_1.64.0
## [51] GenomicAlignments_1.32.0 prettyunits_1.1.1
## [53] mclust_5.4.9 svglite_2.1.0
## [55] cluster_2.1.3 RPMM_1.25
## [57] lazyeval_0.2.2 crayon_1.5.1
## [59] genefilter_1.78.0 edgeR_3.38.1
## [61] pkgconfig_2.0.3 nlme_3.1-157
## [63] ProtGenerics_1.28.0 nnet_7.3-17
## [65] rlang_1.0.2 lifecycle_1.0.1
## [67] filelock_1.0.2 dichromat_2.0-0.1
## [69] rprojroot_2.0.3 cellranger_1.1.0
## [71] rngtools_1.5.2 base64_2.0
## [73] Matrix_1.4-1 Rhdf5lib_1.18.2
## [75] base64enc_0.1-3 png_0.1-7
## [77] viridisLite_0.4.0 rjson_0.2.21
## [79] bitops_1.0-7 KernSmooth_2.23-20
## [81] rhdf5filters_1.8.0 blob_1.2.3
## [83] DelayedMatrixStats_1.18.0 doRNG_1.8.2
## [85] stringr_1.4.0 nor1mix_1.3-0
## [87] readr_2.1.2 jpeg_0.1-9
## [89] scales_1.2.0 memoise_2.0.1
## [91] zlibbioc_1.42.0 compiler_4.2.0
## [93] BiocIO_1.6.0 illuminaio_0.38.0
## [95] Rsamtools_2.12.0 cli_3.3.0
## [97] DSS_2.44.0 htmlTable_2.4.0
## [99] Formula_1.2-4 MASS_7.3-57
## [101] tidyselect_1.1.2 stringi_1.7.6
## [103] highr_0.9 yaml_2.3.5
## [105] askpass_1.1 latticeExtra_0.6-29
## [107] sass_0.4.1 VariantAnnotation_1.42.1
## [109] tools_4.2.0 rstudioapi_0.13
## [111] foreign_0.8-82 bsseq_1.32.0
## [113] gridExtra_2.3 digest_0.6.29
## [115] BiocManager_1.30.17 shiny_1.7.1
## [117] quadprog_1.5-8 Rcpp_1.0.8.3
## [119] siggenes_1.70.0 BiocVersion_3.15.2
## [121] later_1.3.0 org.Hs.eg.db_3.15.0
## [123] httr_1.4.3 AnnotationDbi_1.58.0
## [125] biovizBase_1.44.0 colorspace_2.0-3
## [127] brio_1.1.3 rvest_1.0.2
## [129] XML_3.99-0.9 splines_4.2.0
## [131] statmod_1.4.36 multtest_2.52.0
## [133] systemfonts_1.0.4 xtable_1.8-4
## [135] jsonlite_1.8.0 dynamicTreeCut_1.63-1
## [137] testthat_3.1.4 R6_2.5.1
## [139] Hmisc_4.7-0 pillar_1.7.0
## [141] htmltools_0.5.2 mime_0.12
## [143] glue_1.6.2 fastmap_1.1.0
## [145] BiocParallel_1.30.2 interactiveDisplayBase_1.34.0
## [147] beanplot_1.3.1 codetools_0.2-18
## [149] utf8_1.2.2 bslib_0.3.1
## [151] lattice_0.20-45 curl_4.3.2
## [153] openssl_2.0.1 survival_3.3-1
## [155] rmarkdown_2.14 desc_1.4.1
## [157] munsell_0.5.0 rhdf5_2.40.0
## [159] GenomeInfoDbData_1.2.8 HDF5Array_1.24.0
## [161] impute_1.70.0 gtable_0.3.0
END of report